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CHAPTER I 
 
INTRODUCTION 
 
 
“Quality is never an accident; it is always the result of intelligent effort” 
   
John Ruskin 
(°1819 - †1900, English Philanthropist) 
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CHAPTER I 
INTRODUCTION 
1. QUALITY OF PHARMACEUTICAL DRUGS: CONCEPTS AND 
DEFINITIONS 
Quality is a universal concept which needs to be defined in terms of specific characteristics, which 
vary from product to product [1]. For example, for pharmaceutical products, parameters such as 
medicinal effect, toxicity, physical and chemical characteristics, taste and shelf life may be important 
[2]. Definitions and concepts of pharmaceutical drug quality have been evolving over the years. ICH 
defines pharmaceutical drug quality as the fitness-for-purpose of a drug substance or drug product, 
including attributes as identity, strength and purity, without undesired side effects [3]. Short et al. 
redefined pharmaceutical drugs quality in terms of risk by linking product characteristics to clinical 
attributes, whereby the risk that final product characteristics impose on the safety and efficacy of 
treatment can be modeled [4]. Quality specifications could be defined as critical quality standards 
that are proposed and justified by the manufacturer and approved by regulatory authorities [5].   
The quality of pharmaceutical drugs is a global concern ensuring optimal treatment from medicines, 
and is currently receiving increased attention in an era of globalization and generic manufacturing [6-
8]. Quality assurance and control play an essential role in the pharmaceutical manufacturing process, 
by ensuring that patients are provided with medications that are safe, effective, and produced at a 
high level of quality appropriate to their intended use [9, 10]. The manufacturing process should 
ensure product quality which requires consideration of the physical, chemical, and biologic 
characteristics of all of the drug substances (e.g., the solubility of the drug substance can affect the 
choice of dosage form) and pharmaceutical ingredients to be used in manufacturing the product [11]. 
The drug and pharmaceutical materials must be compatible with one another to produce a drug 
product that is stable, efficacious, attractive, easy to administer, and safe. The product should be 
manufactured with appropriate measures of quality control and packaged in containers that keep the 
product stable. The product should be labeled to promote correct use and be stored under 
conditions that contribute to maximum shelf life [3]. 
Since packaging preserves the stability and quality of medicinal products as well as protects them 
against all forms of spoilage and tampering, and since the information on the labels, packaging and 
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leaflets provide the basis for appropriate use, WHO recommends that all medicinal products need to 
be packaged in containers that conform to prescribed standards with careful labeling [12].  
Despite recent advances in the manufacturing sector, quality issues remain a frequent occurrence, 
and can result in recalls, withdrawals, or harm to patients [10]. 
After a pharmaceutical product leaves the manufacturer’s premises, distributors, procurement 
agencies (purchasers), dispensers, and users are responsible for maintaining the quality of the 
product through proper storage, transport, distribution, dispensing, and use.  National medicines 
regulatory authorities are responsible for ensuring that manufacturers comply with current GMP 
requirements and execute the key regulatory functions that are required to maintain product safety, 
efficacy and quality through out the supply chain until the end user; which may present a challenge 
for countries with limited resources [13]. 
There is growing concern that much of the developing world’s supply of medicines, in particular, its 
supply of anti-infective drugs is of poor quality, resulting in avoidable morbidity, mortality and drug 
resistance [14, 15]. There are different national and international efforts to counter poor quality 
medicines [15-19]. However, efforts to improve the quality of medicines in developing countries are 
being hampered by confusion over the terms used to describe different types of poor quality 
medicines [20]. There are two main categories of poor quality medicines: substandard and 
counterfeit. According to world health organization (WHO), substandard medicines are genuine 
medicines which have not passed the standards and quality testing protocols set for them. These 
standards and quality tests have been defined in the official pharmacopoeias such as the 
International, the European and the United States Pharmacopoeias [21].  A counterfeit or falsified 
medicine is one which is deliberately and fraudulently mislabelled with respect to identity and/or 
source. Counterfeiting can apply to both branded and generic products and counterfeit products may 
include products with the correct ingredients, wrong ingredients, without active ingredients, with 
insufficient quantity of active ingredient or with fake packaging [21, 22].  
It needs to be mentioned that the relationship between combatting counterfeit medicines, 
addressing safety, quality and efficacy issues, and enforcing privately owned intellectual property (IP) 
rights has become controversial. This debate between health and legal arguments lead to the 
concern that a wider definition of ‘counterfeit’ threatens the trade in generic medicines of assured 
quality on which many developing countries depend [23]. 
In the past, WHO distinguished between “substandard” and “counterfeit” medicines as defined 
above, but in March 2011, its member states chose to lump them together in the new term 
“substandard/spurious/falsely-labeled/falsified/counterfeit medical products” (SSFFC) [24]. However, 
placing all illegitimate medicines under the SSFFC umbrella gives the misleading impression that they 
are all deficient in the same way, when actually there are many possible deficiencies, each requiring 
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different solutions. Thus, Attaran et al. proposed new definitions, which refine the views of WHO 
member states as presented in Figure 1 [22]. 
An important strength of the new definitions proposed by Attaran et al. is that they do not draw on 
any IP questions or use the confusing word counterfeit. According to international intellectual 
property law, a “counterfeit” medicine is one that infringes a registered trademark by bearing an 
identical or near identical mark [25]. Deliberate counterfeiting is a private economic wrong, which 
can occur separately from or together with the public health wrong of poor medicine quality. Thus, it 
is a mistake (although a common one) to use the adjective “counterfeit” to refer to medicines that 
endanger public health [22]. “Substandard” medicines are those that for unintentional reasons do 
not meet the legally required quality specifications of a country’s regulators (usually a specialised 
medicine regulatory authority). As noted elsewhere, substandard medicines have various deficiencies 
and causes; for example, the raw ingredients may be of poor quality, errors may occur in 
manufacturing, or mishandling may cause the medicine to degrade unexpectedly rapid [26]. Each of 
these technical problems requires a different solution. 
 
 
Figure 1. A two-dimentional description of medicine quality and registration. (Attaran et al. 2012 BMJ 
345:e7381) 
 
As presented in Figure 1, unregistered medicines may be of good quality. Accordingly, good quality 
unregistered medicines are separated from other types of illegitimate drugs. Hence in spite of the 
strengths, the new definitions of poor quality medicines proposed by Attaran et al. have some 
drawbacks: (1) it does not have clear definitions and classifications for unregistered medicines of 
poor quality; (2) it catagorises the unregistered drugs of good quality as illegitimate only due to 
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diversion or theft, where these medicines could in fact fulfil the quality standards but diversion and 
theft have no guarantee for good transport and/or storage; (3) those unregistered medicines of good 
quality can also be called falsified as regard to their history since they are not following the 
legal/formal supply anymore or can be re-introduced wrongfully; and (4) in the worst case scenario, 
those unregistered medicines can be tampered with and can be classified as falsified as regards to 
their identity and/or source. 
“Unregistered” medicines are those not legally approved by the local drug regulatory authority to be 
imported or sold in the country [27]. Unregistered medicines are vulnerable to quality failures and 
are more prone to substandard quality as well. They do not enter the market through reputable 
channels and are often transported under poor conditions; situations where quality problems can 
easily go undetected [28]. With unregistered medicines (which are also often substandard), some 
aspect of the medicine does not meet the regulator’s legal requirements. Generally, such products 
also deviate from the regulator’s approved packaging/labelling (correct and legible labeling of active 
ingredients and strength, expiration date, batch number, manufacturer, and country of origin) [22].  
Since the definition of counterfeit medicines affects IP [25], the term “falsified” medicines is used to 
distinguish the issue from IP violations, thereby protecting and facilitating the trade in affordable 
generics. Thus, a falsified medicine is defined to be one that falsely represents the product’s identity 
or source or both. Thus, a falsified medicine may or may not contain the wrong ingredients, 
ingredients of low quality or in the wrong doses, but they are deliberately and fraudulently 
mislabelled with respect to their identity or source, and thus have fake packaging [29].  
Similar to substandard medicines, the falsified medicines are unlawful in violating the regulator’s 
quality specifications, but what truly defines and distinguishes them is criminal intent. Thus it takes 
more than a negligent breach of the regulator’s legal requirements to make a medicine falsified; 
there must also be a deliberate intent to deceive [22].  
Therefore, public health-oriented concepts and definitions (avoiding unnecessary controversy and 
thus better enabling governments, companies, advocates, and the health professions to protect 
public health) must be used in consensus to improve the overall quality of the world’s supply of 
medicines. Moreover, in order to avoid such confusions, the semantics ‘poor quality’ is 
recommended to represent substandard and/or counterfeit medicines [19, 22]. 
 
 
2. THE IMPACT OF POOR QUALITY PHARMACEUTICALS 
Access to medicines of good quality is a basic human right of everyone: it improves the chances of 
successful treatment for the individual patients and promotes better outcomes for public health in 
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general [30-32]. The presence of poor quality medicines in the market is a global threat on public 
health, especially in developing countries by critically challenging the efforts of treatment and control 
of diseases [33, 34]. 
Medicine quality problems could be fatal in extreme clinical outcomes and have also been associated 
with severe economic consequences. More than 700,000 deaths from tuberculosis and malaria have 
been strongly linked with ineffective poor quality medicines worldwide [35, 36]. Mortality has also 
been reported after glycerol contamination in different countries, heparin contamination in the 
United States and Germany, and after using sexual enhancement drugs adulterated with large 
contents of hypoglycemic drugs in Singapore [37-41].  
The WHO estimates that around 10% of all global pharmaceutical supply is counterfeit and 
substandard, reaching up to 50% of the supply in developing countries and as low as 1% in the 
developed world. About 100,000 deaths a year in Africa are linked to the counterfeit drug trade [35, 
42-44].  
The impressive globalization of the pharmaceutical market that characterized the last two decades 
has led to an increased risk of poor quality medicines, where the quality of medicines largely 
depends on the countries’ level of regulation [45]. Counterfeit drugs are estimated to be less than 1% 
of the market in strictly regulated countries, but have been reported ten times more often within the 
last 5 years in the United States [46, 47]. In Europe, the number of counterfeit products increased by 
118% and their confiscations had a relative increase by 57% within one year (2007-2008) [47], a 
trend confirmed by more recent estimations. In developing countries, counterfeit drugs are 
estimated to account for between 10% and 30% of all drugs sold, with rates higher than 30% in some 
regions of South-east Asia, Sub-Saharan Africa and Latin America [48]. In a recent literature review 
44%, 30% and 9% of 163 counterfeit antibiotics were detected in South-East Asia, Sub-Saharan Africa 
and Europe/North America, respectively [47]. Overall, up to 60% of antimicrobials in Africa and Asia 
may have low quality [48].  
The 2015 Nobel Prize in Physiology or Medicine awards discoveries regarding novel therapies for 
some of the most devastating parasitic diseases. Youyou Tu, a Chinese professor born in 1930 in 
China, was awarded for her discovery of artemisinin, a drug that has significantly reduced the 
mortality rates for patients suffering from malaria. However, the circulation of poor quality 
antiparasite medicines including artemisinin containing combination therapies (ACT) is pouring cold 
water on similar innovative endeavors and public intervention strategies. Studies indicated 48% 
mebendazole [49] and 37% antimalarial medicines of poor quality in Nigeria [50]. More than 12% 
poor quality antimalarial medicines were reported in Tanzania [51], while very poor quality 
anthelmintic preparations were reported in Kenya [52]. These findings reveal the importance of 
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addressing similar problems with respect to selected antiparasitic medicines of public health 
importance in Ethiopia.    
Despite different efforts of countering the problems of poor quality medicines, recent literatures still 
report the widespread presence of poor-quality medicines [53].  They also show that there is an 
urgent need to develop more accurate and standardized methods for mapping their distribution and 
characteristics. The knowledge generated by well-designed surveys will inform national regulators for 
identifying and correcting the vulnerabilities of the pharmaceutical supply chain [54].  
To counter the problems associated with poor quality medicines, correct determination of the 
prevalence is of paramount importance [15]. However, determination of the epidemiology of poor 
quality medicines is challenging either due to inaccurate sampling methodologies or randomization 
problems. Moreover, the tests and analytical techniques were often not adequate or insufficient for 
a complete quality assessment, e.g. the important but relatively expensive dissolution test is not 
included in most studies [15, 53]. Therefore, implementation of cost-effective, simple and accurate 
analytical methods that can identify the distribution of poor quality medicines together with effective 
regulatory mechanisms is of paramount importance to reduce this poor-quality problem. 
 
 
3. COUNTERING POOR QUALITY MEDICINES: ANALYTICAL AND 
REGULATORY CONTRIBUTIONS 
As a serious but generally neglected public health problem, poor quality medicines are urged to be 
fought [55]. Various intervention approaches are used in combatting poor quality medicines 
including effective legislation and regulatory mechanism to establish a robust quality assurance 
system that ensures quality of medicines throughout the pharmaceutical supply chain [56, 57]. To 
measure is to know, and hence, there is a need for fast, efficient, simple, robust and transferable 
analytical methods that can be used for detection and analysis of poor quality medicines [58]. 
Moreover, independent medicine quality control laboratories for continuously monitoring the quality 
of medicines throughout the supply chain, i.e. from manufacturing to consumer use, are desperately 
needed [59]. El-Jardali et al. developed a conceptual framework for all the intervention strategies 
against poor quality medicines, presented in Figure 2 [60]. 
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Figure 2. A framework for the different strategies against poor quality medicines. Note: The shaded cells in the 
framework portray areas where evidence about the intervention exists.  (El-Jardali et al. 2015 BMJ Open 
5:e006290). 
 
Factors contributing to poor quality medicines include lack of legislation and weak or absent 
regulatory authorities, and lack of quality control laboratories or field tests.  
 
 
Analytical contributions 
Combatting poor quality medicines requires quality investigation of medicines, and this is based on 
the availability of robust and reliable analytical methods, which preferably should be as fast and 
cheap as possible while possessing high information content [61]. There are diverse techniques to 
analyse pharmaceuticals and identify poor quality medicines, going from simple visual inspections, 
testing of physical properties up to chemical evaluations involving chromatographic separation 
techniques with different detection modes [58, 62].  
A three-level approach proposed by Pribluda et al. consists of different quality control procedures to 
detect poor quality medicines. Level 1 includes inspection to determine the quality of packaging and 
labelling. Level 2 encompasses methods that can be done in the field. Level 3 requires the equipment 
of an established laboratory to determine drug quality according to established specifications [59].  
The visual inspections (Level 1) are a quick and easy way to detect poor-quality medicines. They are 
focussed on labeling, packaging integrity, package information and the appearance of the medicine. 
This visual inspection can make use of comparison of the sample to the authentic product if available 
to verify its falsified status. It is the standard first step in any medicine quality analysis [63].  
Various screening tests could be used to perform Level 2 analyses. Several methodologies are 
currently available for this purpose, such as Raman spectroscopy, infrared spectroscopy, and Thin-
Layer Chromatography (TLC). Taking into account price, availability of required supplies and extent of 
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information that can be gathered, promoting quality of medicines (PQM) currently recommends for 
this level the use of TLC and for solid dosage forms disintegration [59, 64, 65].  
The Global Pharma Health Fund Minilab is a portable drug quality analysis toolkit consisting of 
equipment and instructions for TLC, chemical colorimetry, and disintegration tests, as well as a visual 
inspection protocol. Testing and inspection protocols and materials are included for more than 50 
WHO essential medicines, including reference standards for 63 drug compounds [66, 67]. However, 
field tests are no substitute for definitive laboratory techniques; they cannot test all aspects of a 
product’s quality, including its drug content, impurity profile and dissolution profile. 
Level 3 analyses use the most advanced tests and are the only ones that can assess compliance with 
the formal quality attributes and specifications established during development and approved by the 
competent authorities. These analyses are capable of evaluating content and impurities with more 
accuracy and precision and hence discriminating power, than those described above for level 2 
testing [59].  
The most common L3 analyses that apply to practically all dosage forms are tests for identification, 
strength/content (assay), and impurities (organic, inorganic, and/or residual solvents) and thus 
involve the use of high-tech instruments like high pressure/performance liquid chromatography 
(HPLC), gas chromatography (GC), and mass spectroscopic techniques.  HPLC represents the gold 
standard for chemical separation, quantification and identification [63]; and mass spectrometry (MS) 
has become an important tool for elucidating the structures of low level unknown impurities and 
pharmaceutical degradants because of its unique analytical features [68].  
To reduce the costs, simplicity and speed of analysis is becoming increasingly important in the HPLC 
applications in routine quality assurance (QA)/quality control (QC) activities. High speed analyses 
without loss in separating power can be achieved by reduction of particle size of the column, typical 
characteristics of fused-core Halo® columns [69] stressing the importance of analytical techniques 
involving this fused-core technology in resource-limited settings.   
Impurities present in the active pharmaceutical ingredient (API) have to be identified to make sure 
no mutagenic or toxic substances will be administered to patients. Drug product degradation profiles 
need to be established to guide stable formulation and provide suitable drug shelf life assessment. 
Drug regulatory agencies also have requirements for characterization of the impurity profile of a 
pharmaceutical. The analysis of these low level unknown impurities and degradants can be very 
challenging [70]; and thus the first step in a general analytical strategy is to measure the molecular 
weight (MW) of the unknown by suitable ionization methods, commonly carried out either by 
electrospray ionization (ESI) [71, 72].  
 Moreover, Baert and De Spiegeleer in their investigation of internet-pharmaceuticals recommended 
a cost-efficient tierced system (Figure 3), which starts with the simplest and inexpensive methods. 
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They proposed the tierced approach in assessing the different quality attributes related to the overall 
quality of internet obtained pharmaceuticals. In a first step, the product classification is compared 
with the regional and/or national legislation. Secondly, the labelling and packaging should be 
carefully examined for legal conformity. If more detailed chemical information is required, 
determination of the physicochemical properties of the pharmaceutical product should be a starting 
point, followed by non-destructive chemical testing. In the last stage, destructive analytical 
techniques, often in a remote laboratory, will be applied. Whenever non-conformity is found, the risk 
for public health is to be evaluated, e.g. by toxicity testing. Evidently, pharmaceutical products that 
do not comply should be withdrawn from the market and their origin traced back for legal action 
[73].  
Apart from methods used in countering poor quality medicines and because some advanced 
techniques need a laboratory setting, WHO recommends access to pharmaceutical quality control 
(QC) laboratories which are committed to provision of quality analytical services of international 
standards [74]. With the vision of good quality medicines for every one, WHO launched medicines 
prequalification program in March 2001 starting with essential medicines and expanded to include 
pharmaceutical QC laboratories in April 2004 [75]. From the 39 total list of of prequalified QC 
laboratories published by WHO-Prequalification programme in 2015, only 8 are from WHO Africa 
region and no QC laboratory is prequalified from the horn of Africa [76] outlining the importance of 
such prequalified QC-laboratories to support the quality survey of essential medicines in the region. 
In one way or the other, the analytical technique applied in routine QA/QC activities should be 
robust. Currently, robustness of analytical methods is easily evaluated by using a quality-by-design 
(QbD) principle [77]. As defined by Janet Woodcock in 2004, "QbD means that product and process 
performance characteristics are scientifically designed to meet specific objectives, not merely 
empirically derived from performance of test batches" [78]. International conference on 
harmonization (ICH) Q8(R2) defines quality-by-besign (QbD) as a systematic approach to design and 
develop a product and/or service based on sound science and quality risk management [3]. It is 
already frequently applied in the pharmaceutical industry mainly in the development of 
pharmaceutical products [78-80] and analytical methods [81-85], but is not well established in the 
set-up of facilities like quality control (QC) laboratory triggering the importance of such scientific 
principles in such facilities. 
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Figure 3. Tierced flow chart for quality evaluation of internet pharmaceuticals. NC non-conformity. (Baert B and 
De Spiegeleer B 2010 Anal Bianal Chem 398: 125-136). 
 
 
Regulatory contributions 
To protect public health, governments need to approve comprehensive laws and to establish 
effective national competent authorities to ensure that the manufacture, trade and use of medicines 
are appropriately regulated to ensure the quality, safety and efficacy of medicines used by 
appropriate patients [86]. Medicines regulation, operating within a legal framework, demands the 
application of sound medical, scientific and technical knowledge and skills. It also involves 
interactions between the various stakeholders (manufacturers, traders, patients, health 
professionals, researchers and governments). Key to an effective medicines regulation is the 
government’s political commitment including legal powers, human and financial resources, and 
appropriate strategies and methods to implement the various regulatory tasks [87]. A sound 
medicines regulatory system is essential to combat the problem of poor quality medicines [88]. 
However, according to WHO estimate, nearly a third of its member states currently have very limited 
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medicines regulation [89]. Assessment of medicines regulatory systems in sub-saharan Africa 
indicated that the overall regulatory system presented some critical weakeness (Figure 4) [90], with 
QC-unassignment the largest relative weakness, and thus need to be strengthened. 
 
 
Figure 4. Number of sub-saharan African countries out of 26 surveyed meeting the main function of a 
regulatory authority. Note: NMRA = National medicine regulatory authority (Source: WHO 2010). 
 
Strengthening the medicine regulatory authorities (MRAs) including enforcement possibilities, 
improving quality of production, and facilitating the availability of relatively inexpensive medicines is 
likely to be key factors in improving the overall quality of medicines [14]. Support for MRAs in 
developing countries, and the development of regional pharmaceutical QC laboratories to allow the 
regulation of medicines supply is crucial to allow effective intervention on the problem of poor 
quality medicines.  
Governments in low- and middle-income countries should support their regulatory agencies to 
develop strategic plans for compliance with international manufacturing and quality control 
standards. In the least developed countries, international organizations should support their efforts 
[91]. As poor quality medicines are a global problem and the capacities of national MRAs in 
developing countries is currently limited, they can only be combatted by regional and international 
collaboration. Attaran et al. [22] and Binagwaho et al. [88] thus proposed the need of a global treaty 
to guarantee sustainable progress towards higher quality medicines by bringing regulatory, technical, 
legal, and financial mechanisms together (Figure 5). 
A binding international law under the form of a treaty on drug quality is needed to complement the 
existing trade treaties, putting public health on an equal plane. A successful treaty is considered a 
first step to counter the problem of poor quality medicines. The growing political energy to fight poor 
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quality medicines could, if wisely channelled into a treaty, provide new financing and reinforced 
capabilities against poor quality medicines [22]. 
 
 
Figure 5. Elements of a treaty to improve the safety of medicines. The figure shows the linkages between treaty 
elements (green), directly supported actions (red), and supporting information exchanges (orange).  (Attaran et 
al., 2012 BMJ 345: e7381). 
 
Next to a treaty, regional co-ordination of medicines regulatory activities is another approach to 
overcoming resource constraints. Regional co-operation can help participating countries to share 
expertise and experience, support each other in implementing national drug strategies, and, 
ultimately, avoid duplication, thereby making the best use of scarce regulatory resources, very 
similar to the European regional regulatory systems. In Africa, the East African Community (EAC) and 
Southern African Development Community (SADC) are pursuing harmonization, supported by a new 
initiative called the African Medicines Registration Harmonization Initiative (AMRHI). The goal of 
AMRHI is to foster regionalization of certain aspects of medicines regulation within economic 
groupings in Africa [26, 92]. Such regulatory harmonizations and collaborative initiatives are however 
only deemed to be succesful if the current national legal-regulatory status is well-known, inter-
nationationally compared as well as to benchmark it versus internationally accepted standards.  
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4. OBJECTIVES OF THE THESIS 
High quality medicines should be accessible to the community in developing countries to control 
diseases of public health problem. The spread of poor quality medicines worldwide and particularly 
in developing countries are seriously affecting the success of patient treatments. WHO reported that 
6% of medicines worldwide are poor quality [93]. According to the US Food and Drug Administration 
(FDA), poor quality medicines may account for more than 10% worldwide; and up to 25% of all 
medicines in developing countries have low quality [94]. Therefore, to guarantee an access of 
populations to safe and sure medicines, it is important to set up appropriate measures that will allow 
evaluating and preserving the quality of those medicines. Different intervention approaches are used 
in combating poor quality medicines including effective legislation and regulatory mechanism to 
establish a robust medicines quality assurance system throughout the pharmaceutical supply chain 
[56, 57]; fast, efficient, simple and transferable analytical method that can be used for detection and 
analysis of poor quality medicines [58]; and medicine quality control laboratory for continuous 
montoring of the quality of medicines [59]. Therefore, the global objective of this thesis is to increase 
the quality of medicines in Ethiopia.  
In order to address this goal, different questions are put forward as objectives:  
1. Is it possible to set up a well functioning and an accredited pharmaceutical quality control 
laboratory in resource-limited setting? 
A quality-by-design (QbD) principle will be applied to establish an accredited pharmaceutical 
QC laboratory in Ethiopia. Analoguous to process/product QbD and analytical QbD, 
laboratory QbD will be introduced. Quality scheme based on WHO-prequalification 
supported by ISO/IEC 17025 2005 requirements will be applied for prequalification and 
accreditation. The first objective was thus to set up a well functioning and an accredited 
pharmaceutical QC laboratory in Jimma, Ethiopia. 
2.  Could suitable analytical methods be developed for artemisinin-based anti-malarial 
medicines? 
Artemisinin-based (ACT) anti-malarial medicines are recommended by WHO as a first-line 
treatment for malaria. However, the current artemisinin FDC products, such as β-artemether 
and lumefantrine, are inherently unstable and require controlled distribution and storage 
conditions, which are not always available in resource-limited settings. Moreover, quality 
control is hampered by lack of suitable analytical methods. Thus, there is a need for a rapid 
and simple, but stability-indicating method for the simultaneous assay of β-artemether and 
lumefantrine FDC products. The second objective was thus to develop suitable analytical 
methods for artemisinin-based antimalarial medicines. 
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3. How is the quality of ACT anti-malarial medicines in Ethiopia? 
Ethiopia is one of the malaria-endemic countries in sub-Saharan Africa, where fixed-dose 
combination products of artemether and lumefantrine have been used for the treatment of 
uncomplicated Plasmodium falciparum malaria. However, there is a little existing knowledge 
about quality of ACT anti-malarial medicines currently available in the market. The third 
objective was therefore to verify the dichotomous quality of artemisinin-based fixed-dose 
combination anti-malarial medicines circulating in Ethiopia.   
4. What is the prevalence of poor quality medicines used for the treatment of neglected 
tropical diseases in Ethiopia? 
Access to medicines of good quality improves the chances of successful treatment for 
individual patients and promotes better outcomes for public health in general. However, the 
presence of poor quality medicines in the market is a global threat on public health, 
especially in developing countries by critically risking efforts of treatment and control of 
diseases in general and the NTDs in particular. Conventionally, medicine quality has been 
ignored in NTDs, though scattered reports show that serious problems exist. Therefore, the 
fourth objective was to determine the prevalence of poor quality medicines for soil-
transmited helminths and giardia in Ethiopia. 
5.  How is pharmaceutical regulatory framework in Ethiopia? 
Effective and enforceable national regulations describing the manufacture and (re)packaging, 
export and import, distribution and storage, supply and sale, information and pharmaco-
vigilance of medicines are required to consistently ensure optimal patient benefit. Expansion 
of pharmaceutical industries in many countries with advancement in transport technologies 
facilitated not only trade of genuine pharmaceutical products, but also the circulation of 
poor quality medicines across the globe. One of the different intervention approaches used 
in combating poor quality medicines is having effective legislation and regulatory 
mechanism. The fifth objective is thus to investigate the current regulatory frame of 
medicines in Ethiopia, looking at the challenges for future improvements aiming at 
strengthening the system which will increase the quality of medicines. 
 
 
5. THESIS OUTLINE 
The thesis outlines quality of selected medicines in Ethiopia by broadly exploring the evidence from 
both analytical and regulatory perspectives.  
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In Chapter II, the application of a quality-by-design (QbD) principle in setting up a functional and 
accredited pharmaceutical quality control laboratory is presented. The different concepts of QbD are 
presented; analoguous to process/product QbD, a new concept of laboratory QbD is introduced.  
In Chapter III, quality analytics of lumefantrine is presented. HPLC/UV/MS impurity profiling and in-
silico toxicity evaluation results of the different lumefantrine impurities are addressed. Moreover, 
the development and validation of a new stability-indicating gas chromatographic (GC-FID) method is 
documented for the routine regulatory QC application in resource-limited settings.  
In Chapter IV, the development and validation of a rapid, simple and suitable stability indicating 
HPLC-UV for the simultaneous determination of artemether and lumefantrine in fixed dose 
combination products is clearly presented. Moreover, the result of the dichotomous quality 
evaluation of artemisinin-based anti-malarial medicines circulationg in Ethiopia is presented.  
In Chapter V, nationwide quality survey results for two commonly used anthelminthic drugs (MEB 
and ALB) and one antiprotozoal drug (TNZ) in Ethiopia is presented. The analytical results are 
converted into conclusions using two systems: the traditional dichotomous pharmacopoeial 
specification-compliance based approach and the risk-based Taguchi quantitative desirability 
approach. Moreover, the prevalence of poor quality of the three medicines is clearly determined and 
presented. 
In Chapter VI, the pharmaceutical regulatory approval system of Ethiopia is presented 
recommending risk-based regulatory mechanisms. It is clearly described that from legislative point of 
view, the medicines regulation system in Ethiopia fulfils the minimum criteria for effective medicines 
regulation. However, the high prevalence of poor quality medicines documented in chapter V reveal 
that the mere existence legislation and regulatory mechanism is not a guarantee unless strengthened 
for effective implementation of all the regulatory functions. 
In summary, a graphical representation of the different aspects investigated in this work is given in 
Figure 6. 
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Figure 6. Graphical representation of the different aspects investigated. 
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CHAPTER II 
 
QUALITY-BY-DESIGN 
PRINCIPLES APPLIED TO THE 
ESTABLISHMENT OF A 
PHARMACEUTICAL QUALITY 
CONTROL LABORATORY IN 
A RESOURCE-LIMITED 
SETTING: THE LAB-WATER 
 
 
 
"Quality in a service or product is not what you put into it. It is what the 
client or customer gets out of it." 
   
 Peter Drucker 
(°1909 - †2005, Austrian-born American management writer) 
 
 
 
Parts of this chapter were published: 
 
Suleman S, Belew S, Duchateau L, De Spiegeleer B et al. Quality-by-Design principles applied in the 
establishment of a pharmaceutical quality control laboratory in a resource-limitted setting.  
Manuscript under preparation. 
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ABSTRACT 
Quality-by-Design (QbD) is defined as a systematic approach to design and develop a product/service 
based on sound science and quality risk management. It is already frequently applied in the 
pharmaceutical industry mainly in the development of pharmaceutical products as well as analytical 
methods, but is not well established in the set-up of facilities like quality control (QC) laboratory. 
Therefore, this research reports the application of some risk-based scientific QbD principles in the 
establishment of a pharmaceutical QC laboratory in a resource-limited setting with focus on the 
laboratory water. 
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CHAPTER II 
QUALITY-BY-DESIGN PRINCIPLES APPLIED 
TO THE ESTABLISHMENT OF A 
PHARMACEUTICAL QUALITY CONTROL 
LABORATORY IN A RESOURCE-LIMITED 
SETTING: THE LAB-WATER 
Main focus in this chapter: 
 To establish a pharmaceutical quality control (QC) laboratory in Jimma University, Jimma, 
Ethiopia that can contribute to QC analytics of medicines to the Horn of Africa.  
 To present a quality-by-design (QbD) based establishment for obtaining laboratory water.  
 
1. INTRODUCTION 
The term quality-by-design (QbD) was created in 1970s by the quality expert Joseph M Juran and 
popularized in the 1990s [1]. Within the pharmaceutical field, International Conference on 
Harmonization (ICH) Q8(R2) defines QbD as a systematic approach to development that begins with 
pre-defined objectives and emphasizes product and process understanding and process control based 
on sound science and quality risk management [2]. US Food and Drug Administration (FDA) describes 
QbD as one arm of the quality system based on building quality in the development phase and 
throughout a product’s life cycle [3]. QbD as applied in the pharmaceutical industry is thus defined as 
a risk-based and proactive approach to pharmaceutical development [4]. In general, these definitions 
indicate that quality must be designed and built into product or service [5-8].  
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The principles for the successful implementation of QbD for product development involve: 
identification of the product attributes, such as a quality target product profile (QTPP) and critical 
quality attributes (CQAs); design space (the relationship between process inputs and CQAs); a robust 
control strategy to ensure consistent process performance; and finally, ongoing monitoring to ensure 
robust process performance over the life cycle of the product [5, 6]. ICH Q8 (R2) defines QTPP as a 
prospective summary of the quality characteristics of a drug product that ideally will be achieved to 
ensure the desired quality, taking into account safety and efficacy of the drug product. QTPP forms 
the basis of design for product development. Once QTPP has been identified, the next step is to 
identify the relevant CQAs. A CQA is defined as a physical, chemical, biological or microbiological 
property or characteristic that should be within an appropriate limit, range, or distribution to ensure 
the desired product quality [2]. 
The QbD principle applied to product development is called product QbD (pQbD). These same QbD 
principles have also been applied to the development of analytical methods [9-12]. The concept of 
QbD applied to analytical method development is known as analytical QbD (aQbD) [13]. Equivalent to 
pQbD, aQbD plays a key role in the pharmaceutical industry for ensuring the product quality. 
Analytical QbD has different tools such as analytical target profile (ATP) establishment, CQAs, risk 
assessment, method optimization and development with design of experiment (DoE), method 
operable design region (MODR) and control strategy [14].  It helps in the development of a robust and 
fit-for-purpose analytical method [15].  
The ATP and MODR parallel the QTPP and design space defined for a product and its manufacturing 
process. MODR is a multidimensional space based on the method factors and settings that provide 
suitable method performance [15-20]. DoE incorporates a set of characteristics which are essential in 
aQbD and is used for screening of factors, process characterization and optimization of multiple 
responses [21, 22]. Therefore, the steps, tools, and approaches developed for application of QbD to 
manufacturing processes have analogous application in the analytical environment [23].  
Applying the principles and concepts of pQbD and aQbD, a risk-based and robust quality management 
system can be built into quality control (QC) laboratories starting from establishment to  provide 
enhanced flexibility and continuous improvement [18, 24] by reducing variations and producing 
consistent results.  
QC laboratories should generate reliable and traceable analytical quality data that meet user 
requirement specifications (URS). To ensure this, the laboratory needs a well-founded, effective, 
comprehensive and defensible quality system in place [25, 26]. To establish such a system, prior 
knowledge of attributes that critically affect quality of analytical results of the QC laboratory is 
important. Literature indicates that human factors, accommodation and environmental conditions, 
methods, equipments, sampling and sample preparations, and handling of analytical procedures are 
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some of the critical attributes [26-28]. Understanding these attributes and organizing them into a 
quality system can benefit a scientific risk-based approach. Even though information is scarce with 
regard to the application of such risk-based QbD approaches in pharmaceutical QC laboratories, there 
are indications of the usefulness of risk-based approaches to define analytical quality in clinical 
laboratory medicine [29, 30]. Therefore, this chapter reports for the first time the application of risk-
based scientific QbD principles in the establishment of a pharmaceutical QC laboratory in a resource-
limited setting, i.e. the Jimma University Laboratory of Drug Quality (JuLaDQ). In addition to the 
existing product and analytical QbD principles, laboratory QbD (lQbD) concept is introduced and will 
be thus developed using laboratory water as an important part.  
 
 
2. METHODS 
With the objective to contribute to the quality of medicines in Ethiopia and the Horn of Africa by QC 
analytical activities, the issue of establishing a pharmaceutical QC laboratory came into picture. 
Central strategic questions were first defined: (1) what is the purpose of the QC laboratory? (2) what 
standards are required? and (3) what are the laboratory user requirements? Laboratory quality 
attributes that must be considered during establishment and affect the performance of the 
established pharmaceutical QC laboratory were clearly defined and assessed. The laboratory quality 
attributes were then sorted out and criticality of each quality attribute was evaluated based on the 
existing set-up, the purpose of the QC-laboratory (provision of QC-analytical services) and the 
required standard (world health organization and if deemed required, supplemented with Ph. Eur. 
(EDQM) and USP standards). These attributes were considered to design the QC laboratory workflow, 
based upon which JuLaDQ was physically established and became a running pharmaceutical QC 
laboratory. Applying efficient control strategies for each of these attributes, a quality management 
system model based on WHO standards [31], supplemented with guidance from the international 
standards ISO/IEC17025: 2005 [32] was applied. Analogous to pQbD and aQbD, lQbD was thus defined 
and formally recognised, during the recent prequalification inspection by the WHO inspection team 
[33]. This chapter outlines the laboratory water system. 
 
Experimental 
Materials and reagents 
Distilled water was obtained by distillation apparatus (W4000, Bibby Scientific, UK) while ultrapure 
water used as gradient solvent was obtained by a commercially available water purification system 
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(Nanopure Analytical ultrapure water system, model number 7143, Thermofischer Scientific). HPLC 
grade acetonitrile (Fisher Scientific, UK) was used for gradient HPLC while all other chemicals used in 
this study were analytical grade and used as received. 
 
Procedures 
Practical experiments were conducted to evaluate different quality parameters with the objective of 
identifying the fit-for-purpose laboratory water for the QC analytical activities of JuLaDQ. Total 
chromatographic peak area was calculated for tap water, distilled water (before system cleaning), 
distilled water (after system cleaning) and ultrapure water from gradient high performance/pressure 
liquid chromatography (HPLC) analysis conducted using the following method: Agilent 1260 Infinity 
series HPLC, column: Purosphere C18 (4.0 mm x 250 mm, 5 μm, pore size 80 Å with guard column), 
mobile phase: gradient water/acetonitrile, gradient flow rate 2.0 ml/min, run time: 30 min and 
detection using diodearray detector (DAD) with quantification at 210 and 254 nm [34]. Detail of the 
gradient elution system is presented in Table 1.  
 
Table 1. Gradient elution of the mobile phase. 
# Time (min) % Water % Acetonitrile  
1 0.0 100.0 0.0 
2 1.0 100.0 0.0 
3 21.0 0.0 100 
4 30.0 0.0 100 
 
UV-absorbance values for the four water grades was obtained using UV-Visible spectrophotometer 
(Celil instruments CE 7200, Cambridge, England) at wavelength of 210 and 254 nm. Similarly, 
conductivity (μS/cm) was tested using a multi-range conductivity meter (HI9033, Hanna instruments, 
Portugal) for the different water types produced in JuLaDQ. Moreover, different tests were conducted 
on tap water, distilled water and ultrapure water of JuLaDQ to evaluate their quality according to 
WHO water R quality requirements [35].  
A pilot water R stability study was conducted using HPLC to set the time period for which water R 
could be used without compromising its quality. The water was stored in a 4-liter sodalime glass (type 
III) with black plastic closure (Wheaton, USA) standing upwards mimicking normal use, under room 
temperature (15-30˚C). Gradient HPLC analysis was conducted on three consecutive days: day 0, day 
1, and day 2.    
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3.  RESULTS 
The predefined purpose of the pharmaceutical QC laboratory to be established was production of 
reliable analytical QC results, which are essential to take correct decisions on medicines. Therefore, 
the design and establishment of the QC laboratory considered those factors which affect the quality of 
analytical results [25]. In line with this, JuLaDQ was established in Jimma University, Jimma, Ethiopia 
with the main objective to contribute to the quality of medicines in the Horn of Africa region by QC 
analytical activities (e.g. surveys, inspection-supporting, industrial/governmental release of 
medicines). To this end, JuLaDQ has implemented a quality management system, based on WHO, 
European GMP and ISO/IEC17025 (2005) GLP standards [31, 32, 36]. 
 
Table 2. WHO quality requirements in QC laboratories as implemented in JuLaDQ [31]. 
Quality attributes Specifications 
Personnel and 
organization 
Personnel Qualified, trained and experienced 
Legal basis and organization Legal establishment and proper organizational 
structure 
Analytical 
workflow 
Sampling 
 
Appropriate sampling plan and sample 
documentation 
Samples 
 
Samples unique identification and integrity during 
transport and storage 
Test results Appropriate monitoring and evaluation 
Test reports Include test results, and details of sample and test 
conditions 
Records Data integrity and availability 
Methods Proper validation 
Equipment Calibration, servicing and maintenance 
Lab environment Temperature and humidity monitoring and control 
Documentation control Written standard operating procedures for each 
activity 
Out-of-specifications Corrective and preventive actions 
Customers  Complaint handling 
Contracts  Supplier and sub-contractor management 
Quality audits Continuous internal and external quality audits 
 
The establishment of JuLaDQ applied the risk-based QbD principles. The target laboratory 
performance is compliance to quality standards set by WHO quality requirements to obtain the 
prequalification status. Similarly laboratory quality attributes were defined and analogous to pQbD 
and aQbD, the term lQbD is hence introduced. One example of the lQbD activity is the risk 
assessment, visualized by the Ishikawa (Fish-bone) diagram, used in the establishment of JuLaDQ 
(Figure 1).  
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Table 3. General laboratory water types and specifications according to different standards.  
Parameter (unit) 
Standards and specifications 
American Society for Testing and 
Materials (ASTM) 
National Committee for 
Clinical Laboratory 
Standards (NCCLS) 
College of American 
Pathologists (CAP) 
e
Ph. Eur.  
Type 1 Type 2
a 
Type 3 Type 4 Type I Type II Type III Type I Type II Type III 
c
Water R Water for chromatography 
Conductivity at 25 
˚C (μS/cm) 
0.056 1.0 0.25 5.0 0.1 1 10 0.1 0.5 10.0 5.1 
Deionized water R with a 
resistivity not less than 18 
MΩ.cm 
Resistivity at 25 ˚C 
(MΩ.cm) 
18.0 1.0 4.0 0.2 10 1 0.1 10.0 2.0 0.1 0.2 
TOC (μg/l) 100 50 200 NL 50 200 1000 NS NS NS 500 
Sodium (µg/l) 1 5 10 50 NS NS NS NS NS NS NS 
Chloride (µg/l) 1 5 10 50 NS NS NS NS NS NS 
d
Colour 
reaction 
Silica (µg/l) 3 3 500 NL 5 10 100 5 100 1000 NS 
Total solids (mg/l) NS NS NS NS 0.1 1 5 NS NS NS NS 
Bacteria (CFU/ml) 
b 
10 1000 NS 10 1000 NS 100 
Endotoxins 
(IU/ml) 
NS NS NS NS NS NS 0.25 
TOC: total organic carbon, NL: no limit, NS: not specified 
a
Prepared by distillation (= Distilled water)  
b
When bacteria levels need to be controlled, ASTM further classifies reagent grade water types into type A (bacteria: 1CFU/100 ml, endotoxins: 0.03 EU/ml),  type B (bacteria: 10CFU/100 ml, 
endotoxins: 0.25 EU/ml), type C (bacteria: 1000 CFU/100).  
c
Water R: purified water in Ph. Eur. with additional specifications for heavy metals: 0.1 ppm, nitrates: 0.2 ppm, aluminium: 10 ppb, and ammonium: 0.2 ppm. 
d
The colour from solution prepared by addition of water R (10 ml) + dilute nitric acid R (1 ml) + silver nitrate solution R2 shows no change in appearance for at least 15 min. 
e
Other R-types described in the Ph. Eur. for special analytical purposes include: water, distilled (water R prepared by distillation); water, distilled, deionized (deionized water R prepared by 
distillation with a resistivity 18 MΩ.cm); water, ammonium-free; water, carbon dioxide-free (water R boiled for a few minutes and protected from the atmosphere during cooling and storage 
or deionized water R with resistivity 18 MΩ.cm); water, nitrate-free; and water, particle-free (water R filtered through a membrane with a pore size of 0.22 μm).   
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Figure 1. Ishikawa diagram for risk assessment in JuLaDQ laboratory. 
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Laboratory QbD workflow as applied to the establishment of JuLaDQ is presented in Figure 2. The 
overall laboratory quality attributes (LQA) affecting quality of analytical results (laboratory 
performance) were found to be laboratory design, environment, sample, method, personnel, 
equipment, consumables and quality control procedures. Accordingly, appropriate GLP/GMP is being 
maintained in JuLaDQ by implementing appropriate workflow of samples and test data according to 
the WHO standards (Table 2). Moreover, laboratory water was used as a typical but critical QbD-flow 
example (Figure 2) to demonstrate lQbD. Internationally recognised laboratory water quality 
standards define different types presented in Table 3 [37-40].    
Since a single water purification unit operation process could not consistently and with sufficient 
robustness provide the Ph. Int. water R quality requirements,  a customized water purification system 
combining different feasible and setting-suitable water purification processes including filtration, 
distillation, and ultrapure water purification technology (reverse osmosis (RO) and ultra-filtration) was 
set-up as presented in Figure 3. 
 
Table 4. Typical analytical quality results of water R according to Ph. Int. 
# Test Specification limit 
Compliance (√)/Non-compliance (x) 
Ultrapure 
water 
Distilled 
water* 
Tap water 
1 Heavy metals 
Color not darker than the same 
untreated purified water 
√ √ x  
2 Ammonia 
Color of test solution is not more 
intense than standard solution 
√ √ √ 
3 
Calcium and 
magnesium 
Pure blue color  √ √ √ 
4 Chlorides Clear and colorless   √ √ √ 
5 Nitrates  
No blue color appeared at the 
interface of the two liquids 
√ √ √ 
6 Sulfates Clear and colorless  √ √ √ 
7 
Oxidizable 
matter  
Faintly pink test solution √ √ √ 
8 
Non volatile 
residue 
<0.001% √ √ x 
9 Alkalinity/acidity 
No red color up on addition of 
methyl blue and no blue color 
appears up on addition of 
bromothymol blue 
√ √ √ 
*After cleaning 
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The typical analytical quality results of the three water types produced in JuLaDQ (tap water, distilled 
water and purified water) according to Ph.Int water R quality requirements is presented in Table 4, 
while the overall analytical quality for the different water grades is presented in Table 5.  
 
 
Figure 2. Laboratory QbD workflow and its application to laboratory water. 
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Table 5. Overall analytical quality of different water grades in JuLaDQ using different parameters. 
# Water type Typical chromatogram 
Total peak area 
(mAU*s) 
UV-absorbance (AU) Conductivity (μS/cm) 
(resistivity in MΩ.cm) 
Water R Ph. Int. 
compliance 
210 nm 254 nm 210 nm 254 nm 
1 Tap water 
 
92435 8520 0.623 0.111 503 (0.002) Did not comply 
2 
Distilled water 
before cleaning 
 
88206 7199 0.399 0.107 0.53 (1.9) NA 
3 
Distilled water 
after cleaning 
 
43384 3551 0.317 0.097 0.52 (1.9) Complies  
4 Ultrapure water 
 
722 59 0.098 0.054 0.055 (18.2) 
Complies 
 
NA: Not applicable 
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The results of the pilot HPLC stability study for ultrapure water is presented in Table 6. 
 
Table 6. Pilot HPLC stability results of ultrapure water for three consecutive days (sodaline glass (type III) 
container with black plastic closure, standing upwards mimicking normal use, under room temperature (15-30˚C)). 
# Experiment Time (hr) Total peak area (mAU*s) 
1 Day 0 0 12.9 
2 Day 1 24 12.8 
3 Day 2 48 68.7 
 
 
 
Figure 3. Customized JuLaDQ water purification system. 
 
 
4.  DISCUSSION  
An important point in designing a pharmaceutical QC laboratory for improved quality based on the 
QbD principles is defining causes of variability and devising appropriate control strategies in order to 
reduce the associated risks of laboratory performance. The cornerstone concepts in such lQbD 
principles are target laboratory profile (TLP), laboratory quality attributes (LQA), risk assessment, 
critical process parameters (CPPs), control strategy, and continuous improvement (Figure 1).  
Quality target profile (QTP) forms the basis of QbD, which is in relation to the predefined objective 
criteria. The concepts of analytical target profile (ATP) and Target Product Profile (TPP) described and 
defined in ICH Q8 [2] parallel lQbD’s target laboratory profile (TLP). TLP is therefore the prospective 
summary of the quality characteristics of a QC laboratory that ideally will be achieved to ensure the 
desired quality standard. For a QC-laboratory, it implies developing quality system based on 
regulatory requirement guidelines: good laboratory practices (GLP) and/or good manufacturing 
practices (GMP). TLP is compliance to the requirements of good practices for pharmaceutical quality 
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control laboratories (GPQCLs) set by WHO [31] supported mainly by the international standards 
ISO/IEC 17025:2005 [32], which is the prime target for JuLaDQ.  
High quality material and consumables are critical for efficient and precise laboratory performance. 
The quality of reagents can influence quality of test results. For example, reagent water quality affects 
nearly every aspect of HPLC analysis, from sample and standard preparation to column rinsing and 
elution. That makes water the largest reagent consumed in terms of volumes. Between 70% and 80% 
of HPLC performance problems are attributable directly to the quality of water used in preparing HPLC 
eluents, standards, and samples. Poor quality water reduces chromatographic performances by 
affecting resolution and integration, introducing ghost peaks, altering stationary phase selectivity, and 
impacting baselines [41]. Therefore, water R quality is critical for pharmaceutical QC laboratories 
performance.  
Many analytical scientists consider water quality to be one of the critical factors that influence 
accuracy and reliability of the obtained analytical results. Water is used to prepare buffers, blanks, 
controls, sample solutions, and mobile phases in analytical procedures [42]; and using the appropriate 
water quality is of utmost importance in a resource-limited environment where the costs and handling 
also play a role. As our main objective is setting up a QC medicine laboratory according to WHO 
accepted standards, analytical water as defined in the Ph. Int. (water R) is our (minimum) quality 
target.  
For accurate and reliable analytical results obtained from pharmaceutical QC laboratories, water R 
according to Ph. Int. is critical since Ph. Int. methods are/will be mostly used in JuLaDQ. The general 
quality attributes for laboratory water were listed down to be conductivity/resistivity, turbidity, 
microbial content, endotoxins and total organic carbon (TOC) [43-46]. However, TPP reveals that the 
product water should comply with water R requirements set in Ph. Int., and the LTP indicates that 
JuLaDQ is not meant to perform biological and/or microbiological tests; the CQAs for laboratory water 
are those attributes which are described in Ph. Int. Therefore, CQAs for laboratory water include 
heavy metals, ammonia, calcium and magnesium, carbon dioxide, chlorides, nitrates, sulphates, 
oxidizable matter, non-volatile residue and acidity or alkalinity [35].     
To clearly define and identify critical water purification process parameters (CPPs), a number of 
practical experiments were conducted. The literature specifications for different water types (Table 3) 
revealed that no single water purification unit operation process could provide the TPP, analytical 
quality water R of the Ph.Int. Therefore, a customized water purification system combining different 
CPPs including filtration, distillation, and nanopure water purification technology was designed and 
installed (Figure 3).  
Since biological and/or microbiological testing of medicines is currently not performed in JuLaDQ, 
microbial content and endotoxins tests were not defined to be current critical quality attributes.  
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The practical experimental results (Table 4) indicated that not only ultrapure water but also distilled 
water comply with the water R analytical quality specification set in Ph. Int. making cost estimation for 
production of both water types very demanding in such a resource-limited setting. Therefore, the QTP 
was evaluated not only towards the water quality target, but also towards operational cost (Table 7).   
 
Table 7. Estimated cost per liter for production of water R (distilled and ultrapure water) in JuLaDQ. 
1
Water R 
(Ph. Int.) 
Equipment 
name 
Equipment  
cost (USD) 
1
Equipment 
cost/l (USD) 
Operation cost (USD) Subtotal 
cost/l 
(USD) 
2
Total 
cost/l 
(USD) 
Electricity 
cost/l 
Consum
-ables/l 
Operator/l 
Distilled 
water  
Merit Still, 
W4000 
(Bibby 
Scientific, 
UK) 
 
1,270.00 
 
0.3 0.013 0.0001 0.3 0.6 0.6 
Ultra 
Pure 
water  
Nanopure 
Analytical 
ultrapure 
water 
system, 
Model # 
7143 
(Thermo 
Scientific, 
USA) 
 
8,500.00 
 
1.7 0.0001 0.4 0.5 2.6 
3
3.2 
1
Five years (250 weeks) depreciation and 20 l water/week was used for calculation. 
2
The total cost to produce 1l ultrapure water includes cost of distilled water/l since distilled water is used as feed water. 
3
HPLC-gradient grade packed water/l costs 60 USD. 
 
Cost for the production of both distilled and ultrapure water was estimated with the assumption that 
equipment depreciates after 5 years (about 250 weeks) with 20 l water consumption per week in the 
actual setting. Hence both equipment and operational cost per liter of water produced for each water 
R types was calculated providing the total cost per liter for each product. It is obvious that the cost of 
production of ultrapure water (3.2 USD/l), which also includes the cost for distilled water, is about five 
times higher than that of distilled water (0.6 USD/l). However, the water R quality specification set in 
Ph. Int. is the minimum requirement, and distilled water of JuLaDQ does not meet the quality 
requirements of water for chromatography set in Ph. Eur. since its resistivity (1.9 MΩ.cm) (Table 5) is 
by far less than the minimum resistivity requirement (≥ 18 MΩ.cm) (Table 3). Moreover, the cost of 
purchasing HPLC-grade packed purified water is 60 USD/l, which is unimaginable in such a resource-
limited setting. Therefore, production of the ultrapure water (resistivity = 18.2 MΩ.cm) which 
complies with the resistivity requirement set in Ph. Eur.  is very demanding, specially in the case of 
gradient HPLC systems.  
In Ph. Int., most often only isocratic system is used for cost and ruggedness reasons. However, some 
analytical methodologies require gradient HPLC at longer retention times making the gradient system 
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more demanding even in resource-limited settings. Moreover, since in the future, we need to include 
endotoxin test, the ultrapure equipment is able to produce water for bacterial endotoxin test (BET) 
according to Ph. Int.    Therefore, even though there was considerable variation in the resistivity values 
(MΩ.cm) between the two water types, and since resistivity is not a formal quality specification for 
water R in Ph. Int., it is possible to conclude that the ultrapure water (resistivity = 18.2 MΩ.cm) could 
be preserved for gradient HPLC experiments and the proposed future BET, while the distilled water 
can be utilized for isocratic HPLC analysis, glassware cleaning and rinsing analytical activities. 
Standards and norms such as ASTM D1193 specify that water be drawn and used within 8 hr, which 
might not be practical in actual settings. Therefore, optimal time of use should be established and  the 
pilot stability study results (Table 6) reveal that water R can be used for 48 hr without degrading in its 
quality if stored under normal conditions upwards in a sodalime glass (type III) container tightly 
covered with plastic stoppers.  
In pQbD, control strategy is a planned set of controls derived from current product and process 
understanding that assures process performance and product quality. The controls can include 
parameters and attributes related to the product and inputs, facility and equipment operation 
conditions, in-process controls, finished product specifications, and the associated methods and 
frequency of monitoring and control [18, 47].  In aQbD, control strategy includes the system suitability 
tests (SSTs) and revalidation aspects whenever need. Similarly, appropriate SSTs are employed as 
control element to ensure that consistent quality of water R according to Ph. Int. is maintained. 
Routine SSTs for water R are currently not included in Ph. Int., but essential to ensure consistent 
product quality. Moreover, all the quality parameters indicated in the Ph. Int. are qualitative colour 
reactions, and no quantitative specification limits are set. Therefore, our proposed SSTs are new 
elements in the routine control strategy for water R according to Ph. Int.  
The experimental results with regard to the overall analytical quality evaluation of different water 
grades in JuLaDQ (Table 5) indicated that HPLC chromatograms (and the global peak area at 
wavelength of 210 and 254 nm) and conductivity/resistivity are parameters that have strong 
discriminatory effect between different water types than UV-absorbance. In the chromatograms, it is 
observed that there was rise in baseline, number and size of peaks obtained across ultrapure, distilled 
(after and before cleaning), and tap water. Quality parameters like the global peak area (mAU*s) at 
210 and 254 nm, conductivity (μS/cm) (reverse for resistivity (MΩ.cm)) and UV-absorbance (AU) are 
increasing in similar fashion, but with different rates. For example, the ratio of HPLC chromatogram 
global peak area (mAU*s) at 254 nm for distilled water to ultrapure water was found to be 60.2 while 
the same ratio from the UV-absorbance (AU) was only 1.8. Similarly the ratio of resistivity (MΩ.cm) 
between tap and distilled water indicated very significant figure (967.3). Therefore, both HPLC 
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chromatogram global peak area (mAU*s) (at 210 and 254 nm) and resistivity (MΩ.cm) at 25 ˚C should 
be utilized as the routine SST parameters and need to be controlled.  
Using the HPLC chromatograms global peak area (mAU*s) at 210 and 254 nm (Table 5), it is possible to 
effectively discriminate between different water qualities based on compliance to water R quality 
requirements set in Ph. Int. For example, the global peak area (mAU*s) at 254 nm for distilled water 
that complies with water R (Ph. Int.) was 3,551 while that of tap water that failed the water R quality 
requirement was 8,520. Therefore, it is very logical to propose a specification limit of 5,000 mAU*s for 
global peak area at 254 nm as an SST parameter. Similarly, we propose a specification limit of 5,500 
mAU*s for the global peak area at 210 nm. These HPLC-UV SSTs are an alternative for TOC (total 
organic carbon), which requires additional and expensive equipment. 
According to ASTM, water type 2 is produced by distillation and is similar to distilled water in JuLaDQ, 
which complies with water R in Ph. Int. The resistivity (MΩ.cm) for water type 2 (= distilled water) is ≥ 
1.0, a value which can be taken as a routine SST specification for water R. 
 
Table 8. Specifications for system suitability test parameters (Resistivity and HPLC/DAD global peak area) for 
water R of Ph. Int. 
# System suitability test (SST) 
1
Specification set for water R,  Ph. Int. 
1  Resistivity at 25 ˚C (MΩ.cm) ≥ 1 
2 
HPLC chromatogram global 
peak area (mAU*s)   
254 nm < 5000 
210 nm < 5500 
1
Proposed specifications which will be followed-up in the control strategy and adapted if required.  
 
The proposed specification limits will be followed-up in the control strategy and adapted if required. 
Every month, a sample from each water R in JuLaDQ will be taken and subjected to full analysis (Ph. 
Int. tests, HPLC/DAD, UV-absorbance, conductivity/resistivity). Control chart will be constructed and 
the upper control limit (UCL) and lower control limit (LCL) will be calculated for each of the proposed 
SSTs parameter, and the currently proposed SST specification limits evaluated.  
As such effective control strategy for water R quality is currently being implemented in JuLaDQ; 
continuous improvement fundamentally aims to reduce the common causes of variability over these 
SSTs parameters. For pharmaceutical QC laboratories, continuous improvement could be achieved 
through quality meetings (e.g. JuLaDQ has a formal and documented management review meeting 
once annually). This management review seeks to widely and properly evaluate comprehensive 
information from different sources, such as the audit results (WHO inspection report) [33], and 
propose adequate corrective actions to ensure continual improvement of the system [31, 32, 48]. 
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5.  CONCLUSIONS 
Applying QbD principles, Jimma University Laboratory of Drug Quality (JuLaDQ) is established in 
Ethiopia with the goal of contributing to QC analytics of medicines in the Horn of Africa. Analogous to 
pQbD and aQbD, lQbD is proposed here and applied on the QbD-based establishment of laboratory 
water system. Target laboratory profile (TLP), laboratory quality attributes (LQA), laboratory quality 
risk assessment, control strategy and continuous improvement pertinent to lQbD were defined. Water 
of appropriate quality that has critical effect on the quality of analytical results is established in 
JuLaDQ so that the QC laboratory can effectively contribute to the intended purpose.  
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“It is easy to get a thousand prescriptions but hard to get one 
single remedy.”  
 
Chinese Proverb 
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ABSTRACT 
Lumefantrine (benflumetol) is a fluorene derivative belonging to the aryl amino alcohol class of 
antimalarial drugs and is commercially available in fixed combination products with b-artemether. 
To better understand the quality analytics of lumefantrine, firstly HPLC-DAD/UV method of 
analysis was developed and HPLC-DAD/UV-ESI/ion trap/MS was applied for exhaustive impurity 
profiling of lumefantrine. Accordingly, a comprehensive impurity profile was established based 
upon analysis of market samples as well as stress, accelerated and long-term stability results. In-
silico toxicological predictions for these lumefantrine related impurities were made using 
Toxtree® and Derek®. Several new impurities are identified, of which the desbenzylketo derivative 
(DBK) is proposed as a new specified degradant. DBK and the remaining unspecified lumefantrine 
related impurities are predicted, using Toxtree® and Derek®, to have a toxicity risk comparable to 
the toxicity risk of the API lumefantrine itself. Secondly, a simple gas chromatographic method 
coupled to flame ionization detector was developed and validated for quantitative determination 
of lumefantrine through derivatization technique using silylating agent N,O-bis(trimethylsilyl) 
trifluoro-acetamide. Evaluation of the method within analytical quality-by-design principles 
indicated that the method has acceptable specificity, accuracy, linearity, precision, and high 
sensitivity. The developed method was successfully applied to analyze the lumefantrine content 
of marketed fixed dose combination anti-malarial finished pharmaceutical products. 
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CHAPTER III 
ANALYTICS OF THE ANTIMALARIAL DRUG 
LUMEFANTRINE 
Main focus in this chapter: 
 To develop and validate HPLC/DAD method 
 To exhaustively profile the impurities of lumefantrine using HPLC/DAD/UV-ESI/Ion Trap/MS.  
 To develop and validate a simple GC/FID method for lumefantrine determination in finished 
pharmaceutical products that can be utilized for routine regulatory quality control activities. 
 
1. INTRODUCTION 
Lumefantrine (benflumetol) is a 2,4,7,9-substituted fluorene (2,3-benzindene) derivative (Figure 1). It 
was synthesized in the 1970s by the Academy of Military Medical Sciences, in Beijing, and registered 
in China for anti-malarial use in 1987. It is now commercially available in fixed combination products, 
mostly with β-artemether (ACT, artemisinin-based combination therapy), which are proven to be 
highly efficacious for treatment of uncomplicated falciparum malaria. Subsequently, the compound 
proved to possess marked blood schizontocidal activity against a wide range of plasmodia, among 
them chloroquine-resistant Plasmodium falciparum [1-5].  
 
Figure 1. The chemical structure of lumefantrine. 
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Biochemical studies suggest that its anti-malarial effect involves lysosomal trapping of the drug in the 
food vacuole of the intra-erythrocytic parasite, followed by binding to haem that is produced in the 
course of haemoglobin digestion. This binding prevents the polymerization of haem into haemozoin, 
hence inhibiting the detoxification of haem. Investigations involving aryl-methanol compounds have 
suggested the coordination of the iron centre of haem (Fe(III)PPIX) and related porphyrins by the 
alcohol functionality, indicating the structural activity relationship of the anti-malarial drug 
lumefantrine [6]. Hence, structural analogues of lumefantrine also posses marked anti-malarial 
effects. Halofantrine, an aryl amino alcohol analogue of lumefantrine, is also an anti-malarial drug but 
is known to cause cardiotoxicity [7]. Monodesbutyl-benflumetol, a metabolite of lumefantrine, exerts 
higher blood schizontocidal activity in Plasmodium falciparum, as well as in P. vivax where 
monodesbutyl-benflumetol is about 10 times more effective then lumefantrine [8]. The secondary 
alcohol permits the formation of dextrorotatory and levorotatory lumefantrine enantiomers and 
routine syntheses yield the racemate of (+)-lumefantrine and (-)-lumefantrine, which have almost 
identical potency. Therefore, from the activity point of view, there is no reason to use only one of the 
enantiomers of lumefantrine instead of the racemate. Moreover, in view of the low animal and 
human toxicity of lumefantrine racemate, no major toxicological differences between the two 
enantiomers are expected [9]. However, other synthesis impurities might be present. 
Lumefantrine is incorporated in the WHO essential drug list for the treatment of malaria in endemic 
areas of the tropical climate. Due to the logistic system [10], degradation products may be 
spontaneously generated during distribution and storage. Control of such impurities in drug 
substances and finished drug products is required as they might impart different efficacy and 
bioavailability to the drug and/or they might produce different adverse and toxic effects to the 
patients [11].  
The safety of a drug product is dependent not only on the toxicological properties of the active drug 
substance, but also on the toxicological properties of its impurities [12]. Thus, there is an ever 
increasing interest in impurities present in APIs and FPPs [13]. Impurity profiling (i.e. the identity as 
well as the quantity of impurities in the pharmaceutical drug) is now gaining critical attention from 
regulatory authorities. The different Pharmacopoeias, such as the European Pharmacopoeia (Ph.Eur.), 
United States Pharmacopeia (USP) and International Pharmacopoeia (Ph.Int.) are incorporating 
specification limits to allowable levels of impurities present in the API’s or FPPs formulations, based 
upon found levels in approved market samples [11, 14, 15]. Moreover, ICH guideline Q3A(R) stipulates 
different thresholds or action limits based upon the maximum daily dose (MDD). For lumefantrine 
formulations (FPP), with a MDD of 960 mg/day, these are defined as 0.10 % reporting threshold, 0.20 
%  identification threshold and 0.20 % qualification threshold [16].  
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USP-MC and Ph. Int. have already established specification limits for three lumefantrine related 
impurities: lumefantrine related compound A ((RS,Z)-2-(Dibutylamino)-2-(2,7-dichloro-9-(4-chloro-
benzylidene)-9H-fluoren-4-yl) ethanol), lumefantrine related compound BA ((1S,3R,5R)-1,3-bis((EZ)-
2,7-Dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl)-2,6-dio-xabicyclo[3.1.0]hexane) and 
lumefantrine related compound BB ((2-((EZ)-2,6-Dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl)-3’-
((EZ)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluo-ren-4-yl)-2,2’-bioxirane). The USP-MC specification 
limits of these impurities are 0.1% for both impurities A and BA and 0.3% for impurity BB [17]. The 
Ph.Int. lumefantrine monograph lists the same three compounds as identified potential impurities, 
with specification limits of 0.1 % for impurity A and 0.3 % for impurity BA and BB [18].  
Many methods have already been reported for the determination of lumefantrine in FPPs [19-21]. 
HPLC methods are also reported for the simultaneous determination of lumefantrine and β-
artemether in artemisinin-based anti-malarial FDC products [22, 23]. Micro-emulsion electrokinetic 
chromatography was developed as an alternative method to liquid chromatography for the 
determination of lumefantrine [24].  
However, no impurity profile has been established for this drug, while this is considered much more 
critical than the assay value. In this study, the potential impurities are described, including new 
degradants, as well as their relevance towards specification settings and in-silico toxicological 
evaluation. APIs and FPPs containing lumefantrine were evaluated by HPLC, with UV detection for 
quantification and with ESI-iontrap MS detection for identification.  
Moreover, since there is no gas chromatographic (GC) assay method available, despite GC is a suitable 
technique in poor resource economies due to its ease of operation and maintenance, lower use-costs, 
and high separation efficiency [25]. Therefore, this paper reports a GC-FID method for the quantitative 
determination of lumefantrine in anti-malarial FPPs using silylation with N,O–bis(trimethyl-
silyl)trifluoro-acetamide (BSTFA). 
 
 
2. METHODS 
Samples and chemicals 
All drug substance batches (APIs), FPPs (Co-Artesiane®, Artefan®, Lumartem® and Coartem®) and 
standard of desbenzylketo (DBK) lumefantrine derivative were supplied by Dafra Pharma International 
(Belgium), and were either synthesized in-house [21] or purchased from commercial market. 
Standards of lumefantrine and impurity A USP-MC were purchased from U.S. Pharmacopeia (Basel, 
Switzerland). Analytical solutions were prepared in HPLC grade tetrahydrofuran (THF) (Fisher 
Scientific, Leicestershire, UK). Hydrogen peroxide (H2O2), sodium hydroxide (NaOH) and ammonium 
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acetate were purchased from Merck (Darmstadt, Germany), hydrochloric acid (HCl) from Sigma-
Aldrich (St Louis, USA) and glacial acetic acid from Riedel-de Haën (Seelze, Germany). Sartorius 
(Göttingen, Germany) ultrapure 18.2 MΩ.cm quality water and HPLC grade acetonitrile (Romil, 
Cambridge, UK) were used for HPLC-UV/MS analysis. Derivatization for GC analysis was performed 
using extra pure N,O–bis(trimethyl-silyl)trifluoro-acetamide (BSTFA) (Fisher Scientific, Leicestershire, 
UK). 
 
HPLC-UV/MS impurity profiling  
Liquid chromatography  
HPLC-UV investigation of the impurity profiles was performed on a HPLC-PDA apparatus consisting of 
a Waters Alliance 2695 separation module and a Waters 2998 photodiode array detector with 
Empower 2 software for data acquisition (all Waters, Milford, MA, USA). For PDA detection, the UV 
spectrum was recorded at 190–400 nm. Quantification was performed at 266 nm. The positive ion ESI 
and the collision-induced dissociation mass spectra were obtained from the LC-UV/MS apparatus 
consisting of a Spectra System SN4000 interface, a Spectra System SCM1000 degasser, a Spectra 
System P1000XR pump, a Spectra System AS3000 autosampler, and a Finnigan LCQ Classic ion trap 
mass spectrometer in positive ion mode (all Thermo, San José, CA, USA), mass to charge range m/z 
100 to m/z 2000 at unit resolution and with a peak width of 0.25 daltons/z, equipped with a Waters 
2487 dual wavelength UV detector (Waters, Milford, MA, USA) and Xcalibur 2.0 software (Thermo) for 
data acquisition. ESI was conducted using a needle voltage of 4.5 kV. Nitrogen was used as the sheath 
and auxiliary gas with the heated capillary set at 250 °C. UV-detection was used for quantification (at 
266 nm), while ESI-ion trap MS detection was used for identification. 
Liquid chromatographic determination of impurities in lumefantrine samples was performed using a 
Purospher STAR RP-18 endcapped (150 × 4.6 mm, 5 µm particle size) column (Merck, Darmstadt, 
Germany) with guard column at 30 °C under isocratic conditions with a mobile phase consisting of 
ammonium acetate (pH 4.9; 0.1 M) and acetonitrile (10:90, v/v). The flow rate was set at 2.0 ml/min 
(minimal run time: 30 min.). The injection volume was 10 µl. Under these conditions, lumefantrine 
elutes at approximately 22 min. A system suitability test (SST) was established by a minimal resolution 
between lumefantrine and an in-situ prepared N-oxide by H2O2 treatment. Apparent number of 
theoretical plates for lumefantrine peak should be more than 8 x 103, while it should be more than 2 x 
103 for N-oxide of lumefantrine. 
The liquid chromatographic method was validated for the determination of lumefantrine and its 
related impurities. The selectivity of the developed chromatographic method was established by the 
separation of lumefantrine and its impurities. A correlation coefficient (r2) of 0.9998 for lumefantrine 
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(0.0006 to 0.01 mg/ml) and 1.0 for impurity A and DBK (0.001 to 0.1 mg/ml) demonstrated that the 
HPLC method is linear in the lower range. LOD/LOQ values for lumefantrine, DBK and impurity A were 
calculated (S/N = 3 resp. 10): 0.0042 mg/ml and 0.013 mg/ml for lumefantrine, 0.003 mg/ml and 0.009 
mg/ml for DBK and 0.032 mg/ml and 0.107 mg/ml for impurity A. The analytical stability of 
lumefantrine, impurity A and DBK was confirmed over a storage period of 24 hours at 5°C, i.e. the 
sample compartment temperature.  
 
Forced degradation 
Forced degradation of lumefantrine API and FPP was performed under heat, light, acidic, alkaline and 
oxidative stress conditions. In heat stress studies, the FPP powder (one gram) was incubated at 40, 50 
and 60°C for respectively four, three and two days. The placebo powder (one gram) was incubated for 
two days at 60°C. In light stress studies, the FPP and placebo powder (one gram) were subjected to UV 
(three days incubation) and VIS (seven days incubation) light. Finally, FPP and placebo were stressed 
by adding 10 ml of 1 M HCl (acidic), 1 M NaOH (alkaline) or 1 % H2O2 (oxidative) to one gram of the 
powder to be examined. Samples were incubated, up to eight days, at 5, 25, 40, 50 and 60°C. After the 
incubation, samples were neutralized using NaOH (acidic), HCl (alkaline) or Na2S2O5 (oxidative), and 
the solvent evaporated using freeze-drying. Similar stress conditions as that of FPP and placebo 
poweder were followed for API (equivalent to 1 gram of FPP). 
Additionally, different batches of FPP were included in long-term (up to 24 months, 30°C, 70-75 % RH) 
and accelerated (up to 6 months, 40°C, 75 % RH) stability studies according to ICH stability guidelines 
[26]. 
All samples were dissolved in THF (18 mg/ml) and analyzed using HPLC-DAD/UV-ESI/MS. 
 
 In-silico toxicological predictions 
To make in-silico toxicological predictions for lumefantrine and its identified related impurities, two 
sources of toxicological predictions were used: Derek® (12.0.0) for Windows developed by Lhasa 
Limited (Leeds, UK) and Toxtree® (v1.60) developed by Ideaconsult Ltd. (Sofia, Bulgaria). Derek® 
(12.0.0) for Windows is an expert knowledge base system, containing descriptions of molecular 
substructures which have been associated with toxic endpoints (structural alerts), that predicts 
whether a chemical is toxic in humans, other mammals and bacteria. The program applies structure-
activity relationships ((Q)SARs) and other expert knowledge rules to derive a reasoned conclusion 
about the potential toxicity of the query chemical [27, 28]. Toxtree® (v1.60) is an open source 
application, which is able to estimate toxic hazards by applying a decision tree approach and making 
structure-based predictions for a number of toxicological endpoints using different modules. We have 
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generated hazard estimation using three Toxtree® modules: Cramer rules with extensions, 
Benigni/Bossa rulebase and structure alerts for the in-vivo micronucleus assay in rodents.  
 
Gas chromatographic method 
Gas chromatography (GC) 
An Agilent 7820 GC system (Agilent technologies, Waldbronn, Germany) was used to perform the 
analysis with a liquid autosampler. Samples were introduced in a split/splitless injection port and 
detection was performed by means of flame ionization detector (FID). An HP-5 (30 m length x 0.32 
mm id, 0.25 µm film thicknesses) column (Agilent technologies, Waldbronn, Germany) was used for 
separation. The output signal was recorded and processed using EZChrom Elite software.  
The column oven was programmed with initial column oven temperature of 80˚C for 1 min, and 
increased to 325˚C at a rate of 10˚C/min, holding 325°C for 9.5 min. The total run time was 35 min. 
The injector and detector temperatures were kept at 300˚C and 340˚C, respectively. Helium (Air 
Products) was used as carrier gas with a head pressure of 106.7 kPa resulting in an initial column flow 
of 3.2 ml/min and an average velocity of 50 cm/s. Helium was also used as make-up gas for the FID 
detector. The make-up gas flow was 25 ml/min, while for hydrogen and air the flow was 30 ml/min 
and 400 ml/min, respectively. The split ratio was set at 10:1 and a 4 mm i.d. deactivated open-glass 
tube liner, packed with fused silica wool was employed. Samples were injected by the instrument’s 
autosampler with injection volume of 1.0 μL and THF was used to rinse the syringe between 
injections. 
 
Preparation of solutions 
Preparation of lumefantrine standard solution  
Lumefantrine standard solution was prepared at 100 μg/ml concentration in THF. 250.0 μl of this 
standard solution was transferred into a micro-vial and evaporated to dryness under nitrogen to 
obtain the residue providing the final concentration of 500 μg/ml after derivatization.  
 
Preparation of lumefantrine test sample solution  
Four samples of fixed dose combination tablets (Coartem® and Artemine®) containing 120 mg of 
lumefantrine per tablet and one sample of powder for oral suspension (Co-artesiane®) containing 1080 
mg of lumefantrine per bottle were analyzed using the developed GC-FID method. For this, a 
homogeneous FPP powder weight equivalent to 10.0 mg lumefantrine was accurately weighed and 
transferred to a 10.0 ml volumetric flask. THF was added, shaken for 5 min and diluted to volume 
using the same solvent. The mixture was centrifuged (3 minutes at 1914 g) and a test sample solution 
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was prepared at 100 μg/ml concentration (10 x dilution) in THF. 250.0 μl of this test sample solution 
was transferred into a micro-vial and evaporated to dryness under nitrogen to obtain the residue 
providing the final concentration of 500 μg/ml after derivatization.  
 
Preparation of lumefantrine impurity solutions  
Four different lumefantrine impurity [desbenzyl derivative (DB), lumefantrine USP-MC related 
impurity A (alcohol isomer), N-oxide-lumefantrine and desbenzylketo derivative (DBK)] solutions were 
prepared at 1 mg/ml concentration in tetrahydrofuran (THF) (Nicolas and Scholz, 1998). 25.0 μl of 
each of these lumefantrine impurity solutions was quantitatively transferred into a micro-vial and 
evaporated to dryness under liquid nitrogen to obtain the residue providing the final concentration of 
500 μg/ml after derivatization.  
This solution can also be used as a system suitability solution as part of the control strategy of 
analytical QbD. 
 
Derivatization 
The BSTFA derivatives of standards and sample solutions were prepared from the dry residues 
obtained as described above by reacting with 50.0 µl BSTFA solutions in the air-tight glass vials at 70˚C 
for 30 min in an oven. The resulting solutions were cooled and injected into GC without removing any 
excess of the derivatizing agent. 
For optimization and robustness evaluation of the sample derivatization process, a centralized 
composite face-centered (CCF) design with 11 runs including 3 center points was used evaluating the 
influence of incubation time (min) and temperature (˚C). A lumefantrine reference standard solution 
at 100% lc was prepared and analyzed using the different experimental CCF-conditions indicated in 
Supplementary information (Table S1). Peak area for the main lumefantrine peak and the quantitative 
presence of other peaks (with a reporting threshold of 0.1% with reference to the main peak) were 
evaluated as responses.  
 
Validation 
Validation of the method was performed based on the international conference on harmonization 
(ICH) guideline [29]. 
 
Linearity of calibration curve 
From a stock solution containing 100 µg/ml lumefantrine in THF, different aliquots were transferred 
into a micro-vial and evaporated to dryness under liquid nitrogen to obtain the residue providing the 
final concentrations of 400, 450, 500 (100% lc), 550 and 600 μg/ml after derivatization. Calibration 
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curves for concentration versus peak area were plotted and the obtained data were subjected to 
linear regression analysis. 
 
Precision 
For intra-day precision, six sample solutions (n=6) were prepared at 500 μg/ml lumefantrine 
concentration after derivatization and analyzed using GC. Similarly, the inter-day precision was 
evaluated in three consecutive days (n=18). Lumefantrine concentrations were determined and 
relative standard deviations (RSD) calculated. 
 
Accuracy (Recovery test) 
Accuracy was tested by recovery experiments where lumefantrine reference solutions were added to 
a placebo sample at three levels: 75%, 100% and 125% lc. At each level, samples were prepared in 
duplicate and recovery percentage was calculated.  
 
Specificity 
Specificity of the method was evaluated by injecting lumefantrine reference standard solution and its 
impurity solutions [DB, USP-MC impurity A, N-oxide-lumefantrine and DBK], both separately and 
mixed.   
 
Limit of Detection (LoD) and Limit of Quantitation (LoQ) 
Standard solutions of lumefantrine were prepared by serial dilutions, ranging from 10 to 0.05 µg/ml 
concentration after derivatization, and injected onto the GC system. The LoD was defined as the 
concentration for which a signal-to-noise ratio (S/N) of 3 was obtained and LoQ was considered to be 
the concentration at which S/N was 10.   
 
Robustness 
For robustness evaluation, a Plackett-Burman (fractional factorial) experimental design (PBD) 
consisting of 11 runs, including 3 center points, was used investigating four factors: injector 
temperature (°C), final column temperature (°C), temperature gradient (°C/min) and pressure (kPa) 
(Modde version 8, Umetrics Inc, USA). Two test solutions [lumefantrine reference standard solution at 
100% lc and a solution containing a mixture of lumefantrine (at 100% lc) and its related impurities (at 
1% lc each)] were prepared and analysed using different experimental conditions by varying the 
different analytical parameters: injection temperature (290, 300, and 310 ˚C), final column 
temperature (320, 325 and 330 ºC), temperature gradient (8, 10 and 12 ˚C/min) and pressure (102, 
107 and 112 kPa). Chromatographic resolution [between lumefantrine peak and two related 
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impurities, N-oxide lumefantrine and USP-MC impurity A] (Rs); retention time (tR), peak asymmetry 
(As), peak area of lumefantrine and limit of detection (LoD) for the two lumefantrine impurities (N-
oxide lumefantrine and USP-MC impurity A) were evaluated under each condition. 
 
 
3. RESULTS AND DISCUSSION 
HPLC-UV/MS impurity profiling 
HPLC analysis of lumefantrine containing samples 
Lumefantrine API and FPPs were exposed to diverse stress conditions for different periods. 
Additionally, FPPs were put on long-term and accelerated stability studies as well according to ICH. 
FPP samples in the long-term stability study were kept for up to twenty-four months at 30°C /75 % RH. 
In the accelerated study, the stability conditions were adjusted and FPP samples were kept for up to 
six months at 40°C/75 % RH. The unstressed and stressed API samples, as well as the unstressed 
(release), accelerated, long-term and stressed FPP samples were analyzed with the validated HPLC 
method. Five synthesis and four stress related lumefantrine impurities have been observed in 
lumefantrine containing samples (Table 1). The relative retention time (RRT), relative to lumefantrine, 
of these impurities was defined and normalized quantification was performed with a reporting 
threshold of 0.10 %. Maximal actually observed levels of lumefantrine related impurities in different 
samples under different conditions were obtained (Table 2). None of these lumefantrine related 
degradation-impurities were observed above the reporting threshold (i.e. > 0.10 %) in unstressed API 
and release (T0) FPP samples. However, these lumefantrine degradants were observed in stressed API 
and FPP samples, and in FPP stability studies. Compound 1, 2 and 3 were observed in oxidative 
stressed API samples. Three lumefantrine related impurities were observed in stressed FPP stability 
samples: compound 1 (60°C, 1 M NaOH, T2d), compound 3 (60°C, 1 % H2O2, T2d) and compound 4 
(50°C, 1 M HCl, T3d). Compound 3 and 4 were also detected in the accelerated (40°C/75 % RH, T6m) and 
long-term stability studies. A typical UV chromatogram illustrating the separation of lumefantrine N-
oxide, DBK, desbenzyl lumefantrine derivative and lumefantrine is given in Figure 2.  
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Table 1. Structural information for the observed and/or reported lumefantrine related impurities. 
# Compound [formula, mono-isotopic mass] Structure Origin 
1 
Desbenzylketo N-oxide 
[C23H27NO3Cl2, MW 435.14] 
Cl
Cl
OH
N
+
CH3
CH3
O
O
-
 
Alkaline stress 
Oxidative stress 
2 
Lumefantrine (mono-)desbutyl derivative 
[C26H24NOCl3, MW 473.09] 
Cl
Cl
Cl
OH
NH CH3
 
Oxidative stress 
Metabolite 
3 
Lumefantrine N-oxide 
[C30H32NO2Cl3, MW 543.15] 
Cl
Cl
Cl
OH
N
+
CH3
CH3
O
-
 
Oxidative stress 
Degradation 
4 
2,7-dichloro-4-[2-(di-n-butylamino)-1-hydroxyethyl]-9H-fluoren-9-one; Desbenzylketo 
derivative (DBK) 
[C23H27NO2Cl2, MW 419.14] 
Cl
O
Cl
OH
N CH3
CH3
 
Oxidative stress 
Acidic Stress 
Degradation 
5 
2-(di-n-butylamino)-1-[2,7-dichloro-9H-fluoren-4-yl]ethanol;  
Desbenzyl derivative 
[C23H29NOCl2, 405.16] 
Cl
Cl
OH
N CH3
CH3
 
Synthesis 
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Table 1. Structural information for the observed and/or reported lumefantrine related impurities (continued) 
# Compound [formula, mono-isotopic mass] Structure Origin 
6 
Synthesis impurity found in lumefantrine API; 
Lumefantrine oxide 
[C30H32NO2Cl3, MW 543.14] 
Cl
Cl
Cl
OH
N CH3
CH3
 
O 
Synthesis 
7 
Synthesis impurity found in lumefantrine API; 
Lumefantrine oxide  
[C30H32NO2Cl3, MW 543.14] 
Cl
Cl
Cl
OH
N CH3
CH3
 
 O 
Synthesis 
8 
(RS,Z)-2-(Dibutylamino)-2-(2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-
yl)ethanol (isomeric compound ); 
Impurity A (Ph. Int. / USP Salmous) 
[C30H32NOCl3, MW 527.15] 
Cl
Cl
Cl
N
OH
CH3
CH3
 
Synthesis 
9 
Synthesis impurity found in lumefantrine API; 
Lumefantrine oxide 
[C30H32NO2Cl3, MW 543.14] 
Cl
Cl
Cl
OH
N CH3
CH3
 
O 
Synthesis 
10 
(1S,3R,5R)-1,3-bis((EZ)-2,7-Dichloro-9-(4-chlorobenzyl-idene)-9H-fluoren-4-yl)-2,6-
dioxabicyclo[3.1.0]hexane; 
Impurity BA (USP Salmous) 
[C44H24Cl6O2, 797.39] 
Cl
Cl
Cl
O
O
Cl
Cl
Cl  
 
Synthesis 
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Table 1. Structural information for the observed and/or reported lumefantrine related impurities (continued) 
# Compound [formula, mono-isotopic mass] Structure Origin 
11 
2-((EZ)-2,6-Dichloro-9- (4-chlorobenzylidene)-9H-fluoren-4-yl)-3’-((EZ)-2,7-dichloro-9-
(4-chlorobenzylidene)-9H-fluoren-4-yl)-2,2’-bioxirane; Impurity BB (USP Salmous) 
[C44H24Cl6O2, 797.39] 
Cl
Cl
Cl
O
O
Cl
Cl
Cl
 
 
Synthesis 
 
Table 2. Percentage maximum actual levels of lumefantrine related impurities observed (1). 
# Compound 
API
 
FPP 
Unstressed Stressed
 
Release
 
Accelerated
 
Stressed
 
1 Desbenzylketo N-oxide 
 
1.39   0.60 
2 Monodesbutyl derivative 
 
0.56 0.11   
3 Lumefantrine N-oxide  21.32  0.12 0.86 
4 Desbenzylketo derivative    0.34 4.26 
5 Desbenzyl derivative      
6 Lumefantrine oxide (RRT ~ 0.49) 0.19 
 
   
7 Lumefantrine oxide (RRT ~ 0.52) 0.18     
8 Impurity A       
9 Lumefantrine oxide (RRT ~ 0.59) 0.42     
10 Impurity BA      
11 Impurity BB      
(1)
 RT: reporting threshold = 0.10 % 
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Identification of lumefantrine impurities with LC-MS/MS 
The observed lumefantrine impurity peaks (related to synthesis as well as degradation processes) in 
stressed or unstressed API and FPPs were identified using LC-MS/MS, with one of them investigated 
for the first time and proposed as a new specified lumefantrine related impurity. The desbutyl, 
desbenzyl and isomeric compound A derivatives are already known lumefantrine impurities. The 
analytical characteristics of the remaining unidentified lumefantrine related impurities were 
obtained by analysis of MS data: m/z values (Table 3), isotopic-distributions in mass spectra (Figure 2) 
and MS/MS (fragmentation pattern for structural identification). 
 
Table 3. HPLC characteristics of lumefantrine related impurities. 
# Compound tR
(1)
 RRT 
(2)
 
Most abundant  
m/z observed 
1 Desbenzylketo N-oxide 1.79 0.08 436.14 
2 Monodesbutyl derivative 3.25 0.15 474.00 
3 Lumefantrine N-oxide 3.96 0.17 544.08 
4 Desbenzylketo derivative 7.41 0.33 420.13 
5 Desbenzyl derivative 7.69 0.34 406.09 
6 Lumefantrine oxide 10.96 0.49 544.12 
7 Lumefantrine oxide 11.45 0.52 544.12 
8 Impurity A  12.70 0.58 528.10 
9 Lumefantrine oxide 12.97 0.59 544.12 
L Lumefantrine 22.28 1.00 528.10 
(1) 
Retention time (min.); 
(2) 
Relative retention time 
 
The mono-isotopic mass of lumefantrine [(1RS)-2-(Dibutylamino)-1-[(Z)-2,7-dichloro-9-(4-
chlorobenzylidene)-9H-fluoren-4-yl]ethanol] was calculated to be 527.15. The mass spectrum of 
lumefantrine main peak indicated the most abundant ion at an m/z-ratio of 528.10, with an isotopic 
distribution corresponding to the three chlorine atoms in its structure (35Cl at 75.77% and 37Cl at 
24.23%). In the mass spectrum of compound 1 (RRT ~ 0.08), 436.14 is observed to be the most 
abundant m/z. The isotopic distribution is suggestive for a compound possessing two chlorine atoms, 
and is identical to the isotopic distribution of compound 4. The most abundant m/z value for 
compound 4 is 420.13, with a molecular formula of C23H27NO2Cl2, i.e. desbenzylketo derivative (DBK). 
This MS-derived structure was confirmed by chemical synthesis of a DBK reference and its IR and 
NMR spectroscopic structure confirmation. This DBK reference standard gave similar 
chromatographic retention characteristics as well as DAD-UV spectrum as degradant 4 found in the 
samples. Based on the observed m/z values of compound 1 and DBK, compound 1 has an additional 
oxide to its structure, and is thus assigned the N-oxide of DBK. The most abundant ion found for 
compound 2 was m/z 474.00. Its isotopic distribution is characteristic for a compound possessing 
three chlorines and the molecular formula C26H24NOCl3, i.e. the monodesbutyl derivative. As this 
compound is more hydrophilic than lumefantrine, it elutes much earlier than lumefantrine. 
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Compound 3 was found in the oxidative stressed FPP samples. Its most abundant m/z is 544.08, with 
an isotopic distribution corresponding to that of lumefantrine, giving the molecular formula 
C30H24NO2Cl3. Based on the observed m/z values of compound 3 and lumefantrine, compound 3 has 
an additional oxide to its structure. MS/MS fragmentation spectra, by collision induced dissociation 
(CID, energy 100 eV), of compound 3 showed peaks at m/z 526.12 (loss of H2O), 470.10, 396.99, 
380.95, 346.23, 305.58, 298.06 (loss of C14H7Cl2) and 152.30. 
 
Figure 2. UV chromatogram of a mixed sample illustrating lumefantrine N-oxide (3), DBK (4) and 
desbenzyl derivative lumefantrine (5) and lumefantrine (Lum). 
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This impurity was thus identified as lumefantrine N-oxide. Compounds 6, 7 and 9 gave identical mass 
spectra with the most abundant ion found at m/z 544.12. The isotopic distributions are characteristic 
for a compound containing three chlorines and a molecular formula C30H32NO2Cl3, i.e. oxides of 
lumefantrine. As these three impurities are eluting at different retention time, they are most 
probably isomeric compounds with an –OH function at different positions on the lumefantrine 
aromatic ring structure. 
 
Specified lumefantrine impurity DBK  
The lumefantrine related compound 4, DBK (RRT ~ 0.33), was not only formed in stress stability 
samples, but was also observed in accelerated and stressed stability samples of FPP. Moreover, DBK 
was found to be present in market samples at a concentration ranging between 0.03 % and 0.12 %, 
determined by area normalization. Subsequently, DBK was synthesized for further analytical 
characterization, including confirmation of its relative retention time (RRT) and determination of its 
relative response factor (RFF). The RRT and the RRF of DBK relative to lumefantrine were 
experimentally determined to be 0.33 and 2.87 respectively. The UV spectra recorded for 
lumefantrine and DBK showed the wavelength of maximum absorption to be higher for DBK (app. 
266 nm) than for lumefantrine (app. 234 nm), due to the benzyl group being replaced by the keto 
function. This impurity was observed in oxidative and acidic stress degradation, as well as in the 
accelerated and long-term ICH stability studies, justifying this degradant to be classified as a specified 
degradant, which was up till now not yet reported.  
 
In-silico toxicological predictions of lumefantrine and its related impurities 
Using the knowledge-based expert systems Toxtree® and Derek®, general toxicological and 
carcinogenic alerts for lumefantrine, as well as for its related observed and already described 
impurities, have been investigated. Since DBK is a specified lumefantrine related compound, the 
toxicity profile of DBK is of paramount importance. Based on the Cramer rules with extensions, 
Toxtree® clearly predicted general toxicity risks (class III), and genotoxic alerts (polycyclic aromatic 
hydrocarbons, halogenated benzene and H-acceptor-path3-H-acceptor) for DBK, which are identical 
to the API lumefantrine itself. According to the toxicological concern (TTC), the daily dosage for 
compounds classified in class III should be below 90 µg/person (60 kg)/day to be validated as non 
toxic [30]. Hence, the TTC value of 90 µg on the MDD of 960 mg lumefantrine corresponds to a limit 
of 0.01 % (90 µg/960 mg), which is far below the levels actually found.  
The toxicity profile by Derek® of DBK is defined by several general toxicity alerts which are similar to 
lumefantrine: hERG channel inhibion and α2µ-globulin nephropathy [31] plus additional photo-toxicity 
and -allergenicity. However, Derek® did not trigger any genotoxicity or carcinogenicity for DBK.  
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The other lumefantrine related impurities were also predicted in Toxtree® to have a high general 
toxicity similar to lumefantrine itself (depicted Class III), based on the Cramer rules with extensions, 
and genotoxicity risks. Again, Derek® clearly indicated a limit toxicity profile for the majority of 
lumefantrine related impurities compared to lumefantrine (hERG channel inhibion, α2µ-globulin 
nephropathy). Only impurity BB triggered additional toxicity alerts (carcinogenicity/ mutagenicity, 
chromosome damage, eye/skin irritation, developmental toxicity, skin sensitization), indicative for a 
non-toxic profile compared to lumefantrine itself.  
 
Gas Chromatographic method  
Method development 
The analytical target profile (ATP) was to develop a stability-indicating quantitative assay for 
lumefantrine in FPPs that can be used in poor resource economies. GC-FID methodology is thus an 
appropriate technique. The quality target method profile includes that the method should be ICH-
validatable within a GMP environment of a QC laboratory, including compliance with general 
pharmacopoeial chromatographic requirements like minimal resolution and maximal asymmetry.   
As lumefantrine has a relatively high melting (128-132°C) and boiling point (642.5°C) at 760 mmHg 
[32, 33], and a free alcohol functional group in its structure (Figure 1) which affects the inherent 
volatility of the compound [34], direct GC analysis without derivatization was unsuccessful. Using 
silylation reactions [35, 36], the non-volatile and unstable (degrading at 200 - 300˚C) lumefantrine 
molecule could however be successfully analyzed with GC. The widely available BSTFA was used as a 
derivatization reagent in our GC-FID method.  
To develop the stability-indicating GC-FID assay for lumefantrine, different chromatographic factors 
were initially evaluated using a one-factor-at-a-time (OFAT) approach. These factors include injection 
port (temperatures from 150 to 400˚C were tested) and oven program. In the final method, 
lumefantrine eluted at a retention time (tR) of 26.0 min. Retention times and relative response factor 
(RRF), defined as the ratio of the response of the impurity and the API under identical 
chromatographic conditions [37], values for lumefantrine and its related impurities are presented in 
Table 4. All the lumefantrine related impurities (DB, USP-MC impurity A, N-oxide-lumefantrine and 
DBK) were eluting at different retention times without any interference with the lumefantrine main 
peak. The run time of analysis was 35 min. A typical chromatogram obtained on a mixture of 
lumefantrine API and its related impurities is presented in Figure 3. 
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Table 4. Retention time (tR) and relative response factor (RRF) for lumefantrine and its related impurities using 
GC-FID analytics. 
Compound DB   DBK 
N-oxide 
lumefantrine 
Lumefantrine  USP-MC impurity A 
tR (min) 20.14 20.54 23.78 26.04 26.25 
RRF 0.97 0.56 0.57 1.00 0.76 
 
 
 
Figure 3. GC-FID chromatogram of BSTFA derivatized mixture of lumefantrine API (tR 26.0 min) and its related 
impurities solution: DB (20.1 min), DBK (20.5 min), N-oxide lumefantrine (three peaks at tR 23.8, 25.8 and 26.4 
min) and USP-MC impurity A (26.3 min). 
 
 
Validation 
Linearity 
A linear correlation (regression coefficient, r2 = 0.9986) was found between the peak areas and the 
concentrations of lumefantrine, in the assayed range (80 to 120% lc).  
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Precision 
The mean content (± standard deviation) of lumefantrine in the intra-day precision analysis (n=6) was 
96.1% lc ± 0.9% (RSD = 0.9%) while that of the inter-day precision analysis (n=18) was 96.3% lc ± 0.8% 
(RSD = 0.9%). The intra-day and inter-day precision %RSD values were lower than 2.0 %, 
demonstrating appropriate precision of the method [38]. 
 
Accuracy (recovery test) 
The recovery test was performed by analyzing a spiked placebo. Lumefantrine mean recovery was 
99.5% (RSD = 1.0%), indicating the accuracy of the method. 
 
Specificity 
The chromatogram obtained on the mixture of lumefantrine API and its related impurities (Figure 3) 
showed no related impurity peak interference with the main peak, proving the method can be used 
for the quantification of lumefantrine in the presence of its related impurities including its possible 
degradation products. Moreover, in the analyzed placebo samples, we did not observe any 
interfering peak from the excipients with the main peak. 
 
Robustness of derivatization procedure 
The optimum derivatization conditions were set up to BSTFA solution in the air-tight glass vials at 70 
ºC for 30 min in an oven. A CCF design was applied to optimize the sample derivatization process.   
Two factors, incubation time (from 20 to 40 min) and incubation temperature (from 60 to 80˚C), that 
affect yield of derivatization were considered. The factor levels are indicated in Supplementary 
information (Table S2). Maximization of peak area of the derivatized analyte was the target of the 
optimization process. None of the regression coefficients (with the 95% confidence interval) for the 
linear and quadratic effects of incubation time and incubation temperature and the product of the 
time and temperature differed significantly from zero. Therefore, the effect of both variables and 
their product on peak area is considered not significant at 95% CI. Optimal and most robust 
conditions were assigned to the mid points (0-level), i.e. incubation temperature of 70 ºC and 
incubation time of 30 min.   
Moreover, there was no other peak observed above the reporting threshold of 0.1%, indicating that 
the derivatization mixture was stable and pure within the method operable design region (MODR), 
defined as 70˚C ± 10˚C and 30 min ± 10 min.  
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Robustness of chromatography 
Plackett-Burman design (PBD), a two-level fractional factorial design, was used to test the robustness 
of the chromatographic part of the method.  PBD is selected for robustness evaluation since it 
combines less experimentation with maximal information acquisition in the most efficient way.  
Four factors, with deliberate small deviations from the method settings, were considered: injection 
temperature (from 290 to 310 ˚C), final column temperature (from 320 to 330 ˚C), temperature 
gradient (from 8 to 12˚C/min) and pressure (from 102 to 112 kPa).  
The contour plots of these chromatographic factors for lumefantrine peak resolution (Rs) from N-
oxide lumefantrine is presented in Figure 4 (a-f). All Rs results from both N-oxide lumefantrine and 
lumefantrine related compound A were greater than 1.5 revealing that the small deviations 
introduced in the four method parameters did not have a significant effect on the minimal Rs 
specification set in Ph. Eur., which was defined as a critical method attribute [39, 40]. The retention 
time (tR) for DBK was 20.54 min while that of lumefantrine main peak was 26.04 min indicating a 
clear and non-critical separation of these two peaks.  
The injection temperature, final column temperature and pressure did not have a statistically 
significant effect on the retention time of lumefantrine at 95% CI although the retention time was 
increasing from 24.6 to 27.0 min with the decrease in the final column temperature from the (+) level 
(330 ˚C) to the (-) level (320 ˚C) and the same was true for pressure. Increase in temperature gradient 
from 8 to 12˚C/min led to the decrease in tR from 31.3 to 22.6 min.   
The effect of the deviations of the four chromatographic parameters from the method setting on 
peak area, peak asymmetry (As) and limit of detection (LoD) was also evaluated and the effect of 
these four parameters was not significant at 95% CI. Moreover, all the results of the peak asymmetry 
As comply with the set specification in Ph. Eur. [39]. 
Therefore, the deviations from the target method setting for the four parameters: injection 
temperature, final column temperature, temperature gradient and pressure did not affect the 
chromatographic parameter specifications revealing the robustness of the developed gas 
chromatographic method. 
 
Limit of Detection (LoD) and Limit of Quantitation (LoQ) 
LoD and LoQ of lumefantrine were estimated based on signal-to-noise ratio. According to the 
determined signal-to-noise ratio, the LoD and LoQ for lumefantrine were calculated to be 0.01 µg/ml 
and 0.04 µg/ml, respectively, indicating the sensitivity of the method. 
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                            a                                          b 
   
                                             c                                           d 
  
                                           e                                        f 
  
Figure 4. Contour plots of the different chromatographic factors for lumefantrine peak resolution (Rs) from N-
oxide lumefantrine. 
 
Analysis of marketed FDC products 
Table 5 gives the assay results of marketed samples obtained in Ethiopia.  The lumefantrine content 
varied from 96.2% to 98.3% lc, within the 90 - 110% lc specifications [32].  The results were found to 
be comparable to the assay results obtained on the same samples using fused-core HPLC method, 
97.9% to 101.5% lc [23].  
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Table 5. Contents of lumefantrine in fixed dose combination (FDC) products (n=6 for each). 
FDC samples Batch/Lot No. lumefantrine mean content ± SD 
Artemine
®
 tablets 7711 96.5 ± 0.4 
7976 96.6 ± 1.0 
Coartem
®
 tablets F2010 96.2 ± 0.6 
F2006 96.4 ± 0.9 
Co-Artesiane powder for oral 
suspension 
20460 98.3 ± 0.7 
  SD = standard deviation 
 
 
4. CONCLUSION 
Firstly, an exhaustive impurity profiling of lumefantrine was performed using HPLC-UV/ESI-ion trap 
MS. From unstressed, stressed and accelerated stability samples of lumefantrine API and FPPs, nine 
compounds were detected and characterized to be lumefantrine related impurities. One new 
lumefantrine related compound, DBK, was identified and characterized as a specified degradation 
impurity of lumefantrine in real market samples (FPPs). The in-silico toxicological investigation 
(Toxtree® and Derek®) indicated overall a lesser toxicity for the specified impurity DBK compared to 
the API lumefantrine itself. 
Secondly, a GC-FID method for lumefantrine assay in pharmaceutical preparations was developed 
and validated within an analytical QbD approach. The method is linear, precise and sensitive. It 
makes use of simple sample preparation procedures and is not solvent consuming. The retention 
time of lumefantrine was 26.0 min and there was no interference from its related synthesis and 
degradation impurities and excipients. The developed method was successfully applied to analyze 
lumefantrine content in different marketed anti-malarial FPPs and can thus be applied to routine 
quality control of lumefantrine in pharmaceutical preparations.  
 
 
5. REFERENCES 
[1] Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI. Efficacy and safety of 
artemether-lumefantrine (Coartem (R)) tablets (six-dose regimen) in African infants and children 
with acute) uncomplicated falcipaurum malaria. Trans. R. Soc. Trop. Med. Hyg.  2005; 99:459-
467. 
CHAPTER III – QUALITY ANALYTICS OF THE ANTIMALARIAL DRUG LUMEFANTRINE 
  
 
84 
[2] Hatz C, Abdulla S, Mull R, Schellenberg D, Gathmann I, Kibatala P, Beck HP, Tanner M, Royce C. 
Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to 
treat acute falciparum malaria in Tanzanian children aged 1-5 years. Trop. Med. Int. Health 1998; 
3:498-504. 
[3] Van Vugt M. Concerns about the privatization of public goods: A social dilemma analysis. Soc. 
Psychol. Q. 1997; 60:355-367. 
[4] Van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L, Gathmann I, Mull R, 
Brockman A, White NJ, Nosten F. Artemether-lumefantrine for the treatment of multidrug-
resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 2000; 94:545-548. 
[5] Von Seidlein L, Jaffar S, Pinder M, Haywood M, Snounou G, Gemperli B, Gathmann I, Royce C, 
Greenwood B. Treatment of African children with uncomplicated falciparum malaria with a new 
antimalarial drug, CGP 56697. J. Infect. Dis. 1997; 176:1113-1116. 
[6] De Villiers KA, Egan TJ. Recent Advances in the Discovery of Haem-Targeting Drugs for Malaria 
and Schistosomiasis. Molecules 2009; 14:2868-2887. 
[7] Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, Suter W. Inhibition of 
hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur. J. Pharmacol. 
2004; 484:41-48. 
[8] Pirker-Krassnig DK, Wernsdorfer G, Sirichaisinthop J, Rojanawatsirivet C, Kollaritsch H, 
Wernsdorfer WH. Comparative study on the in vitro activity of lumefantrine and desbutyl-
benflumetol in fresh isolates of Plasmodium vivax from Thailand. Wien. Klin. Wochenschr. 2004; 
116:47-52. 
[9] Wernsdorfer WH, Landgraf B, Kilimali V, Wernsdorfer G. Activity of benflumetol and its 
enantiomers in fresh isolates of Plasmodium falciparum from East Africa. Acta Trop. 1998; 70:9-
15. 
[10] Ballereau F, Prazuck T, Schrive I, Lafleuriel MT, Rozec D, Fisch A, Lafaix C. Stability of essential 
drugs in the field: Results of a study conducted over a two-year period in Burkina Faso. Am. J. 
Trop. Med. Hyg. 1997; 57:31-36. 
[11] Bari SB, Kadam BR, Jaiswal YS, Shikhedkar AA. Impurity profile: Significance in active 
pharmaceutical ingredient. Eurasian J. Anal. Chem. 2007; 2:32-53.  
[12] Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide 
drugs: a regulatory-pharmaceutical approach. J. Pept. Sci. 2007; 15:697-710. 
[13] De Spiegeleer B, Vergote V, Pezeshki A, Peremans K, Burvenich C. Impurity profiling quality 
control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence 
and liquid chromatography-electrospray ionization-mass spectrometry: The obestatin case. Anal. 
Biochem. 2008; 376:229-234. 
 CHAPTER III – QUALITY ANALYTICS OF THE ANTIMALARIAL DRUG LUMEFANTRINE 
  
 
 85 
[14] Nicolas EC, Scholz TH. Active drug substance impurity profiling - Part I. LC/UV diode array 
spectral matching. J. Pharm. Biomed. Anal. 1998; 16:813-824. 
[15] Roy J. Pharmaceutical impurities - A mini review. AAPS Pharm. Sci. Tech. 2002; 3:article 6. 
[16] International Conference on Harmonization (ICH) Q3A(R2). Impurities in new drug substances 
CPMP/ICH/2737/99. Geneva, Switzerland, 2006.  
[17] United States Pharmacopoeia. Authorized Lumefantrine USP Salmous Standard. Rockville, USA, 
2009.  
[18] World Health Organization (WHO). Lumefantrine - Document QAS/06.186/FINAL. Geneva, 
Switzerland, 2008.  
[19] Cesar ID, Nogueira FHA, Pianetti GA. Comparison of HPLC, UV spectrophotometry and 
potentiometric titration methods for the determination of lumefantrine in pharmaceutical 
products. J. Pharm. Biomed. Anal. 2008; 48:223-226. 
[20] Patil KR, Rane VP, Sangshetti JN, Shinde DB. A Stability-Indicating LC Method for Lumefantrine. 
Chromatographia  2009; 69:375-379. 
[21] Verbeken M, Suleman S, Baert B, Vangheluwe E, Van Dorpe S, Burvenich C, Duchateau L, Frans H 
Jansen, De Spiegeleer B. Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-
malarial drug lumefantrine.  Malar.  J. 2011; 10: 1-9. 
[22] Cesar ID, Nogueira FHA, Pianetti GA. Simultaneous determination of artemether and 
lumefantrine in fixed dose combination tablets by HPLC with UV detection. J. Pharm. Biomed. 
Anal. 2008; 48:951-954.  
[23] Suleman S, Vandercruyssen K, Wynendaele E, D’Hondt M, Bracke N, Duchateau L, Burvenich C, 
Peremans K, De Spiegeleer B. A rapid stability-indicating fused core HPLC method for 
simultaneous determination of β-artemether and lumefantrine in anti-malarial fixed dose 
combination products. Malar. J. 2013; 12: 145. 
[24] Amin NC,  Fabre H, Blanchin MD,  Montels J, Aké M. Determination of artemether and 
lumefantrine in anti-malarial fixed-dose combination tablets by microemulsion electrokinetic 
chromatography with short-end injection procedure. Malar. J. 2013; 12: 202.  
[25] Dogaroiu C, Sugden R. Practical implications of GC and HPLC methods for the analysis of drugs of 
abuse in blood. Rom. J. Leg. Med. 2008; 16: 95-102.  
[26] International Conference on Harmonization (ICH) Q1A(R2). Stability testing of new drug 
substances and products. Geneva, Switzerland, 2003. 
[27] Ellison CM, Madden JC, Judson P, Cronin MTD. Using In Silico Tools in a Weight of Evidence 
Approach to Aid Toxicological Assessment. Mol. Inform. 2010; 29: 97-110. 
[28] Mohan CG, Gandhi T, Garg D, Shinde R. Computer-assisted methods in chemical toxicity 
prediction. Mini Rev. Med. Chem. 2007; 7:499-507. 
CHAPTER III – QUALITY ANALYTICS OF THE ANTIMALARIAL DRUG LUMEFANTRINE 
  
 
86 
[29] International Conference on Harmonization (ICH) Q2(R1). Validation of Analytical Procedures: 
Text and Methodology. Geneva, Switzerland, 2006. 
[30] Munro IC, Renwick AG, Danielewska-Nikiel B. The Threshold of Toxicological Concern (TTC) in 
risk assessment. Toxicol. Lett. 2008; 180:151-156. 
[31] Kristiansen E, Madsen C.  Induction of protein droplet (alpha(2-mu)-globulin) nephropathy in 
male-rats after short-term dosage with 1,8-cineole and L-limonene. Toxicol. Lett. 1995; 80:147-
152. 
[32] World Health Organization (WHO). International Pharmacopoeia (4th ed.) Geneva, Switzerland’ 
2008. 
[33] Royal Society of Chemistry (RSC). The ChemSpider: The free chemical database. Cambridge, UK, 
2015.  
[34] Sobolevsky TG, Alexander IR, Miller B, Oriedo V, Chernetsova ES, Revelsky IA. Comparison of 
silylation and esterification/acylation procedures in GC-MS analysis of amino acids. J. Sep. Sc. 
2003; 26: 1474–1478.  
[35] Chen BG, Wang SM, Liu RH. GC-MS analysis of multiply derivatized opioids in urine. J. Mass 
Spectrom. 2007; 42: 1012-1023. 
[36] Lin DL, Wang SM, Wu CH, Chen BG, Liu RH. Chemical derivatization for the analysis of drugs by 
GC- MS - A Conceptual Review. J. Food and Drug Anal. 2008; 16: 1-10. 
[37] De Spiegeleer BMJ, D’Hondt M, Vangheluwe E, Vandercruyssen K, De Spiegeleer BVI, Jansen H, 
Koijen I, Van Gompel J. Relative response factor determination of β-artemether degradants by a 
dry heat stress approach. J. Pharm. Biomed. Anal. 2012; 70: 111-116. 
[38] Shabir GA. Validation of high-performance liquid chromatography methods for pharmaceutical 
analysis: understanding the differences and similarities between validation requirements of the 
US Food and Drug Administration, the US Pharmacopeia and the International Conference on 
Harmonization. J. Chromatogr. A 2003; 987: 57–66. 
[39] European Directorate for the Quality of Medicines (EDQM). European Pharmacopoeia (5th ed.) 
Strasbourg, France, 2006. 
[40] Bracke N, Barhdadi S, Wynendaele E, Gevaert B, D’Hondt M, De Spiegeleer B. Surface Acoustic 
Wave biosensor as a functional quality method in pharmaceutics. Sens. Actuators B. Chem. 2015; 
210: 103–112. 
 
 
 
 
 
 CHAPTER III – QUALITY ANALYTICS OF THE ANTIMALARIAL DRUG LUMEFANTRINE 
  
 
 87 
 
SUPPLEMENTARY INFORMATION  
Table S1. Central composite face-centered (CCF) design experimental conditions and responses for 
sample derivatization procedure. 
Exp. # 
Factors Response 
Incubation temperature (˚C) Incubation time (min) 
Lumefantrine 
peak area 
1 60 20 4723313 
2 80 20 4835205 
3 60 40 4870620 
4 80 40 4899217 
5 60 30 4775814 
6 80 30 4711999 
7 70 20 4934172 
8 70 40 5019758 
9 70 30 4998861 
10 70 30 4796128 
11 70 30 4628999 
 
Table S2: Plackett-Burman design: experimental conditions and response results for GC robustness evaluation. 
# 
Factors Responses 
Injection 
T (˚C) 
Final 
column 
T (˚C) 
T  
gradient 
(˚C/min) 
P 
(kPa) 
Rs from 
N-oxide 
Lum 
Rs from 
USP-MC 
impurity A 
Lum 
tR 
Lum 
As 
LoD, 
N-oxide 
lum 
LoD, USP-
MC 
impurity A 
1 310 320 12 102 1.8 1.7 22.9 0.8 0.129 0.430 
2 310 330 8 102 2.1 2.0 31.5 0.8 0.081 0.269 
3 310 330 8 112 2.0 1.8 31.1 0.8 0.075 0.251 
4 290 330 12 112 1.8 1.8 22.3 0.8 0.050 0.168 
5 310 320 12 112 1.9 1.8 22.5 0.8 0.081 0.271 
6 290 330 12 102 1.8 1.7 22.6 0.8 0.072 0.240 
7 290 320 8 112 2.1 1.8 31.1 0.8 0.061 0.202 
8 290 320 8 102 2.2 1.9 31.5 0.8 0.080 0.266 
9 300 325 10 107 1.9 1.9 26.1 0.7 0.047 0.158 
10 300 325 10 107 1.9 2.0 26.1 0.8 0.050 0.168 
11 300 325 10 107 1.9 1.9 26.1 0.8 0.054 0.180 
T: temperature; P: pressure; Lum: lumefantrine. 
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“If Drug B costs 70 percent of Drug A, but has a side effect 
profile that brings every second patient to the hospital for a 
four-day admission, then it does not have value” 
 
Derek Raghavan 
(Australian medical oncologist) 
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ABSTRACT 
Malaria is one of the most serious infectious disease and great public health problem caused by 
Plasmodium parasite infection predominating in Africa. Because of high efficacy and the ability to 
limit development of resistance, fixed dose combination of β-artemether and lumefantrine has been 
used as the first line malaria treatment in most malaria-endemic countries like Ethiopia. However, 
the current artemisinin FDC products like β-artemether and lumefantrine are inherently unstable and 
require controlled distribution and storage conditions, which are not always available in resource 
limited settings. Moreover, quality control is hampered by lack of suitable analytical methods. 
Therefore, there is a need for a rapid and simple, but stability-indicating method utilized for routine 
regulatory quality control of the products assisted by surveys for sustainable monitoring of their 
quality in the actual supply chains. For this, a rapid, robust, precise and accurate stability-indicating 
quantitative fused-core isocratic HPLC method was developed for simultaneous assay of β-
artemether and lumefantrine. Moreover, quality survey for artemether-based FDC anti-malarial 
products was conducted in Jimma zone using visual inspection for packaging and labelling, 
identification, mass uniformity and assay as critical quality attributes. The results revealed 
compliance for all the investigated quality attributes with the acceptance criteria set in Ph. Int.  
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CHAPTER IV 
QUALITY OF ARTEMETHER-BASED 
ANTIMALARIAL MEDICINES IN ETHIOPIA 
Main focus in this chapter: 
 To develop a rapid, robust, precise and accurate stability-indicating quantitative fused-core 
isocratic HPLC method that can be used for routine regulatory QC of β-artemether and 
lumefantrine.  
 To give an overview of the quality of artemether-based antimalarial products in Ethiopia. 
 
1. INTRODUCTION 
Malaria is the most serious infectious disease of great public health concern endemic throughout 
most of the tropics and subtropics. In 2013, there is a total of 104 countries and territories in which 
malaria is endemic. Globally, an estimated 3.4 billion people are at rik of malaria. Approximately 243 
million people annually develop symptomatic malaria [1, 2]. Most of these can be attributed to 
Plasmodium falciparum, but P vivax and P knowlesi can also cause severe diseases. The populations 
living in sub-Saharan Africa have the highest risk of acquiring malaria, and children under five years 
of age and pregnant women are the most severely affected [2, 3]. Malaria case management remains 
a vital component of malaria control strategies. This entails early diagnosis and prompt treatment 
with effective anti-malarial medicines [4]. World Health Organization (WHO) has recommended that 
all anti-malarials should consist of a combination of an artemisinin derivative with a co-drug such as 
lumefantrine, amodiaquine or mefloquine; most malaria endemic countries have now adopted 
artemisinin-based anti-malarial combination therapy (ACT) as first-line treatment of P falciparum 
malaria in place of chloroquine, quinine and sulphadoxine-pyrimethamine fixed dose combinations 
[5]. However, the emergence of resistance is of great concern [6-8], and this problem is fuelled by 
poor quality anti-malarial drugs.  
Poor quality anti-malarials are a severe under-recognized public health problem, reducing the 
effectiveness of these drugs and threatening current treatment policies [9]. There are three main 
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types of poor quality medicines: substandard, degraded and counterfeit. Substandard drugs are 
produced with inadequate attention to good manufacturing practices and may have content outside 
accepted limits. The term counterfeit refers to medicines which are deliberately and fraudulently 
mislabeled with respect to identity and/or source and substandard medicines are genuine medicines 
produced by authorized manufacturers but do not meet the quality requirements, incl. GMP and QC-
results, set for them by national standards [10-13]. Degraded formulations may result from 
(unwanted) exposure of initially well produced, good quality medicines to light, heat and humidity [9, 
14]. Therefore, the ultimate purpose of stability testing is to provide evidence on how the quality of a 
drug varies with time under the influence of a variety of environmental factors such as temperature, 
humidity and light and enables recommendations of storage conditions, retest periods and shelf life 
to be established. The two main chemical aspects of the drug product that play an important role in 
shelf-life determinations are the assay of active drug (efficacy) and degradants generated during the 
stability study (safety). The assay of drug product in stability test samples obviously needs to be 
determined using a stability-indicating method, as recommended by the International Conference on 
Harmonization (ICH) guidelines [15, 16]. Moreover, the intrinsic stability of a finished drug product 
should also be considered as a possible quality attribute when evaluating and comparing different 
drug products with the same active pharmaceutical ingredient (API). For example, it has been 
demonstrated that the half-life of β-artemether-containing products at 50°C can range between 0.70 
and 9.52 months [17].  
β-artemether is a methyl ether derivative of artemisinin, which is a peroxide lactone isolated from 
the Chinese anti-malarial plant Artemisia annua (Figure 1). Chemically, it is (+)-(3-alpha,5a-beta,6-
beta,8a-beta,9-alpha,12-beta,12aR)-decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-
pyrano(4,3-j)-1,2-benzodioxepin [18].  
 
 
Figure 1. Chemical structure of β-artemether. 
 
Lumefantrine (benflumetol) is a 2,4,7,9-substituted fluorene (2,3-benzindene) derivative. Chemically, 
it is (9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylene]-a-[dibutylamino) methyl]-9H-fluorene-4-
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methanol [19]. Both compounds are now commercially available in fixed combination products 
(ACT), which are proven to be highly efficacious for treatment of uncomplicated P falciparum 
malaria. The increasing use of these β-artemether-lumefantrine combination anti-malarial products 
and the intrinsic stability of these products require controlled storage conditions. However, in 
resource-limited settings, stability of these products is not guaranteed since the supply chains do not 
have consistently appropriate temperature and humidity quality assurance systems [20].  
Therefore, there should be methods of detecting poor quality medicines. Currently, there are HPLC 
methods for the assay of β-artemether in finished pharmaceutical products (FPP) [21-23], as well as 
for lumefantrine analysis [24-26]. Only a few HPLC methods were reported for the quantitative 
determination of β-artemether and lumefantrine in fixed combination anti-malarial products [27-29]. 
However, no simple, rapid and proven stability-indicating method has been reported for the 
simultaneous analysis of both active pharmaceutical drug products. Hence, the study presented in 
this chapter reports a rapid, economical, precise and accurate method for the assay of β-artemether 
and lumefantrine in the presence of their degradants.  
Official policy discourages the use of artemisinin monotherapies and other drugs, such as 
sulfadoxine-pyrimethamine, that are no longer effective against malaria and ACTs are free of charge 
for all age groups at public sector in Ethiopia [30, 31]. However, a grossly neglected aspect of malaria 
control is the importance that patients should not just have access to medicines, but should have 
access to good quality-assured medicines; which was emphasized in the resolution adopted by the 
United Nations Human Rights Council [32]. The consequences of using poor quality medicines range 
from prolonged sickness, treatment failure or variability, side effects, loss of income, increased 
healthcare costs to death. In addition, the society may lose confidence in otherwise effective 
medicines, in healthcare systems and suffer major economic losses [33, 34]. Of particular current 
relevance, poor quality anti-malarials containing subtherapeutic amounts of artemisinin derivatives 
or only one of the two active ingredients in ACT, the primary treatment recommended for 
uncomplicated falciparum malaria, are very likely to contribute to disastrous anti-malarial artemisinin 
resistance [35, 36], increasing mortality and morbidity and risking the loss of these vital medicines for 
malaria control [37]. 
Medicines quality evaluation studies are primarily important to provide information on the drug 
content and identify the cause (if any) of poor quality medicines circulating in the country. However, 
there is little existing knowledge about quality of medicines in general and anti-malarial drugs in 
particular in Ethiopia. This QC study reported in this chapter was, therefore, carried out to assess the 
regulatory quality of fixed-dose combination (FDC) ACT anti-malarial medicines circulating in Jimma 
zone, southwest Ethiopia.  
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2. MATERIALS AND METHODS 
HPLC method development and validation 
Samples and chemicals  
β-artemether and lumefantrine APIs, Co-Artesiane® FPP powder for oral suspension, 
dihydroartemisinin (DHA), artemisinin, 9,10-anhydroartemisinin (AHA; late eluting impurity (LEI)) and 
α-artemether standards were supplied by Dafra Pharma International (Belgium). Coartem® and 
Artemine® samples were collected from different markets in Ethiopia. Analytical solutions were 
prepared using HPLC grade unstabilized tetrahydrofuran (THF) (Fisher Scientific, Leicestershire, UK) 
obtaining a concentration of 0.2 mg/ml β-artemether and 1.2 mg/ml lumefantrine corresponding to 
100% label claim (lc). Hydrogen peroxide (H2O2) and sodium hydroxide (NaOH) were purchased from 
Merck (Darmstadt, Germany), hydrochloric acid (HCl) and o-phosphoric acid from Sigma-Aldrich (St 
Louis, USA). Sartorius (Göttingen, Germany) ultrapure 18.2 mΩ.cm quality water and HPLC grade 
acetonitrile (Fisher Scientific, UK) were used for HPLC-UV analysis. 
 
Liquid chromatography and analytical conditions  
The HPLC analyses were carried out using HPLC-PDA apparatus consisting of a Waters Alliance 2695 
separation module and a Waters 2998 photodiode array detector with Empower 2 software for data 
acquisition (all Waters, Milford, MA, USA). The following fused-core stationary-phase chemistries 
were evaluated: (i) Halo RP-Amide (50×4.6 mm id; 2.7 µm particle size); (ii) Halo C18 (50×4.6 mm id; 
2.7 µm particle size); and, (iii) Halo Phenyl-hexyl (50×4.6 mm id; 2.7 µm particle size), all Achrom 
(Machelen, Belgium) and all thermostated at 30 °C. Detection was performed from 190-400 nm. 
Lumefantrine quantification was done at 335 nm, a wavelength at which β-artemether and its related 
impurities are not absorbing. For β-artemether, quantification was performed at 210 nm. As N-oxide-
lumefantrine might interfere if present, back-calculating the peak area of N-oxide-lumefantrine using 
peak area conversion factor from 335 nm to 210 nm (1.64) was performed and the obtained value 
was subtracted from the peak area at 210 nm. The injection volume was 3 µl. Isocratic mobile phases 
containing acetonitrile and 1 mM phosphate buffer pH 3.0 were used at a flow of 1.0 ml/min. The 
separation of β-artemether and lumefantrine was evaluated using different proportions of these 
mobile phase solvents and, for each condition, the retention factor (k’) and asymmetry factor (As) 
were calculated based on the method described in European Pharmacopoeia (Ph. Eur.) 2.2.46 [38].  
The optimal condition was achieved using the Halo RP-Amide column and a mobile phase composed 
of acetonitrile and 1 mM phosphate buffer pH 3.0 (52:48 V/V). 
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Preparation of solutions  
Preparation of β-artemether and lumefantrine standard solution 
Approximately 20.0 mg β-artemether and 120.0 mg lumefantrine reference standards were 
accurately weighed and transferred to a 100.0 ml volumetric flask. Eighty ml tetrahydrofuran was 
added to dissolve both compounds and the solution was diluted to volume using mobile phase.  
 
Preparation of test sample solutions 
Four samples of fixed dose combination tablets (Coartem® and Artemine®) containing 20 mg β-
artemether and 120 mg lumefantrine and three powders for oral suspension stability samples (Co-
artesiane®) containing 180 mg β-artemether and 1080 mg lumefantrine were analysed using the 
validated fused-core HPLC method. For this, a homogenous FPP powder amount equivalent to 20.0 
mg β-artemether and 120.0 mg lumefantrine was accurately weighed and transferred to a 100.0 ml 
volumetric flask. Eighty ml tetrahydrofuran was added, shaken for 5 min and diluted to volume using 
mobile phase. The mixture was filtered through 0.45 μm HPLC syringe filters and analysed using 
HPLC.   
 
Preparation of stress solutions 
Preparation of oxidative degradation of lumefantrine API solution 
Approximately 120.0 mg lumefantrine API was accurately weighed and transferred into 100 ml 
Erlenmeyer flask; 45.0 ml tetrahydrofuran was added to ensure complete dissolution of lumefantrine 
and then 5.0 ml 30% hydrogen peroxide was added. The solution was boiled for 120 min under 
constant reflux and analysed using HPLC.  
Preparation of acidic degradation of lumefantrine solution 
Approximately 120.0 mg of lumefantrine API was accurately weighed into 100 ml Erlenmeyer flask; 
10.0 ml of 1 M hydrochloric acid solution was added and incubated at 70ºC for 30 hours. 
Subsequently, the solution was neutralized by addition of 2.0 ml of 5 M sodium hydroxide solution 
and then 38.0 ml of THF was added. The mixture was sonicated for 5 min, filtered and analysed.  
Preparation of heat stressed β-artemether API solution 
Preparation of heat stressed β-artemether was performed as described by De Spiegeleer et al [23]. 
Briefly, approximately 20.0 mg of β-artemether API was accurately weighed and transferred into a 
glass HPLC vial. The vial was put in a heating block at 145ºC for 30 min, resulting in approximately 
70% conversion of β-artemether to related degradation products. Then 1.0 ml tetrahydrofuran was 
added and the solution was quantitatively transferred to a 50.0 ml volumetric flask by addition of 40 
ml tetrahydrofuran. The solution was then diluted to volume using mobile phase. 
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Validation  
Linearity 
A stock solution containing 250 µg/ml β-artemether and 1,500 µg/ml lumefantrine in THF was 
prepared in triplicate. Different aliquots of these solutions were diluted in a dilution solvent 
consisting of THF/mobile phase (80:20 V/V) to five different concentrations, corresponding to 160, 
180, 200, 220 and 240 µg/ml of β-artemether, and 960, 1,080, 1,200, 1,320 and 1,440 µg/ml of 
lumefantrine. Calibration curves for concentration versus peak area were plotted for each compound 
and the obtained data were subjected to linear regression analysis. 
 
Precision 
For intra-day precision, six sample solutions (n=6) were prepared at 0.2 mg/ml β-artemether and 1.2 
mg/ml lumefantrine concentrations and analysed using HPLC. Similarly, the inter-day precision was 
evaluated in three consecutive days (n=3×6). β-artemether and lumefantrine concentrations were 
determined and relative standard deviations (RSD) were calculated. 
 
Accuracy (recovery test) 
Accuracy was tested by recovery experiments where β-artemether and lumefantrine reference 
solutions were added to a placebo sample at three levels: 75%, 100% and 125% of the label claim. At 
each level, samples were prepared in duplicate and recovery percentage was calculated.  
 
Selectivity 
Selectivity of the method was evaluated by injecting the stressed β-artemether and lumefantrine 
solutions as well as reference standard solutions of α-artemether, artemisinin, DHA and AHA. 
Moreover, UV-spectral purities of β-artemether and lumefantrine chromatographic peaks were 
evaluated using Waters’ peak purity PDA evaluation.  
 
Robustness 
A Plackett-Burman experimental design consisting of 12 experiments with two replicates in block was 
used for the robustness testing (Modde version 8, Umetrics Inc, USA). Three sample solutions 
(stressed, test sample and reference solutions) were prepared at 100% lc and analysed using 
different experimental conditions by varying different analytical parameters: flow (0.8, 1.0, and 1.2 
ml/min), acetonitrile proportion (50%, 52% and 54%), mobile phase pH (2.8, 3.0 and 3.2), and column 
temperature (25ºC, 30ºC and 35ºC). β-artemether and lumefantrine contents and different 
chromatographic characteristics were determined under each condition.  
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Limit of detection (LoD) and limit of quantitation (LoQ) 
Combined standard solutions of β-artemether and lumefantrine were prepared by serial dilutions, 
ranging from 0.4 to 25.0 µg/ml for β-artemether and 0.2 to 11.5 µg/ml for lumefantrine, and injected 
onto the chromatographic system. The LoD was defined as the concentration for which a signal-to-
noise ratio (S/N) of three was obtained and LoQ was considered to be the concentration at which S/N 
was 10.   
 
In-silico toxicological predictions 
In-silico toxicological study for lumefantrine and its related impurities was reported in previous 
publication [26]. Exhaustive impurity profiling of β-artemether (including its possible degradants) was 
also reported [23, 39]. Therefore, to make in-silico toxicological comparative predictions for β-
artemether and its identified related impurities, Derek Nexus v2.0 for Windows developed by Lhasa 
Ltd (Leeds, UK) was used. Derek Nexus® is an expert knowledge-based system, containing 
descriptions of molecular substructures which have been associated with toxic endpoints (structural 
alerts), that predicts a probability whether a chemical is toxic in humans, other mammals and 
bacteria. The program applies structure-activity relationships ((Q)SARs) and expert knowledge rules 
to derive a reasoned conclusion about the potential toxicity of the query chemical [40-42].  
 
Quality of artemether-based anti-malarial drugs in Ethiopia 
Study area  
Jimma zone of oromia regional state which is located in the southwest Ethiopia (Figure 2) was 
selected for this study where almost all of its districts are malarious. Jimma zone harbours Gilgel Gibe 
hydropower dam, which has already contributed to the aggravation of malaria incidence and 
prevalence. It is the commercial hub for the southwest part of Ethiopia and thus complex 
pharmaceutical transactions occur in the region. Currently, there are 7 wholesales (all of them in 
Jimma city), 71 private drug shops (31 in Jimma city, and 40 in the districts of the zone), 101 public 
drug shops in health centers (3 in Jimma city, 98 in the districts of Jimma zone), 18 private 
pharmacies (all of them in Jimma city) and 4 hospital pharmacies in the zone. Informal 
pharmaceutical markets could also exist even though focused studies in the area are lacking. 
 
Materials  
β-artemether and lumefantrine active pharmaceutical ingredients (APIs) were supplied by Dafra 
Pharma International (B-2300 Turnhout, Belgium) through Drug Quality and Registration (DruQuaR) 
laboratory of University of Ghent, Belgium. Purified ultra pure water (18.2 MΩ.cm at 25°C) was 
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obtained by water purification system (Thermofischer Scientific, USA). Ethyl acetate and acetone 
(Fisher Scientific, UK), methanol (Himedia Labs, India), glacial acetic acid and sulfuric acid (ReAgent 
Chemical Services, UK) were analytical grade and used as received. 
 
 
Figure 2. Map of Jimma zone, Oromia regional state, Ethiopia. 
 
Sample collection 
The sampling strategy was defined following the Medicine Quality Assessment Reporting Guidelines 
(MEDQUARG) as proposed by Newton PN et al., 2009 [43] based on the questions: “Are there poor 
quality anti-malarial medicines in the formal distribution outlets in Jimma zone? If there are, what is 
the prevalence?” Moreover, since there is a possible influence of origin and distribution conditions 
on medicines quality as received by the patient, we included the different formal outlets that are in 
practice used by patients in Ethiopia. We also looked at the following question:  “Is there a difference 
in quality of medicines (1) among the different levels of medicines outlets? and (2) among the 
different countries of origin”. Therefore, in function of the questions, sampling units were defined to 
be the medicines sold from the drug retail outlets of the formal supply chain in the zone, the 
different levels of the supply chain system in Ethiopia (drug stores including health centers, 
pharmacies including hospital pharmacies, wholesalers), and country of origin.  
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Based on the sampling strategy, 74 FDC ACT anti-malarial drug samples were collected between May 
and June 2013 through random sampling from all the levels of the formal public and private supply 
chain. All samples were tablet formulations containing artemether 20 mg/lumefantrine 120 mg and 
collected anonymously by mystery shoppers from local area who were trained before to represent a 
confirmed P. falciparum malaria patient of 25 years of age with a prescription stating 4 tablets twice 
per day for three consecutive days (full adult dose of 24 tablets).  
The mystery shoppers were provided with prescription papers. They were blinded about the purpose 
of the study and only instructed to collect medicines in their original primary packaging. For the 
purpose of this study, the relevant information of all collected samples was recorded on a standard 
form as soon as leaving the drug outlet and entered into a database. The information included the 
level of the drug outlet, place of collection, name of the active pharmaceutical ingredient, the 
country of origin, manufacturing company, expiry date, manufacturing date, batch/lot number, and 
labeled dose (strength) of the active ingredient. Medicines purchased from a specific outlet, labeled 
with a specific generic name or brand name, strength, number of units per strip/package, batch 
number, country of origin, manufacturing and expiry dates were considered as one sample. Sampling 
units were the tablet formulations of artemether/lumefantrine combination products circulating in 
the zone. Each sample unit consisted of 24 tablets. The samples were stored at ambient temperature 
(20˚C to 25˚C) until tested, with a storage period of maximally 3 months before testing, and none of 
samples had expired at the time of testing. 
Due to the highest malaria burden reported around Gilgel Gibe dam with incidence rate of 14 
cases/1000 child-months at risk [44] and prevalence of 10.5% among children population [45], all the 
public drug outlets located at 50 km radius surrounding the catchment area of Gilgel Gibe 
hydropower dam were purposively included in the study. Therefore, all artemether/lumefantrine 
combination tablet products of different origin and batch were collected from all drug outlets 
available in these catchment areas and Jimma zone including the city of Jimma.  
 
Tests for products quality 
World health organization (WHO) checklist was used for visual inspection of packaging and dosage 
form as a quick means of checking the quality of the samples [46].  The packaging was checked for 
correct and legible labeling of active ingredients and strength, expiration date, batch number, 
manufacturer, and country of origin. The tablets were also checked for their physical characteristics 
(shapes, colour, breaks, cracks and splits).   
The laboratory tests were carried out according to individual monographs specified in International 
Pharmacopoeias (Ph. Int.) [47] and the general monographs described in European Pharmacopoea 
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(Ph. Eur) [38, 48] in Jimma University Laboratory of Drug Quality (JuLaDQ), Jimma, Ethiopia. JuLaDQ 
follows a formal quality system based on ISO and WHO guidelines. All samples were evaluated by 
determining three clinically relevant critical quality attributes: (i) identification, (ii) mass uniformity, 
(iii) the amount of the active compounds in the ACT FDC products. 
Instrument performance qualification-calibrations as well as system suitability tests (SSTs) were 
successfully performed for the analytical instruments and HPLC methods, respectively. 
 
Identification test 
Thin layer chromatography (TLC) was used to determine the presence of β-artemether and 
lumefantrine in the FPP samples analyzed. Furthermore, chromatographic peak retention time and 
DAD-UV absorption spectra were used for the purpose of identification through comparison with 
retention time and DAD absorption spectra of the peak obtained on a reference standard solution of 
β-artemether and lumefantrine. Customized spectral libraries obtained on the reference standard 
solutions were established and peak identification for each API in each sample was done by 
comparing a spectrum from the sample to a spectrum from the established library. The ChemStation 
software was used to calculate the correlation between the library and the experimental spectra in 
terms of match factors. A match factor of 1000 (correlation factor = 1) describes identical spectra.  
 
Uniformity of mass 
Twenty tablets of each of the samples were randomly selected and individually weighed with a 
calibrated balance (Mettler Toledo, AL204-1C, Switzerland) with an experimentally determined 
operating range of 95 mg to 200 g and an accuracy of 0.006% [49]. This weight variation test was 
evaluated against the Ph. Eur. specification [48]. 
 
API content (assay) 
Assay for β-artemether and lumefantrine content of all the samples was performed using individual 
monographs in Ph. Int.  
For assay evaluation of β-artemether and lumefantrine, Agilent 1260 Infinity Series HPLC system 
(Agilent Technologies, Santa Clara, California, USA) with a C18 column (150 mm x 3.9 mm, 5μ particle 
size) coupled to diode-array detector (DAD) was used. All HPLC conditions including sample and 
mobile phase preparations were based on the individual monograph for artemether/lumefantrine 
tablets described in Ph. Int.  
The analytical method was validated according to International Conference on Harmonisation (ICH) 
Q2(R1) recommendations [50]. The linearity of the method was evaluated around the target label 
claim concentration (analytical aliquot concentration of 200 µg/ml ranging from 160 to 240 µg/ml for 
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β-artemether and 1200 µg/ml ranging from 960 to 1440 µg/ml for lumefantrine. The regression line 
was assessed by determining the 95% confidence interval (95% CI) of slope and intercept parameters 
as well as by evaluating the residual plot. Repeatability precision was evaluated by injecting six 
replicates of 100% test concentration (200 μg/ml for β-artemether and 1200 µg/ml for lumefantrine) 
and percent relative standard deviation (%RSD) of the measurements was calculated. The accuracy 
and range of the method was determined by spike experiments at five different concentrations 
corresponding to 80, 90, 100, 110 and 120% of the nominal analytical concentration for both APIs. 
System suitability was evaluated by the symmetry factor of both β-artemether and lumefantrine 
reference standards, calculated using the Ph. Eur. equation dwAs 2/05.0 , where, w0.05 is width of the 
peak at one twentienth of the peak height, d is distance between the perpendicular dropped from 
the peak maximum and the leading edge of the peak at one twentienth of the peak height; and 
injection repeatability by injecting (6 times) the β-artemether and lumefantrine reference standard 
solution. The Ph.Eur. SST specifications were considered, i.e. As maximally 1.5 and %RSD maximally 2 
[38]. 
In addition, the chromatographic profiles obtained with the FPP sample solutions were evaluated for 
any related impurity above the reporting threshold of 0.05%, recommended for drugs having 
maximum daily dose <2 g for any impurity according to ICH Q3B guideline [51]. 
 
 
3.  RESULTS AND DISCUSSION 
HPLC method development and validation 
Development 
To develop a rapid, simple and stability-indicating isocratic HPLC method, three different fused-core 
stationary phases (Halo phenyl-hexyl, Halo C18 and Halo RP-Amide) and a mobile phase with 
different compositions of acetonitrile and 1 mM phosphate buffer with varying pH (3.0, 5.0 and 7.0) 
were used. Relatively longer run time was obtained with 1 mM phosphate buffer pH 7.0 while pH 5.0 
resulted in poor peak shape for lumefantrine. At all conditions, there was no separation between β-
artemether and lumefantrine using Halo phenyl-hexyl stationary phase. Using Halo C18 stationary 
phase column and a mobile phase composed of acetonitrile and 1 mM phosphate buffer pH 3.0, the 
retention factors obtained for β-artemether and lumefantrine were 11.8 and 3.0, respectively. Under 
these conditions, in spite of achieving good separation between β-artemether and lumefantrine, the 
peak shape of lumefantrine was found to be out of pharmacopoeial specifications (Ph Eur. 
specification As ≤ 1.5) [38] and the total run time was relatively long, i e, 6 min. Substituting the Halo 
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C18 with a Halo RP-Amide stationary phase, different proportions of mobile phase solvents were 
evaluated. The optimal mobile phase, composed of acetonitrile and 1 mM phosphate buffer pH 3.0 
(52:48, V/V), gave an adequate retention factor k’ and lumefantrine peak shape (As 1.3) that complies 
with pharmacopoeial specifications within a short period of total run time of 4 min (Figure 3).  
 
 
Figure 3. Typical chromatogram obtained on solution of β-artemether (Art) (tR: 3.07 min) and lumefantrine 
(Lum) (tR: 1.70 min) in tetrahydrofuran (THF) with their UV spectrum in the infronts. 
 
As indicated in the UV-spectra of Figure 3, β-artemether only shows reasonable UV-absorption at the 
lower wavelengths of the spectrum (200-230 nm), due to the absence of UV-chromophores in its 
structure. Thus, its quantification was performed at 210 nm. For lumefantrine with a tR of 1.70 min, 
quantification was performed at 335 nm, the wavelength at which no UV-absorption interference 
from β-artemether was observed (Table 1). 
 
Table 1. Retention time (tR) for β-artemether and lumefantrine and their related impurities. 
# 
β-
artemether 
DHA 
Artemisini
n 
α-
artemether 
LEI lumefantrine DBK 
N-oxide of 
lumefantrine 
tR 
(min) 
3.069 1.615 1.675 2.142 2.705 1.700 1.256 3.167 
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It was reported that the desbenzyl keto derivative (DBK) is the major degradation product after acidic 
degradation of lumefantrine, while the oxidative degradation of lumefantrine was reported to yield 
N-oxide-lumefantrine [26]. Under the chromatographic conditions, DBK eluted before lumefantrine 
at retention time (tR) of 1.26 min, while N-oxide-lumefantrine was eluting after lumefantrine at tR of 
3.17 min (Table 1).  
β-artemether and all its identified related impurities (α-artemether, DHA, artemisinin and AHA) were 
eluting at different RT without any interference with the main peak. Previous studies have indicated 
that AHA-β-artemether is the most critical pair to be separated [39], while other impurities like DKA 
or furano acetate are sufficiently well separated from β-artemether. Moreover, lumefantrine and its 
related degradation impurities (DBK and the N-oxide of lumefantrine) were also eluting at different 
tR. However, while some of β-artemether impurities (DHA, artemisinin and other degradation 
products from dry heat stress β-artemether) co-elute with lumefantrine, which however does not 
interfere with its assay due to negligible UV-absorption of these β-artemether impurities at 335 nm, 
the N-oxide-lumefantrine problematically co-elutes with β-artemether peak, making selective 
quantification of β-artemether at 210 nm difficult. Therefore, the method quantifies lumefantrine 
separated from its related impurities at 335 nm (where β-artemether and its related impurities are 
not absorbing). Since lumefantrine and its related impurities have strong UV absorption at 210 nm 
and N-oxide-lumefantrine is co-eluting with β-artemether, it is possible to selectively obtain the UV210 
nm peak area of β-artemether alone by back-calculating the peak area of N-oxide-lumefantrine using 
the peak area conversion factor from 335 nm to 210 nm (i.e, 1.64) and subtracting the value from the 
co-eluting peak area at 210 nm.  
Therefore, compared to the method described in Ph. Int. [29] which uses conventional HPLC, the 
developed fused-core method uses simple sample extraction technique and is isocratic, rapid, less 
costly and stability-indicating.  
 
Validation 
Linearity 
Almost all the variation in peak area was explained by the linear concentration (0.9997 for β-
artemether and 0.9997 for lumefantrine), indicating the linearity of the method in the assayed range 
(80 to 120% label claim). The regression analysis data are presented in Table 2. 
 
Precision 
In the prepared solutions for analysis, 100% label claim (lc) represents 0.2 mg/ml β-artemether and 
1.2 mg/ml lumefantrine solution. 
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Intra-day precision: Mean contents and RSD of β-artemether and lumefantrine in the intra-day 
precision analysis (n=6) were 99.6% lc with RSD = 1.2% and 99.2% lc with RSD = 0.5%, respectively.  
Inter-day precision: Mean contents and RSD values of β-artemether and lumefantrine in the inter-day 
precision analysis (n=3×6) were 99.6% lc with RSD = 1.1% and 99.4% lc with RSD = 0.6%), respectively.  
For both compounds, the intra-day and inter-day precision % RSD values were lower than 2.0%, 
revealing precision of the method [52]. 
 
Table 2. Calibration curve for β-artemether and lumefantrine. 
Regression parameters β-artemether lumefantrine 
Regression coefficient, r
2
 0.9995 0.9996 
Slope ± standard error 99.65±1.33 8844.67±97.29 
Intercept ± standard error 589.60±268.83 -192512.80±117909.37 
Concentration range (µg/ml) 160-240 960-1440 
  
Accuracy (recovery test) 
The recovery test was performed by analysing a spiked placebo. β-artemether mean recovery (n=6) 
was 99.7% (RSD = 0.7%) and lumefantrine mean recovery was 99.7% (RSD = 0.6%), indicating the 
accuracy of the method. 
 
Selectivity 
The chromatograms obtained with the stressed lumefantrine API solutions showed degradation 
impurity peaks separated from the main API peak, and similar findings were observed for the 
stressed β-artemether solutions. Acid-stressed lumefantrine resulted in DBK eluting before 
lumefantrine at tR of 1.26 min, while oxidative stress resulted in N-oxide-lumefantrine eluting after 
lumefantrine at tR of 3.17 min. β-artemether and all its identified related impurities (α-artemether, 
DHA, artemisinin and AHA) were eluting at different tR without any interference with the β-
artemether peak. However, at 210 nm, N-oxide-lumefantrine was co-eluting with β-artemether and 
some degradants of β-artemether were co-eluting with lumefantrine. There is no interference from 
β-artemether and its impurities for the estimation of lumefantrine and its related impurities at 335 
nm. Therefore, for the quantification of the two APIs, the method uses two wavelengths, 210 nm for 
β-artemether and 335 nm for lumefantrine. 
The peak purity indices for both β-artemether and lumefantrine in different marketed FDC anti-
malarial drug sample solutions determined with PDA detector under optimized chromatographic 
conditions indicated that the purity angle for both APIs was less than the purity threshold, revealing 
no significant excipient interference. 
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Robustness 
A Plackett-Burman design was used to test the robustness of the method. Plackett-Burman design is 
a two level fractional factorial design where main effects are heavily confounded with two factor 
interactions. It is selected for robustness evaluation since it combines less experimentation with 
maximal information acquisition in the most efficient way.  
Four factors, with deliberate small deviations from the method settings, were considered: 
percentage V/V of acetonitrile in mobile phase (from 50 to 54%), flow (from 0.8 to 1.2 ml/min), pH 
(from 2.8 to 3.2) and column temperature (from 25 to 35˚C). 
Mobile phase pH significantly affects the peak shape of lumefantrine while it did not reveal 
prominent influence on that of β-artemether. Thus, lumefantrine peak symmetry was selected as a 
critical quality parameter for the robustness test. The final method provided lumefantrine peak 
shape (As 1.3) that complies with pharmacopoeial specifications. Moreover, even the deliberate 
method variations provided better lumefantrine peak shapes (As 1.4 and 1.8) than the much tailed 
lumefantrine peak shape (As 2.1) reported in the literature [26]. In the stressed sample solutions, 
there was no difference in selectivity between the results of the method setting and the deliberate 
variations of both β-artemether and lumefantrine APIs and their respective degradation products.   
Typical contour plots for different chromatographic parameters as a function of operational variables 
levels is presented in Figure 4. Figure 4 (a, b and c) is the visual representation of sensitivity, i.e. how 
quantitatively acetonitrile proportion (% ACN), flow rate and temperature influence the retention 
factor (k’). Moreover, it is revealed in Figure 4 that small deviations from the method setting 
introduced in the four parameters do not affect As and k’-specifications set in Ph. Eur. [38]. The 
observed effects for peak symmetry (As) of lumefantrine and k’ for β-artemether and lumefantrine 
are presented in Figure 5. Flow rate and %ACN have more pronounced effect on k’ of both 
compounds while lumefantrine peak shape was more affected by % ACN. 
The mean content of β-artemether and lumefantrine was found to be 100.9 % lc ± 1.0 (RSD 1.0 %) 
and 99.7 % lc ± 0.4 (RSD 0.4 %), respectively. Therefore, the deliberate changes from the method 
settings in chromatographic conditions (% V/V of acetonitrile in mobile phase (from 50 to 54 %), flow 
(from 0.8 to 1.2 ml/min), pH (from 2.8 to 3.2) and column temperature (from 25 to 35˚C)) have little 
impact on the assay of β-artemether and lumefantrine containing anti-malarial FDC products 
indicating the robustness of the method. 
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Figure 4. Contour plots: (a) Acetonitrile (ACN) (% V/V) vs flow (ml/min) for retention factor (k’) of β-artemether, 
(b) ACN (% V/V) vs flow (ml/min) for k’ of lumefantrine, (c) Temperature (˚C) vs flow (ml/min) for k’ of β-
artemether, (d) ACN (% V/V) vs flow (ml/min) for As of lumefantrine. For (a), (b) and (d) mobile phase: pH 3, 
Column temperature: 30 °C and for (c) % ACN: 52, mobile phase: pH 3. 
 
Limit of detection (LoD) and limit of quantitation (LoQ) 
According to the determined signal-to-noise ratio, the LoD and LoQ for β-artemether were calculated 
to be 3.4 µg/ml and 10.0 µg/ml, respectively. For lumefantrine, LoD was 0.1 µg/ml and its LoQ was 
0.4 µg/ml. As the purpose of this developed method is to quantitatively determine both β-
artemether and lumefantrine simultaneously in FDC anti-malarial products where the compounds 
exist in the mass ratio β-artemether: lumefantrine of 1:6, the LoD and LoQ values obtained for β-
artemether should be considered as the overall detection and quantification limits, while for 
lumefantrine, the risk of overloading the HPLC system is to be considered. Both opposing aspects are 
solved with the proposed method.  
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Figure 5. Observed effects for peak symmetry (As) of lumefantrine and retention factor (k’) of β-artemether and 
lumefantrine in the experimental design space. 
 
Analysis of marketed FDC products 
The results of real sample analysis are presented in Table 3. All the analysed batches presented β-
artemether and lumefantrine contents complying with the 95-105% lc specifications. The β-
artemether content in the tablet samples varied from 98.2% to 103.2% while lumefantrine content 
varied from 97.9% to 101.5%. In Co-Artesiane powder for oral suspension FDC product, β-artemether 
content was in the range of 99.7% to 101.1% while that of lumefantrine was ranging from 100.8% to 
102.0%. 
 
In-silico toxicological predictions of β-artemether and its related impurities  
In-silico toxicity profile of lumefantrine and its related impurities was reported in previous 
publication [26]. In this study, mutagenicity, chromosome abrasion, genotoxicity, skin irritation, 
hepatotoxicity and nephrotoxicity endpoints for β-artemether, as well as for its related observed and 
already described impurities, have been investigated using Derek Nexus® and the result is presented 
in Figure 6. The toxicity profile of β-artemether and all its identified related degradants and synthetic 
impurities is defined by several general toxicity alerts. DHA, α-artemether and β-artemether were 
found to have toxicity endpoints for mutagenicity, chromosomal abrasion, genotoxicity, skin 
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irritation, hepatogenicity and nephrotoxicity. β-artemether and all its identified related impurities, 
except desoxyartemisinin which has structural alert for hepatotoxicity, have substructures for skin 
irritation. Derek Nexus® did not trigger mutagenicity, chromosomal abrasion and genotoxicity for 
artemisinin, 9-epi artemisinin, artemisitene, desoxyartemisinin and AHA. 
 
Table 3. Contents of β-artemether and lumefantrine in fixed dose combination (FDC) products (n=6). 
FDC samples Batch/Lot No. Content (%) ± SD 
β-artemether Lumefantrine 
Artemine
®
 tablets A 102.7 ± 0.8 101.8 ± 0.5 
B 102.0 ± 1.2 101.6 ± 0.5 
Coartem
®
 tablets A 98.5 ± 1.0 98.2 ± 0.6 
B 99.5 ± 0.7 99.2 ± 0.4 
Co-Artesiane powder for 
oral suspension 
A 103.6 ± 0.9 101.6 ± 0.8 
B 102.6 ± 0.8 102.3 ± 0.8 
C 103.7 ± 1.1 101.1 ± 0.7 
  SD = standard deviation 
 
Quality survey 
A total of 74 FDC ACT anti-malarial drug samples containing β-artemether (20 mg) and lumefantrine 
(120 mg) were collected between May and June 2013 from malarious districts of Jimma zone. The 
samples had been collected from 27 premises (wholesales, hospital pharmacies and health center 
drug stores). Of these, 34 samples were Coartem®, USA; whereas 6 samples were Artefan® and 32 
samples were generic products of artemether/lumefantrine from India. One sample was Coartem® 
which was manufactured in China whereas 1 Artemine® sample was Ethiopian origin. The origin 
(place of manufacturing) of samples was domestic and foreign (China, India, and USA).  
 
Visual inspection for packaging and dosage form  
The visual inspection of the dosage forms and packaging showed 100% compliance of the samples 
with the requirements set by WHO [53]. Labeling information regarding dosage form, brand name, 
active ingredient/strength, batch number, manufacture and expiry dates were provided. Tablets did 
not present with non-uniform coloration or signs of breakage. 
Evaluation of quality of medicines starts with checking the packaging/labeling and dosage form of the 
medicine samples [54]. Thus, visual inspection for signs of poor quality such as improper packaging, 
labeling, description of dosage, and product source/origin was carried out using WHO checklist [46].  
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Figure 6. In-silico toxicity profile of β-artemether and its impurities. 
 
The visual inspection did not find obvious falsified packaging and/or mislabeling of the surveyed 
medicines, which goes in line with previous reports [55, 56]. This can be explained by the fact that 
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the investigated ACT anti-malarial samples were those supplied to government owned public 
facilities through donation and patients can access free of charge. Therefore, this zero percent failure 
rate with regard to packaging and labeling does not necessarily proof the efficacy of the overall 
regulatory system in Ethiopia, as for example poor quality albendazole and mebendazole products 
were previously found [56].  
Weak pharmaceutical regulatory system in general and weak regulation of medicines packaging and 
labeling in particular has more pronounced effect on the spread of poor quality medicines [57]. Since 
packaging preserves the stability and quality of medicinal products as well as protects them against 
all forms of spoilage and tampering, and since the information on the labels, packaging and leaflets 
provide the basis for appropriate use, WHO recommends that all medicinal products need to be 
packaged in containers that conform to prescribed standards with careful labeling [58]. Different 
countries have different regulatory frameworks and guidelines to control packaging and labeling of 
medicines with the same primary objective, i.e. the unambiguous identification of the medicines and 
the clear conditions for their efficacious and safe use. According to food, medicine and health care 
administration and control proclamation 661/2009 of Ethiopia, any producer, importer, distributor, 
retailer or health institution of medicine shall not supply it to the market or distribute it otherwise 
unless it is duly packed and labeled.  Similarly, regulation (EC) No 726/2004 and directive 2001/83/EC 
of European Union (EU) have provisions on the text of the label and package of medicinal products 
placed on the EU market. The US Food and Drug Administration (FDA) regulates packaging and 
labeling of medicines using Code of Federal Regulations Title 21 Part 211 (21CFR211) Subpart G-
Packaging and Labeling Control. Overview of the regulatory aspect of pharmaceutical packaging in 
Ethiopia in comparison to those of WHO, EU and USA is described in Table 4. Even though Ethiopia 
does have legal framework for pharmaceutical packaging and labeling control, there is no 
consolidated regulatory guideline and/or inspection checklist contrasting WHO, EU and USA. For the 
regulatory control of packaging (including packaging materials) and labeling, Ethiopia uses its GMP 
guideline for pharmaceutical products which contains specifications for packaging materials, 
packaging and labeling operations and instructions [59].  
Such packaging and labeling control through careful visual inspection must be followed by chemical 
analysis, most often using HPLC, which is considered as the gold standard analytical method in drug 
analysis [54]. Therefore, quality evaluation using identification, mass uniformity and assay as critical 
quality attributes was conducted based on the conventional viewpoint, i.e. the dichotomous 
acceptance/reject decision based on the pharmacopoeial specifications, which contrasts the 
desirability approach [56]. This dichotomous perspective was based on the acceptance criteria set in 
the individual monographs of Ph. Int. [47] and the general monographs of Ph. Eur. [38].   
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Table 4.  An overview of regulatory aspects of pharmaceutical packaging in Ethiopia in comparison with WHO, EU and USA. 
# Features Ethiopia WHO EU USA 
1 Current medicine law pertaining 
to pharmaceutical packaging 
Food, Medicine and Health 
care Administration and 
control proclamation 
No.661/2009 
WHO Technical Report 
Series 902, 2002 
European Medicines Agency (EMA) 
(Regulation (EC) No. 726/2004) 
Code of Federal Regulations 
Title 21 Part 211 (21CFR211) 
2 Guidelines for pharmaceutical 
packaging 
No separate guideline but part 
of the GMP guideline for 
pharmaceutical products 
Guideline on packaging 
for pharmaceutical 
products 
Guideline on plastic immediate 
packaging materials 
CPMP/QWP/4359/0 3, 
EMEA/CVMP/205/04 
FDA guidance for industry 
“Container Closure Systems 
for Packaging Human Drugs 
and Biologics” 
3 Standard monographs for 
pharmaceutical packaging 
requirements 
No Pharmacopoeia, but uses 
monographs in other 
Pharmacopoeias: USP, Ph. Eur, 
and Ph. Int. 
International 
Pharmacopoeia 
(Ph.Int.) 
European Pharmacopoeia (Ph.Eur.) United States Pharmacopoeia 
(USP) 
4 Presence of checklist for visual 
inspection of packaging and 
dosage form 
No Yes Yes Yes 
5 Regulatory requirements for 
pharmaceutical packaging 
Protection of the drug product (chemical and physical stability, protection from mechanical damage and maintaining product 
integrity), provision of all the necessary information about the medicine (identification including strength, batch, or expiration 
date and proper physical characteristics (no moisture, dirty marks, abrasion erosion, cracks, or any other adulterations 
 
CHAPTER IV – QUALITY EVALUATION OF SYNTHETIC QUORUM SENSING PEPTIDES 
  
 
112 
Identification tests  
All samples had the intended active ingredient as demonstrated by the positive identification tests.  
 
Uniformity of mass 
The results of uniformity of mass for ABZ tablets of each brand are presented in Table 5. The results 
revealed that all analyzed samples complied with pharmacopoeial specification limit [48]. 
 
Table 5. Mass uniformity test results (% deviation) distribution among products of FDC ACT. 
# Brand/generic drug 
product (n) 
%Deviation Minimum %Deviation Maximum Mean 
%Deviation 
1 Coartem
®
 (35) 0.75 7.11 1.61 
2 Generic (32) 0.80 2.64 1.78 
3 Artefan
®
 (6) 0.99 4.50 2.55 
4 Artemine
®
 (1) 1.34 1.34 1.34 
 
API content (Assay)  
The validation and SST results of the HPLC method revealed that the test method is fit for the 
intended purpose. The method was linear over the concentration range of 160 to 240 µg/ml for β-
artemether (r2 = 0.9998) and 960 to 1440 µg/ml for lumefantrine (r2 = 0.9999). The regression 
analysis results for method linearity are presented in Table 6. Percentage relative standard deviation 
for repeatability (%RSD= 0.85 for β-artemether and %RSD = 0.76 for lumefantrine) of the method 
were within the specification limit (%RSD ≤2). The results of percent recovery (mean % ± %RSD = 
99.60 ± 0.76% for β-artemether and mean % ± %RSD = 99.92 ± 0.58 % for lumefantrine) were within 
acceptable range. The symmetry factor of β-artemether was found to be 1.0 while that of 
lumefantrine was 0.9, which reveals compliance with the Ph.Eur. SST specifications [38]. 
 
Table 6. The HPLC method linearity for assay of  β-artemether and lumefantrine. 
Regression parameters β-artemether lumefantrine 
Regression coefficient, r
2
 0.9998 0.9999 
Slope ± standard error 1.15 ± 0.01 80.65 ± 0.15 
Intercept ± standard error 10.34 ± 0.71 8.12 ± 18.06 
Concentration range (µg/ml) 160-240 960-1440 
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With regard to both β-artemether and lumefantrine content in the tablet dosage forms analyzed, all 
the samples analyzed comply with the acceptance specification set in Ph. Int. [47], i.e. 90 -110 % label 
claim (% lc), except one generic product failed with overage of 111.9% lc for lumefantrine. Therefore, 
in all the samples analyzed, β-artemether content ranges from 89.8 to 108.8% (mean 99.1%, SD: 
3.9%), while that of lumefantrine content was from 90.0 to 111.9% (mean 98.2%, SD: 3.8%).  
A box plot of assay for both β-artemether and lumefantrine by product type (brand and/or generic) 
and country of origin is indicated in Figure 7 and assay test results by product brand and/or generic is 
presented in Table 7. 
 
Table 7. Assay test results for both β-artemether and lumefantrine by product brand and/generic type (in 
percent label claim). 
# Brand/generic drug product (n) Minimum Maximum Mean SD Median 
1 Coartem
®
 (35) β-artemether 90.9 103.6 98.9 3.0 99.6 
Lumefantrine 90.0 104.1 97.4 3.4 97.7 
2 Generic (32) β-artemether 91.5 106.7 99.2 4.3 99.7 
Lumefantrine 93.6 111.9 98.8 3.8 98.7 
3 Artefan
®
 (6) β-artemether 89.8 103.4 98.2 5.0 99.4 
Lumefantrine 91.2 104.2 98.7 4.7 99.6 
4 Artemine
®
 (1) β-artemether 108.8 108.8 108.8 NA 108.8 
Lumefantrine 108.0 108.0 108.0 NA 108.0 
SD: standard deviation; NA: not applicable 
 
With regard to β-artemether and lumefantrine related impurities, the chromatographic peaks 
obtained on solutions of the tablet samples were evaluated for any impurity according to ICH Q3B 
guideline and all samples did not reveal any related impurity above the reporting threshold of 0.05% 
recommended for drugs having maximum daily dose < 2 g.  
In this quality survey study, the semantics ‘poor quality’ was used since it represents both 
substandard and counterfeit medicines [34] and there were no obvious features which suggest that 
the investigated samples were counterfeit, falsified and/or unregistered; although the study did not 
explicitly search for counterfeits, falsified and/or unregistered medicines.  
All the analyzed drug products complied with the stated pharmacopeoial acceptance criteria for the 
three quality attributes: identification, mass uniformity and assay. The zero failure rate observed in 
this survey was found to be similar with a study conducted across Ethiopia [55], despite the reports 
on poor quality anti-malarials, both non-artemisinin and artemisinin containing, in Africa [55, 60]. 
However, this cannot be fully explained by the efficiency of the overall regulatory system, as it can be 
CHAPTER IV – QUALITY EVALUATION OF SYNTHETIC QUORUM SENSING PEPTIDES 
  
 
114 
revealed (1) in the WHO survey that 41% of the collected samples were not registered by the national 
medicine regulatory authority [55]; (2) a national quality survey conducted in Ethiopia on three other 
products (albendazole, mebendazole and tinidazole) indicated the high prevalence of poor quality 
products (45.3%) for the three products [56].  This might be due to the fact that the surveyed 
medicines in this study were collected from strictly regulated public facilities, while the previous 
reports included both licensed and unlicensed medicines retail outlets, indicating that the risk of poor 
quality medicines is greatest in the unregulated pharmaceutical sectors.  
 
 
Figure 7. Box plot for assay of artemether and lumefantrine by product brand-generic and by country 
of origin. 
 
Although the sample size was too small to generalize, there was a significant difference in the assay 
values for both β-artemether and lumefantrine in the analyzed fixed dose combination products 
(FPPs) between countries of origin (P < 0.05) but there was no significant association for place of 
collection and brands and/or generic products (P > 0.05).  
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Contrasting the public health facilities explored in this study, where those medicines are given 
without payment to the patients, in the private sector, significant price differences between products 
of different origin are observed. While the availability of artemether/lumefantrine FDC tablet 
products in the private sector is low, where available, the prices for a full adult dose of 24 tablets are 
immensely high, even for the lowest-priced generic (ETB 88 = 4.4 USD) and between ETB 96 (4.8 USD) 
and ETB 199 (10.0 USD) for the originator brand (Coartem®) (Exchange rate: 1 USD = 20 ETB). This 
significantly high price makes the medicines unaffordable for the majority of malaria patients at the 
private sector [61]. Therefore, as part of improving access to malaria treatment, ACT tablets are 
dispensed to patients free of charge at public health facilities. This effort has significantly and 
positively contributed to the malaria prevention and control strategies set by the country [62]. 
Despite those encouraging progresses, evidence reveals frequent stock depletions and shortages of 
such drugs at the formal, public health facilities [63]. Consequently, patients often must visit the 
private sector for an alternative source of ACTs. Therefore, with extremely limited stocks of ACTs by 
private facilities, expanding the involvement of the private sector toward the availability and rational 
use of ACTs has been recommended [61], which will require an extended strict regulatory control 
system implemented to assure the quality of these medicines through the private channel as well. 
 
 
4.  CONCLUSIONS 
A stability-indicating HPLC method for simultaneous assay of β-artemether and lumefantrine fixed 
dose combination anti-malarial products was developed, using a fused-core reversed-phase amide 
stationary phase combined with an isocratic acetonitrile sodium phosphate mobile phase 
[Acetonitrile/1 mM phosphate buffer pH 3.0 (52:48, v/v)]. It is a rapid (four minutes total run time), 
precise and accurate method that can be utilized to quantify these anti-malarials in the presence of 
their related degradation products or impurities produced during inadequate transportation and 
storage. This method can be applied in the routine regulatory quality control of β-artemether and 
lumefantrine containing FDC drug products. The in-silico toxicological investigation using Derek 
Nexus® indicated overall a toxicity risk for β-artemether-related impurities comparable to that of the 
API β-artemether itself. 
From visual inspection, the quality survey study revealed that there were no falsified packages and 
labels for the samples obtained from formal outlets. All the sampled ACT products did contain the 
stated active ingredient and all (except one sample with 111% lc for lumefantrine) comply with the 
acceptance criteria set in Ph. Int. for assay (90-110 % lc) and Ph. Eur. for mass uniformity. Even 
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though this is good for the malaria control program of the country, it does not necessarily imply the 
efficiency of the overall national regulatory system of Ethiopia, including the private sector as well. 
Therefore, regulatory and policy strategies including nationwide surveys of quality of medicines for 
the containment of poor quality anti-malarials should always be active and implemented. 
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ABSTRACT 
Access to medicines of good quality improve the chances of successful treatment for individual 
patients and promote better outcomes for public health in general. At present, the prevailing 
strategy for improving access to medicines for neglected tropical diseases (NTDs) is drug donation 
programs. However, the presence of poor quality medicines in the market is a global threat on public 
health, especially in developing countries by critically risking efforts of treatment and control of 
diseases in general and the NTDs in particular. Conventionally, medicine quality has been ignored in 
NTDs, though scattered reports show that serious problems exist. Therefore, we assessed the quality 
of two commonly used anthelminthic drugs (MEB and ALB) and one antiprotozoal drug (TNZ) in 
Ethiopia. The analytical results were converted into conclusions using two systems: the traditional 
dichotomous pharmacopoeial specification-compliance based approach and the risk-based Taguchi 
quantitative desirability approach. Overall, the results showed high prevalence of poor quality of the 
three medicines, mainly determined by the country of origin. We conclude that risk-based regulatory 
quality control procedures should be based on identification of the most critical quality attribute and 
apply desirability functions to quantify and classify the quality of medicines.  
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CHAPTER V 
QUALITY OF MEDICINES USED FOR THE 
TREATMENT OF SOIL TRANSMITTED 
HELMINTHS AND GIARDIA IN ETHIOPIA: A 
NATIONWIDE SURVEY 
Main focus in this chapter: 
 To assess the pharmacopoeial quality of three medicines (mebendazole, albendazole and 
tinidazole) circulating in Ethiopia. 
 To assess the criticality of quality attributes and apply risk-based desirability function approach 
to quality evaluation of medicines.  
 
1. INTRODUCTION 
Intestinal parasites are a diverse group of organisms that include single-celled protozoans and multi-
cellular intestinal helminths that affect the gastro-intestinal tract of humans and other animals [1]. 
Soil-transmitted helminthiasis is caused primarily by four species of nematodes, i.e. Ascaris 
lumbricoides (roundworm), Trichuris trichiura (whipworm), and Ancylostoma duodenale and Necator 
americanus (hookworms) that parasitize human gastrointestinal tract [2]. These major human soil-
transmitted helminths (STH) have significant impact on human health in many parts of the world, 
particularly in developing countries [3]. If not treated early and efficacious, they may lead to 
malnutrition, chronic diarrhea, anemia, and other public health problems that can impair physical 
and intellectual development in children [4-6].  
Currently, four drugs are recommended by the World Health Organization (WHO) for STH: MEB, ALB, 
levamisole and pyrantel pamoate [7, 8]. MEB and ALB are increasingly deployed in mass drug 
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administration programs [8] which require a single drug administration to all subjects without prior 
diagnosis or checking for contra-indications. For this reason, the two benzimidazole 2-carbamates 
MEB and ALB (Figure 1) are preferred over levamisole and pyrantel pamoate, which require weight-
based dosing and which are also intrinsically less potent. 
 
Figure 1. Chemical structure of albendazole (ALB), mebendazole (MEB) and tinidazole (TNZ). 
 
Literature reports indicate that TNZ, a 5-nitroimidazole compound (Figure 1), also has some 
anthelmintic efficacy [9], although it is therapeutically mainly used against protozoan infections and 
infections caused by anaerobic bacteria in humans. As such TNZ is often used by the same patients 
treated with STH drugs [10, 11].  
Effective treatment and prevention strategies for these neglected tropical diseases can be delivered 
cheaply, but reports of treatment failure are frequent in developing countries most likely because of 
poor quality medicines, which includes spurious/falsely labeled/falsified/counterfeit (SFFC) 
medicines, chemical and/or physicochemical instability, inappropriate storage and transport, and 
poor quality control during manufacturing and importing medicines [12]. SFFC medicines are 
medicines that are deliberately and fraudulently mislabeled with respect to identity and/or source 
and include products with the correct ingredients or with wrong ingredients, without active 
ingredients, with insufficient or too much active ingredient, or with fake packaging [13]. Substandard 
medicines, i.e. not having the appropriate quality (which is expected to be equivalent to the 
regulatory quality), may be SFFC but also approved medicines. In a quality survey in Nigeria, 48% of 
the samples of different categories of medicines were found to be outside the British Pharmacopoeia 
(BP) limits for active pharmaceutical ingredient (API) assay. Some medicines were even lacking the 
active ingredient [14]. The use of substandard medicines may result in therapeutic failure, resistance 
development, and occurrence of serious adverse events or even death due to excessive dose or the 
presence of toxic impurities [15-17]. A study conducted in sub-Saharan Africa in 2010 on the quality 
of selected anti-malarial medicines reported 64% overall quality failure in Nigeria, from which one 
artemisinin-based anti-malarial drug sample did not contain any of artemether API [18].  
The presence of substandard and SFFC medicines not only poses threats to the individual users in 
terms of the health and side effects experienced, but also to the public and government in terms of 
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trade relations and economic implications [19]. Hence, like many other public health problems, the 
issue of the presence of these substandard and SFFC medicines for public consumption should 
receive careful attention in developing countries [16].  
Finished pharmaceutical products (FPPs) are tested for quality by assessing whether they meet 
pharmacopoeial or any other approved specifications. If not, they are discarded as non-conforming. 
This is a dichotomous decision without differentiation of the seriousness of failure and/or importance 
of quality attributes towards clinical use for the patient [20]. The evaluation of quality of any product 
poses thus a common problem due to a multiplicity of measures which must be balanced one against 
the other. Even when the quality attributes are precisely measurable, a serious challenge exists in 
combining the individual measurements into one index representing the total quality [21]. Such 
balance problems can be solved by using a Derringer’s desirability function [22].  
In general, this study was carried out to assess the pharmacopoeial quality of three medicines (MEB, 
ALB and TNZ) circulating in Ethiopia. The quality in terms of quality attributes like assay/content, 
dosage uniformity, dissolution, disintegration and friability was evaluated. The criticality of the 
quality attributes was assessed using FMEA risk-based analysis and Derringer’s desirability function 
was applied to obtain one global quality index for each sample investigated.  
 
 
2. MATERIALS AND METHODS 
Materials 
MEB USP working standard [Cadila Pharmaceuticals (Ethiopia)], ALB reference standard [Greenfield 
Pharmaceuticals (China)] and TNZ reference standard [Greenfield Pharmaceuticals (China)] were 
kindly donated from Food, Medicine and Health-care Administration and Control Authority 
(FMHACA) of Ethiopia and used as received. Purified ultra pure water was obtained by water 
purification system (Thermofischer Scientific, USA, 18.2 MΩ.cm at 25°C). All other chemicals used in 
this study were analytical grade and used as received.  
 
Sample Collection 
The sampling strategy was defined following the Medicine Quality Assessment Reporting Guidelines 
(MEDQUARG) as proposed by Newton PN et al., 2009 [23] based on the questions: “Are there 
medicines of poor quality in the formal distribution outlets in Ethiopia? If there are, what is the 
prevalence of these poor quality medicines?” Moreover, since there is a possible influence of origin 
and distribution conditions on medicines quality as received by the patient, we included the different 
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formal outlets that are in practice used by patients in Ethiopia. So, we also looked at the following 
question:  “Is there a difference in quality of medicines (1) among the different levels of medicines 
outlets? (2) across different geographic areas of the country? (3) among the two national economies: 
government and privately owned medicines outlets and (4) among the different countries of origin”. 
Therefore, in function of the questions, sampling units were defined to be the medicines sold from 
the drug retail outlets of the formal supply chain in the country, the different levels of the legal 
(registered) supply chain system in Ethiopia (drug stores incl. health centers, pharmacies incl. hospital 
pharmacies, wholesalers), the geographic areas, government/privately owned medicines outlets and 
country of origin. According to the legal pharmaceutical supply system in Ethiopia, the distinction 
between pharmacy and drug store is based on the dimension of the store and the degree of 
specialization of the professionals employed. Pharmacies can handle broader scope of medicines 
than drug store/shop, and are run by a professional with a pharmacist degree. Drug stores/shops are 
run by a pharmacy technician. 
Based on the sampling strategy, 106 drug samples were collected between January and March 2012 
through multilevel stratified random sampling from all the levels of the supply chain system of the 
country (n = 3) covering all types of government and privately owned drug outlets (n = 2). All 
available drug samples of the three study medicines were collected from each of the selected drug 
outlet. Through proportional allocation to each stratum of the supply chain, 59.4% (n = 63) of the 
drug samples were collected from drug stores; 36.8% (n = 39) were from pharmacies while the 
remaining 3.8% (n = 4) samples were from wholesales. 17.9% (n = 7) of pharmacy collected drug 
samples were obtained from hospitals, while four of the drug samples collected from drug stores was 
from health centers. Depending on the geographic locations and drug markets, the samples were 
collected from 7 major cities of the country: Addis Ababa, Hawasa (and its region including 
Arbaminch and Shashemene), Jimma, Assosa (and its region including Nekemte), Adama, Mekele and 
Bahirdar; which represent all four directions starting from Addis Ababa, the major central commercial 
center. All samples were tablet formulations and purchased anonymously by mystery shoppers from 
local area who were trained before. The mystery shoppers stated, if needed, that they were a 
travelling five member family and the family head, a man of 35 years old, abruptly caught a stomach 
ache (‘kurtet’ in Amharic) due to worm infestations and requested the dispenser at the medicine 
outlet for some mebendazole (for ‘kurtet’) and albendazole tablets (for ascariasis) as he used both 
medicines from his past experiences. At the same time, the family’s 18 years old son was suffering 
from diarrhea and thus requested the dispenser for any medicines which could be given for him 
describing that he was taking tinidazole tablets two months ago for similar symptoms. Since the 
travelling family was in a worry of coming up with shortage of the medicines while travelling they 
requested a sufficient quantity of tablets of the medicines. 
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The mystery shoppers were blinded about the purpose of the study and only instructed to purchase 
medicines in their original primary packaging as supplied by the manufacturer. For the purpose of 
this study, the relevant information of all collected samples was recorded on a standard form as soon 
as leaving the drug outlet and entered into database. The information included the level of the drug 
outlet, place/city of collection, name of the active pharmaceutical ingredient, the country of origin, 
manufacturing company, expiry date, manufacturing date, batch/lot number, and labeled dose 
(strength) of the active ingredient. Medicines purchased from a specific outlet, labeled with a specific 
generic name or brand name, strength, number of units per strip/package, batch number, country of 
origin, manufacturing and expiry dates were considered as one sample. Since the mystery shoppers 
stated that they were a travelling five member family, they were able to buy enough units per 
sample. For MEB, 50 tablets per sample were purchased while for ALB and TNZ, a sample contained 
100 tablets. The samples were stored at ambient temperature (20˚C to 25˚C) until tested, with a 
storage period of maximally 3 months before testing, and none of samples had expired at the time of 
testing. 
 
Test Methods for Product Quality  
The quality control laboratory tests were performed in Jimma University Laboratory of Drug Quality 
(JuLaDQ), Jimma, Ethiopia. JuLaDQ follows a quality system based on WHO and ISO guidelines.  
The laboratory tests were carried out according to the general and individual monographs specified 
in different Pharmacopoeias, as indicated in Table 1.  
Instrument performance and system suitability tests were successfully performed for the analytical 
instruments and HPLC methods, respectively. 
For any drug product, identification of the active pharmaceutical ingredient (API) is a critical quality 
attribute. The three drugs (ALB, MEB and TNZ) belong to biopharmaceutical classification system 
(BCS) class II, with low aqueous solubility and high permeability [24, 25]. Moreover, disintegration is 
an integral part of and/or pre-requisite for dissolution of immediate release dosage forms [26].  
Therefore, quality attributes based upon which the products were evaluated were defined to be 
identification, assay/content, dissolution, dosage uniformity, disintegration and friability tests. 
Quality failure was defined as a sample failing any single test of the aforementioned tests for which it 
was evaluated.  
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Table 1. Quality attributes and corresponding pharmacopoeial specifications for ALB, MEB and TNZ tablet 
products. 
# Attributes Product 
Specifications 
Remarks 
USP Ph Eur BP 
1 Assay (%lc) ALB, MEB, 
TNZ 
90.0-110.0 NA NA No individual 
monographs in BP 
and Ph Eur 
2 Disintegration 
time (min) 
ALB, TNZ 15 15 15 The specification is 
based on general 
monographs 
3 Dissolution (% 
dissolved within 
specified time, 
min) 
ALB Not <80% in 
30 min 
For the first 6 
tablets, no 
unit not < Q+5 
Not < 70 The specifications 
are based on 
individual 
monographs for 
USP 
TNZ Not <75% in 
120 min 
Not < 70 
4 Dosage 
uniformity (%lc) 
ALB, MEB, 
TNZ 
85.0-115.0 85.0-115.0 
 
85.0-115.0 
 
The specification is 
based on general 
monographs 
5 
Friability (% loss 
of mass) 
ALB, MEB, 
TNZ 
<1 < 1 < 1 
 NA: Not applicable. Q: the specified amount of dissolved active substance expressed as %lc. 
 
Identification test 
Thin layer chromatography (TLC) was used to determine the presence of ALB and MEB, whereas TNZ 
was identified using UV-spectrophotometry (CECIL CE7200, England) based on the measurement of 
specific absorbance at 310 nm according to USP 2007.  
 
Assay 
Assay for all the three FPPs was performed using individual monographs in USP 2007. For assay 
evaluation of MEB and ALB, reversed phase (RP) HPLC system (KONIK HPLC 550A, Model 600, Spain) 
with LC software coupled to UV-VIS detector was used. The separation technique was carried out 
using C18, 4.6 mm × 150 mm analytical column that contains 5-µm packing. The HPLC conditions 
were detection wavelength of 254 nm (Konik 600 UV-VIS detector), isocratic flow rate of 1 ml/min 
and mobile phase consisting of methanol and 10 mM monobasic ammonium phosphate buffer of pH 
5.5 (60:40).  Before conducting the assays, the HPLC method used was validated for linearity, 
precision and accuracy.  
ALB sample solutions were prepared from 20 tablets which were weighed and finely powdered. A 
portion of the powder equivalent to 100 mg of ALB was transferred to a 50.0 ml volumetric flask. 
Then, 5.0 ml of sulfuric acid in methanol and 25ml of methanol were added and shaken. The solution 
was diluted and mixed with methanol to volume. 5.0 ml of a clear filtrate (Whatman No. 1 filter 
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paper) of the resulting solution was transferred to a 50.0 ml volumetric flask and diluted to volume 
using methanol. The reference standard solution was prepared using the same procedure as the 
sample preparation and both were analyzed using HPLC. 
Similarly, MEB sample solutions were prepared from 20 tablets which were weighed and finely 
powdered. A portion of the powder equivalent to about 500 mg of MEB was transferred to a 100.0 
ml volumetric flask. Fifty ml of formic acid was added and heated in a water bath at 50°C for 15 min. 
The solution was diluted with water to volume and it was mechanically shaken for 1 hour. 5.0 ml of a 
clear filtrate (Whatman No. 1 filter paper) of the resulting solution was transferred to a 25.0 ml 
volumetric flask and diluted to volume with the mobile phase. Finally, the diluted solution was mixed 
and filtered with a sintered glass filter (Millipore®, Darmstadt, Germany) with a pore size of 47 µm. 
The reference standard solution was prepared using the same procedure as the sample preparation, 
except the amount of MEB reference standard transferred was 25.0 mg and 10 ml of formic acid was 
added to the 100.0 ml volumetric flask. Finally, both the sample solutions and the reference were 
analyzed using HPLC. 
For the assay of TNZ, three techniques were formulated by Basavaiah K, et al., 2005, giving reliable 
results of high accuracy and precision: potentiometry, spectrophotometry and HPLC. However, since 
USP 2007 uses the potentiometric method, TNZ was assayed using this pharmacopoeial method. 
Twenty tablets were weighed, finely powdered and a portion of the powder equivalent to 150 mg of 
TNZ was accurately weighed and dissolved in 25 ml of glacial acetic acid and titrated with 0.1 N 
perchloric acid standardized volumetric solution. The endpoint was determined potentiometrically 
using combined glass pH electrode (A1131B, Adwa Instruments, Szeged, Hungary).  
Measured drug content was expressed as a percent of labeled claim (%lc). According to USP 
individual monographs for ALB and MEB tablets, they should contain not less than 90% and not more 
than 110% of the labeled amount based on USP 2007 requirements. Since there was no specific assay 
specification for TNZ tablets in USP, the same acceptance limits as used for ALB and MEB tablets 
were applied.  
 
Disintegration test  
With the assumption that the patient swallows with proper chewing, the disintegration test was not 
performed for MEB chewable tablets. 
Disintegration test was thus carried out for ALB and TNZ tablet samples using USP <701> general 
monograph. Six tablets from each drug product were tested for disintegration times in 900 ml 
distilled water at 37±2 ºC using a disintegration apparatus A (PTZ-2E, PharmaTest, Germany) without 
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disk. The disintegration time was taken to be the time at which no tablet was left on the meshes of 
the apparatus under given set of conditions.  
The general USP monograph for tablets requires that uncoated tablets, except for chewable tablets 
which are exempted from this test, disintegrate within 15 min.  
 
Dissolution study 
An in-vitro dissolution study was carried out for TNZ and ALB using a six vessels Dissolution Tester 
(Tian-Jin, RC-6D, China) following individual monographs in USP 2007. Dissolution study was not 
conducted for MEB samples since there were no sufficient samples left from the other tests.   
For ALB tablets, it was performed using USP type II dissolution apparatus (paddle), while for TNZ 
apparatus type I (basket) was used. The dissolution medium was 900 ml of 0.1N hydrochloric acid at 
a temperature of 37±1oC and 50 rpm. Dissolution was carried out based on the pharmacopoeial 
defined timings for complete dissolution, which was 30 minutes for ALB and 120 minutes for TNZ. 
Considering the rapid disintegration and dissolution, 4 ALB products (3 brands and 1 generic product) 
and 7 TNZ products (4 brands and 3 generic products) were purposefully selected to represent the 
products and tested for a complete release profile. At time intervals of 5 min for ALB and 10 min for 
TNZ, samples of 10.0 ml were withdrawn and replenished with an equal volume of fresh dissolution 
medium at the same temperature. Samples were filtered using Whatman No. 1 filter paper, suitably 
diluted and assayed using UV/Visible spectrophotometer (CECIL CE7200, England) at 350 nm and 317 
nm, respectively. The calibration curves for ALB and TNZ were prepared as specified in individual 
monographs in USP 2007 by preparing six different concentrations from stock solution. The percent 
cumulative release was calculated and plotted against time of release.  
For ALB tablets, the official tolerance limits according to USP individual monograph is that more than 
80.0% should be released within 30 min, where as for TNZ tablets, more than 75.0% of the dose 
should be released within 120 min.  
 
Dosage uniformity 
The dose uniformity of tablets can be determined by two general approaches: the weight variation 
between the sampled tablets or the drug content uniformity. In this study, the weight variation test 
was performed as a means of quantifying uniformity of dose units since all tablet samples contain 
100 mg or more active ingredient, i.e. all the drug products have a dose greater than 25 mg and a 
ratio of drug substance over finished product greater than 25% according to the specifications set in 
USP 2007 and Ph. Eur 2012. Ten tablets were selected at random, weighed all together using the 
analytical balance (Mettler Toledo, AL-204 AC, USA) and the average weight was calculated. Then, 
each tablet was weighed individually and the percentage deviation from average weight was 
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calculated. The acceptance value was calculated using the individual tablet weights and the assay 
result. The requirements for dosage uniformity are met if the acceptance value of 10 dosage unit is 
less than or equal to L1% (15.0). If the acceptance value is greater than L1%, further 20 tablets were 
taken and calculated for the acceptance value, which should then be below L2% (25.0). 
 
Friability test 
To evaluate the friability of the tablets of each drug product, a number of tablets, adding up to 6.5 g, 
were taken for MEB (unit mass < 650 mg), while 10 tablets were taken for ALB and TNZ (unit mass > 
650 mg).  Prior to the test, the tablets were carefully de-dusted and accurately weighed. The tablets 
were then placed in the drum of the friability test apparatus, PharmaTest Friabilator (PTF-20E, 
PharmaTest, Germany) and subjected to its tumbling action at 25 rpm for 4 min. After 4 minutes only 
intact tablets were once again de-dusted and weighed to determine the percentage weight loss by 
tablets due to mechanical action during test. If cracked, cleaved, or broken tablets were present in 
the tablet sample after tumbling, the sample was considered to fail the friability test.  
According to USP general monograph, a maximum mean weight loss of not more than 1.0% is 
considered acceptable for most products based on USP 2007.  
 
Risk Analysis 
Risk analysis is a general quality tool which has its roots in engineering [27], but is now becoming a 
well-established tool in the pharmaceutical field as well. As such, ICH has devoted a separate 
guideline (Q9) to quality risk management, which is being embraced by pharmaceutical authorities 
[28]. Risk analysis, i.e. the estimation of the risk associated with the identified hazards, is an 
important part of this global risk management. Several quality risk management tools like FMEA 
(Failure Mode Effects Analysis) are available, as mentioned by ICH in Q9. Therefore, FMEA was used 
to evaluate the criticality of product quality attributes in this study. Criticality was evaluated using 
RPN, based on evaluations about the probability of occurrence of the failure (O), the severity of the 
failure (S) and the probability of not detecting the failure (D).  These judgments are converted into 
numerical values using descriptive scales and finally combined in the RPN [29] by means of Equation 
(1): 
                                                                 DSORPN ..                                                              (1) 
Used scales for severity, occurrence and detectability of failure are presented in Tables 2 to 4 [30]. 
For severity ratings, five pharmaceutical experts in Belgium (4) and Ethiopia (1) were assigned to 
score it and the median score was taken. For occurrence, literature was reviewed for the three 
products (MEB, ALB and TNZ) in Africa and for other drugs in Ethiopia as there was no previous 
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quality study conducted for these three products in Ethiopia. In Nigeria, 48% of MEB samples 
contained amounts of active ingredient outside the appropriate assay limits [31]. Assay based 
pharmaceutical quality assessment in Kenya reported very poor quality for majority of marketed 
anthelmintic preparations [32]. Therefore, the highest occurrence score of 8 was assigned for assay. 
Studies conducted in Ethiopia indicated that occurrence of failure of identification, disintegration and 
friability tests are very low making the scores assigned to each of these failures to be 1 [18, 33, 34].  
 
Table 2. Evaluation criteria and ranking system for the severity of effects. 
Effect Criteria: severity of effect Rank 
Hazardous Failure is hazardous, and occurs without warning. It suspends operation of the system 10 
Serious Failure involves hazardous outcomes and/or noncompliance with government 
regulations or standards 
9 
Extreme Product is inoperable with loss of primary function. The system is inoperable 8 
Major Product performance is severely affected but functions. The system may not operate 7 
Significant Product performance is degraded. Comfort or convince functions may not operate 6 
Moderate Moderate effect on product performance. The product requires repair 5 
Low Small effect on product performance. The product does not require repair 4 
Minor Minor effect on product or system performance 3 
Very 
minor 
Very minor effect on product or system performance 2 
None No effect 1 
  
 
Table 3. Evaluation criteria and ranking system for the occurrence of failure. 
Probability of failure Possible failure rates Rank 
Extremely high: failure almost inevitable ≧1 in 2 10 
Very high 1 in 3 9 
Repeated failures 1 in 8 8 
High 1 in 20 7 
Moderately high 1 in 80 6 
Moderate 1 in 400 5 
Relatively low 1 in 2000 4 
Low 1 in 15,000 3 
Remote 1 in 150,000 2 
Nearly impossible ≦1 in 1,500,000 1 
 
 
Since 19.1% (8/42) of our MEB samples did not meet the pharmacopoeial acceptance criteria for 
dosage form uniformity, the probability of occurrence of this failure is moderately high and thus a 
score of 6 was assigned for its occurrence.  For scoring the detectability, the scaling ranged from the 
low score assigned to the easiest detection to the highest score for the more difficult detection 
method. Friability can be detected through simple visual/weighing observation; hence, a score of 1 
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was assigned to its detectability. On the other hand, assay and dissolution studies involve 
quantitative tests, requiring fully equipped laboratory system and trained personnel. Therefore, 
detectability was scored to be 8 for each of these failure modes.  Since identification requires field 
tests like color reactions and/or TLC, a score of 5 was assigned to detectability of identity failures. 
 
Table 4. Evaluation criteria and ranking system for the detection of a cause of failure. 
Detection Criteria: likelihood of detection by design control Rank 
Absolute 
uncertainty 
Design control does not detect a potential cause of failure or subsequent failure 
mode; or there is no design control 
10 
Very remote Very remote chance the design control will detect a potential cause of failure or 
subsequent failure mode 
9 
Remote Remote chance the design control will detect a potential cause of failure or 
subsequent failure mode 
8 
Very low Very low chance the design control will detect a potential cause of failure or 
subsequent failure mode 
7 
Low Low chance the design control will detect a potential cause of failure or 
subsequent failure mode 
6 
Moderate Moderate chance the design control will detect a potential cause of failure or 
subsequent failure mode 
5 
Moderately high Moderately high chance the design control will detect a potential cause of failure 
or subsequent failure mode 
4 
High High chance the design control will detect a potential cause of failure or 
subsequent failure mode 
3 
Very high Very high chance the design control will detect a potential cause of failure or 
subsequent failure mode 
2 
Almost certain Design control will almost certainly detect a potential cause of failure or 
subsequent failure mode 
1 
 
 
Desirability function 
Desirability function, just like risk analysis, is a quality tool first proposed by Harrington in 1965 for 
use in the optimization of quality of manufactured products. The approach has basic foundation in 
engineering [35, 36] and is widely adopted in the manufacturing industry. 
The central idea of a desirability function is to create one ball-mark figure which is a composite 
number reflecting different response. This is done by mapping the value of each property/response 
onto a unit-less score in the range from zero to one based on the appropriateness (or desirability) of 
the property/response. Therefore, Derringer’s desirability function was applied for the assessment of 
the quality of the three pharmaceutical products (MEB, ALB and TNZ). The desirability function can 
be used to combine multiple responses into one response called the “overall desirability function” D, 
ranging between a value of 0 (one or more product characteristics are completely unacceptable) to 1 
(all product characteristics are on target). This overall desirability function D is obtained from the 
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geometric mean of the individual desirabilities (di) which provide a way to assess the quality of one 
property. The formula to calculate the overall D-value is presented in Equation 2:  
                                                               n
n
i
d i
pi
1
                                                                  (2) 
In this equation, pi was the weight or relative importance assigned to the response. For this study, n 
equals 4 since four characteristics were considered in the global evaluation of ALB and TNZ, while n = 
3 for MEB since dissolution study was not performed. The advantage of calculating the geometric 
mean is that when one of the criteria has an unacceptable value, the overall product will be 
unacceptable as well. The highest global desirability value represents the product with the highest 
quality.  
Individual desirability functions were defined for each of the quality attributes, based on a 
psychophysical scale and the results obtained from the FMEA quality assessment. Desirability 
function possessing values in the range (0–1) classifies the conversion of the quantity value of a 
specific quality indicator into the assessment of the desirability (preference) of a certain condition of 
evaluated subject (pharmacopoeial quality of the three medicines). Among the specific ways to 
implement the desirability function for the corresponding estimation, a psychophysical scale of 
Harrington is chosen providing universal application. The scale served to establish the 
correspondence between physical and psychological parameters. All the numeric desirability values 
(0-1) of the measured parameters/quality attributes are regarded as physical parameters, while a 
purely subjective assessment of a researcher (e.g. excellent, good, acceptable, low, bad) to express 
degree of satisfaction are regarded as psychological parameters. 
A rough estimation constructs a five–interval quality scale (Table 5) [37]. For assay and dissolution, a 
two-sided desirability function was used where it becomes zero at the lowest and upper limit. For 
identity and dosage form uniformity, a one-sided desirability function was used. Absence of API is 
assumed to be clinically completely undesirable and thus this point was assigned d = 0 where as 
100%lc was assigned d = 1 (i.e. optimal desirability).  Since the pharmacopoeial specification for assay 
is 90-110%lc for all the three products and the pychophysical Harrington’s scale of quality specifies 
desirability range from about 0.7 to 1.0 to be good, d = 0.7 was assigned for assay values of 90 and 
110%lc. Moreover, d = 0.3 was assigned for both 70% and 130%lc, while d = 0.01 was assigned to 
50% and 150%lc. The individual desirability function for assay was then defined as different linear 
sections of different slopes in the range of 100%lc to 90%lc (slope = 0.03), 90%lc to 70%lc (slope = 
0.02) and from 70%lc to 50%lc (slope = 0.01).  Similar but negative slopes were used for assay values 
greater than 100%lc, mirroring the under-dosing profile.  
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For dissolution, %drug release was considered. According to USP acceptance criteria (supporting 
information S1-2), ALB should release 80% within 30 minutes, while TNZ should release 75% within 
120 minutes. However, BP sets acceptance criteria for both drugs at 70%. Therefore, d = 1 was 
assigned for 100% drug release, while d = 0.7 was assigned for the average 75% and 125% drug 
release for both ALB and TNZ. Moreover, d = 0.3 was assigned for both 50% and 150% drug release, 
while d = 0.01 was assigned to 40% and 160% drug release. 
 
Table 5. Modified psychophysical Harrington’s scale of quality and results of risk-based desirability function 
approach. 
# Intervals in global desirability 
(D-global) 
Quality, descriptive 
evaluation 
Number of products in each 
quality scale (percentage) 
1 0.90-1.00 Excellent 14 (13%) 
2 0.80-0.90 Good 24 (23%) 
3 0.70-0.80 Acceptable 38 (36%) 
4 0.37-0.70 Low* 29 (27%) 
5 0.00-0.37 Bad* 1 (1%) 
*Unacceptable qualities  
 
For dosage uniformity, the relative standard deviation (RSD) was considered as response. According 
to Ph. Eur. (2012), RSD should be not more than 2%; and thus d = 1 was assigned for RSD = 0% while 
d = 0.7 for RSD = 2%. Following Harrington’s scale, d = 0.3 was assigned for RSD of 6% and d = 0.01 for 
RSD of 15%; while for RSD = 25%, d was assigned to be 0. 
For identity, d = 1.0 was assigned for those complying with pharmacopoeial specifications for identity 
and d = 0 for those which do not comply.  
 
Data analysis 
Data entry and analysis was carried out using Statistical Package for Social Sciences software (version 
16.0 for windows; SPSS). The assay was carried out in triplicate and data were expressed as mean 
values. The Fisher exact test was used to test the association of the binary quality attributes with the 
country of origin (5 origins), collection sites (7 cities) and drug outlets (3 types). A more detailed 
statistical data analysis, based on the fixed effects model with different response variables (product 
quality attributes) and different categorical covariates derived from our sampling strategy questions 
was done. FMEA was used to assess the criticality of the quality risks associated with each quality 
attribute and Derringer’s desirability function was applied to evaluate quality of the products. 
 
 
CHAPTER V – QUALITY OF MEDICINES USED FOR THE TREATMENT OF SOIL TRANSMITTED HELMINTHS AND GIARDIA IN ETHIOPIA: A NATIONWIDE SURVEY 
  
 
136 
3.  RESULTS 
Quality of the investigated products 
A total of one hundred and six samples of MEB, ALB and TNZ were collected between January and 
March 2012 in seven major cities that represent most parts of the country considering 
pharmaceutical market and geographic areas. The samples had been collected from 38 premises 
(wholesales, pharmacies and drug stores). Of these, 42 samples were MBZ, 25 samples were ALB and 
39 were TNZ samples. The origin (place of manufacturing) of samples was domestic and foreign 
(China, India, Korea, and Cyprus). Domestic products constituted 45.3% (48/106), followed by Indian 
products with 26.5% (28/106). All samples had the intended active ingredient as demonstrated by 
the positive identification tests. No gross mislabeling (incorrect, inadequate or incomplete 
identification) was observed for the samples. However, the quantitative laboratory experiments 
indicated that 45.3% (48/106) of the samples did not meet the expected pharmacopoeial quality 
specifications: 45.2% (19/42) MEB, 48.0% (12/25) ALB and 43.6% (17/39) TNZ samples. The results of 
the different quality control tests of the samples are presented in Table 6 and are detailed below. 
 
Table 6. Pharmacopoeial quality test results by product. 
Product and 
strength (mg) 
Samples failing quality parameters test 
Assay Dissolution Dosage uniformity Friability Overall 
ALB (400)  8% (2/25) 42% (8/19) 0% (0/25) 20% (5/25) 48% (12/25) 
MEB (100) 45% (19/42) - 19% (8/42) 7% (3/42) 45% (19/42) 
TNZ (500) 26% (10/39) 18% (7/39) 0% (0/39) 8% (3/39) 44% (17/39) 
Overall 29% (31/106) 26% (15/58) 7% (8/106) 10% (11/106) 45% (48/106) 
-  Not performed. 
 
Assay 
The assay values for MEB drug products ranged from 68.6 to 132.9 %lc (mean: 106.2%), while that of 
ALB ranged from 87.1 to 111.0 %lc (mean: 98.6%). For TNZ drug products, the assay values ranged 
from 86.1 to 120.6 %lc (mean: 105.7%). Assay test results by product brand is presented in Table 7, 
while a box plot of assay by product type, country of origin, supply chain and place of collection is 
indicated in Figure 2. 
This study revealed that 29.2 % (31/106) of samples did not meet the pharmacopoeial acceptance 
specification for the assay, and thus are formally classified as substandard medicines [13]. A high 
failure rate, 45.2% (19/42) was found for MEB tablets followed by TNZ with failure rate of 25.6 % 
(10/39) and 8.0% (2/25) of ALB samples. From those 31 samples failing to meet the official 
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specification limit for assay, 80.7% (25/31) of the samples were over-dosed and 19.4% (6/31) were 
under-dosed. MEB samples showed the highest variation for assay test with a relative standard 
deviation (RSD) of 12.5%, followed by TNZ and ALB with RSD 6.7% and 4.8% of the labeled amount, 
respectively. Considering the time left to expiry date, all ALB samples expired in 2013, while for MEB 
and TNZ, the expiry date was longer, i.e. 2015/16, which can explain the difference in assay values 
between the 3 drug product classes.  
 
Table 7. Assay test results by product type. 
Drug products (n) Brands (n) Minimum Maximum Mean SD Median 
MEB (42) M1 (14) 98.6% 131.1% 108.6% 9.7% 106.6% 
M2 (14) 68.6% 132.9% 107.6% 17.2% 107.7% 
M3 (7) 81.0% 109.4% 95.0% 10.3% 93.0% 
M4 (5) 98.7% 115.6% 105.8% 7.4% 102.2% 
M5 (1) 121.1% 121.1% 121.1% NA 121.1% 
M6 (1) 118.7% 118.7% 118.7% NA 118.7% 
      Sub total   68.6% 132.9% 106.2% 13.3% 106.0% 
ALB (25) 
  
  
  
  
  
  
A1 (1) 92.0% 92.0% 92.0% NA 92.0% 
A2 (9) 96.7% 108.0% 99.2% 3.5% 97.9% 
A3* (6) 94.2% 102.4% 97.5% 3.1% 96.4% 
A4 (2) 99.5% 103.3% 101.4% 2.7% 101.4% 
A5 (1) 104.0% 104.0% 104.0% NA 104.0% 
A6 (3) 87.1% 100.0% 95.3% 7.1% 98.8% 
A7 (1) 96.3% 96.3% 96.3% NA 96.3% 
A8 (1) 94.3% 94.3% 94.3% NA 94.3% 
A9 (1) 111.0% 111.0% 111.0% NA 111.0% 
Sub total 87.1% 111.0% 98.6% 4.8% 97.9% 
TNZ (39) T1 (3) 86.1% 99.1% 94.7% 7.5% 99.1% 
T2 (7) 107.7% 112.0% 108.9% 2.1% 107.7% 
T3* (5) 99.1% 112.0% 104.2% 4.7% 103.4% 
T4* (9) 99.1% 107.7% 102.4% 2.9% 103.4% 
T5 (8) 99.1% 120.6% 113.6% 7.6% 114.1% 
T6 (5) 94.8% 103.4% 101.6% 3.9% 103.4% 
T7* (2) 107.7% 107.7% 107.7% 0.0% 107.7% 
Sub total 86.1% 120.6% 105.7% 7.0% 103.4% 
 Total (106)  68.6% 132.9% 104.2% 10.1% 103.4% 
*Generic products; SD= Standard deviation; NA = Not applicable 
 
The assay results reveal that the majority of the failed samples contain too much active ingredient 
that may be introduced intentionally during production (i.e., overages applied). However, as a 
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general principle, use of an over-dose of a drug substance to compensate for loss during manufacture 
or degradation during a product's shelf life to extend its shelf life, is discouraged [38].  
 
 
Figure 2. Box plot for assay versus (a) product type, (b) origin, (c) premises/supply chain and (d) place of 
collection. Numbers are given between the brackets. 
 
Disintegration test 
In this study, all tablet samples met the official requirement for disintegration time test.   
 
Dissolution test 
As shown in Table 6, from 19 ALB and 39 TNZ samples tested for their in-vitro dissolution, 42.1% 
(8/19) of ALB and 17.9 % (7/39) of TNZ samples failed to meet the official tolerance limits. There is a 
significant difference between countries of origin with respect to the in-vitro dissolution profile, with 
all samples manufactured in Ethiopia (19/19) meeting the official tolerance limit and 25.9% (15/58) 
failure rate observed for the imported products. From the 11 products (4 ALB and 7 TNZ) 
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purposefully selected for the release profile study, two brands of the four ALB products released 
more than 80.0 %lc in 30 minutes while a brand and one generic ALB products failed to comply with 
the release profile. Except for the generic product, a fast release was observed from all ALB products 
in which more than 70.0 %lc was released within 10 minutes as presented in Figure 3a. All four TNZ 
brands and three generic products released more than 75.0 %lc of the dose within 120 minutes as 
indicated in Figure 3b.  
 
    
                          (a)                                       (b) 
Figure 3. Comparative in-vitro release studies of (a) four different products of albendazole (ALB) tablets and (b) 
different products of tinidazole (TNZ) tablets. All data points presented are mean values of triplicate 
experiments (n=3) and error bars indicate standard deviations. Percent drug release should be between 70 and 
130% within 30 min (ALB) and 120 min (TNZ). 
 
Dosage uniformity 
Dosage uniformity is measured to ensure a constant dose of drug between individual dosage forms. 
All ALB and TNZ samples were in line with pharmacopoeial acceptance criteria for dosage uniformity, 
but 19.1% (8/42) of MEB samples did not meet these specifications as indicated in Table 6. 
 
Friability test  
A relatively high failure rate (20%) of ALB samples followed by TNZ (7.7%) and MEB (7.1%) was 
observed in the present study. Overall 10.4% (11/106) of samples failed to meet the friability test. 
The higher friability for ALB products might be related to the rapid disintegration and dissolution of 
these products.   
 
Risk analysis  
The results of the RPN values after scores assigned for severity, occurrence and detectability of the 
failure mode are presented in Table 8. In the quality attributes subjected to FMEA, a total of 5 failure 
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modes with RPN scores ranging from 2 to 512 were identified. Risk analysis showed that assay (RPN 
=512) is the most critical quality attribute followed by dissolution (RPN = 336) and dosage uniformity 
(RPN 144). Friability was found to be the quality attribute of the least concern according to FMEA 
analysis applied to product quality assessment.  
 
Derringer’s desirability function  
The individual desirability values assigned to the different segments were fitted to the segmented 
linear model as indicated in Figure 5.  
 
 
Figure 5. Linear desirability functions: (a) assay (%label claim), (b) dissolution (%drug release), (c) dosage 
uniformity (%RSD) and (d) identity (compliance to specification). 
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For each medicine analyzed for the retained 4 quality attributes (assay, dissolution, dosage form 
uniformity and identity), a global D was finally calculated using the above mentioned d-functions and 
evaluated using the psychophysical Harrington’s scale of quality as presented in Table 5.  According 
to this scale, it was revealed that 13.2% (14/106) of the products were excellent, while 22.6% 
(24/106) were good and 35.8% (38/106) were of acceptable quality. Thirty products (28.3%) were 
found to be of unacceptable quality (low and bad). Moreover, the distribution of the D-values among 
the investigated products is presented in Figure 6. 
 
Table 8. Failure mode effects analysis (FMEA) for the different MEB, ALB and TNZ drug product quality 
attributes. 
# CQA Failure mode Failure effects S O D RPN 
1 Identity No (intended) active 
ingredient in the sample 
or mislabeling (incorrect, 
inadequate or 
incomplete 
identification) 
Treatment failure, death 
due to untreated disease 
10 1 5 50 
2 Assay Under-dose, over-dose Treatment failure, toxicity 
due to over-dose, drug 
resistance due to 
underdose 
8 8 8 512 
3 Disintegration 
 
Inability to sufficiently 
disintegrate within the 
specified time period 
No or poor absorption 
and bioavailability thus 
leading to treatment 
failure and resistance 
6 1 5 30 
4 Dissolution Inability to sufficiently 
dissolute within the 
specified time period 
Poor absorption and 
bioavailability thus 
leading to treatment 
failure and resistance 
7 6 8 336 
4 Dosage 
uniformity 
Non-uniform 
distribution of 
dose/content within the 
individual dosage units 
Sub-optimal therapy for a 
patient taking the sub-
standard dosage unit only 
once and resistance 
6 6 4 144 
5 Friability Tablets weight loss due 
to distribution or any 
other logistic related 
factors 
Sub-optimal therapy due 
to loss of the active 
ingredient 
2 1 1 2 
CQA: critical quality attributes; S: severity; O: occurrence; D: detectability and RPN: risk priority number 
 
 
4.  DISCUSSION 
To address the subject of quality of medicines, different internationally accepted semantics and 
definitions are used. In this study, the semantics “poor quality” was used due to the following 
reasons:  
CHAPTER V – QUALITY OF MEDICINES USED FOR THE TREATMENT OF SOIL TRANSMITTED HELMINTHS AND GIARDIA IN ETHIOPIA: A NATIONWIDE SURVEY 
  
 
142 
1) We did not find obvious features which suggest that the investigated samples were counterfeit, 
falsified and/or unregistered; although we did not explicitly search for counterfeits, falsified 
and/or unregistered medicines. Therefore, without a detailed investigation involving the 
manufacturer, distribution-chain and health authorities, it is impractical to rule out this 
perspective. 
2) Poor quality can have good manufacturing practice (GMP) and/or good distribution practice 
(GDP) reasons, and as such, we do not differentiate explicitly between GMP-substandard (at 
manufacturer) versus degraded substandard (while being good quality at manufacturer). In this 
study, it was not practical to easily differentiate if poor quality was due to weak GMP or rather 
inadequate GDP. Moreover, the WHO as well as US-IOM (institute of medicine), and recent 
expert opinions [39] do not make this distinction and prefer to use the term ‘substandard’ to 
address both. Finally, quality does also include the intrinsic stability of the medicine (a very 
important aspect in tropical climates), which is a function of its composition, quality of 
ingredients/packaging and manufacturing process [40]. 
 
 
Figure 6. Distribution of D-values among the investigated products. 
 
3) Even though the term ‘substandard’ literally means “under the standard”, it is obviously related 
to a legally required specification mostly interpreted in the national regulations in the approved 
marketing registration file and/or national pharmacopoeia/compendia, where some still use 
other quality standards, e.g. Ph.Int. or USP-MC. They all differ not only in quality attributes and 
methods, but also in acceptance criteria as well. As in Low and Middle Income Countries (LMIC), 
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the legally required standards are often absent and incomplete. Therefore, we prefer to use 
“poor quality” over “substandard”, as for the investigated products, we were not aware of the 
legally binding national Ethiopian quality standards. Moreover, we did not only use more 
international quality specifications, but also wanted to introduce the Taguchi-concept in our 
quality-evaluation, thus (to some extent) avoiding the “standard” issue, with an on-off decision, 
and replacing it by a quantitative quality number. 
4) While other semantics like (S)SFFC, fake, and the like are sometimes used, we believe in 
accordance with EMA, US-IOM, and recent expert opinions, that for the purpose of this study, a 
simple 2-dimensional division between falsified and substandard will be sufficient. 
In this study, we conducted quality evaluations based on two different approaches: the conventional 
viewpoint (dichotomous decision based on arbitrarily pharmacopoeial acceptance limits) and the 
risk-based desirability function approach. The conventional perspective is based on the acceptance 
criteria set in general and individual monographs of different pharmacopoeias and guidelines, while 
the desirability function approach is based on quality-by-design (QbD) and risk-based principles 
whereby clinical relevance is a key factor. A medicine can have many different quality attributes, 
which are certainly not equally important, i.e. each quality attribute has a different criticality for the 
clinical use of the medicine. This ICH-recommended risk-based approach is derived from the Taguchi 
quality philosophy, where any deviation from the optimal point is considered as a less optimal 
situation and there is no dichotomous decision. 
Therefore, this study reports not only the percentage compliant with the generally accepted 
pharmacopoeial specification limits for each of the quality attributes using the conventional, 
dichotomous approach, but also derived a global quality number which encompasses the clinical 
importance of the different quality attributes. This clinical importance, i.e. criticality or risk if 
deviating from the optimum, was assessed by quality risk tools: within FMEA, one uses the risk 
priority number (RPN) to estimate this risk.  
 
Conventional quality of investigated medicines  
In general, the prevalence of poor quality medicines was the highest for ALB tablets (48.0%, 95% CI: 
28.4 to 67.6), followed by MEB (45.2%, 95% CI: 30.2 to 60.3) and TNZ (43.6%, 95% CI: 28.0 to 59.2) 
tablets (Table 6). Overall, 45% (48/106) of the analyzed drug samples failed to meet the official 
tolerance limits for assay, dissolution, friability and uniformity of dose.  
A similar survey conducted on anti-malarial drugs in Senegal, Madagascar and Uganda identified 44%, 
30%, and 26% substandard anti-malarial drugs, respectively [41]. Assay and dissolution profile study 
for anti-malarial samples conducted in south-east Nigeria reported 37% substandard medicines [42]. 
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Assay based pharmaceutical quality assessment in Kenya reported that many anthelmintic 
preparations marketed in Kenya were of very poor quality [32].  
The probable causes for the presence of poor quality medicines in developing countries like Ethiopia 
might be due to poor storage conditions, insufficient quality assurance, poor compliance with good 
manufacturing practice standards, lack of scientific expertise in manufacturing sector, limited 
technical capacity and insufficiently well developed regulatory system to evaluate and take action to 
solve the problems related to drug quality [43].  
From those drug samples collected from pharmacy, about 51.1% (24/46) failed while 46.9% (23/55) 
and 20.0% (1/5) were the failure rates for those collected from drug store and wholesale, 
respectively. Even though the sample size was small to generalize, there was significant difference in 
the pharmacopoeial quality parameter of medicines between the country of origin (P<0.05) but there 
was no significant association for place of collection and outlets, P>0.05 as presented in Table 9 and 
Figure 2.  
 
Table 9. Association between the test results and areas of collection, types of drug outlets, and countries of 
origin. 
Variable Registered quality failure P- value 
Place of collection (number of samples) 
0.07 
            Assosa  (14) 4/14 (28.6%) 
            Hawasa (19) 3/19 (15.8%) 
            Addis Ababa (20) 10/20 (50.0%) 
            Jimma (16) 10/16 (62.5%) 
            Adama (18) 9/18 (50.0%) 
            Bahirdar (11) 6/11 (54.5%) 
            Mekele (8) 6/8 (75.0%) 
            Total (106) 48/106 (45.3%) 
Drug outlets (number of samples) 
0.46 
            Wholesale (5)  1/5 (20.0%) 
             Pharmacy (46) 24/46 (52.2%) 
             Drug stores (55) 23/55 (41.8%) 
             Total (106) 48/106 (45.3%) 
Origin (number of samples) 
0.04 
             Ethiopia (48) 21/48 (43.6%) 
             India (28) 11/28 (39.3%) 
             Cyrus (15) 8/15 (53.3%) 
             China (6) 6/6 (100.0%) 
             Korea (9) 2/9 (22.2%) 
             Total (106) 48/106 (45.3%) 
 
Regarding the collection areas, a high failure rate was observed for samples collected from Addis 
Ababa, Jimma and Adama areas.  Since these areas are commercial centers due to their geographic 
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location, it requires special attention by the regulatory offices to control the circulation of these 
anthelmintic medicines to combat poor quality medicines circulation.  
All analyzed samples contained the intended active ingredient. Even though a single case of API-
absent medicine is unacceptable, the finding of this study was good as compared to other studies, 
e.g. in Cambodia (4.2%) [44]. However, 29.2% (31/106) of the samples did not comply with the 
pharmacopoeial acceptance criteria for assay. Of the MEB samples, 45.2% were found to be of poor 
quality with respect to assay as per the official tolerance limit. This result is in agreement with the 
study conducted in Nigeria’s pharmacies in which 48% samples of MEB did not comply with set 
pharmacopoeial limits [31]. On the other hand, ALB samples showed relatively better compliance but 
still unacceptable as 8.0% did not meet the official acceptance limit for assay. In general, from those 
drug samples which failed assay test, 19.4% (6/31) were under-dosed. One of the contributing factors 
for the development of drug resistance is under-dosing due to poor quality medicines [45].   
Uniformity of dosage unit is defined as the degree of uniformity in the amount of active substance 
among individual dosage units. Content uniformity depends on a number of formulations and 
manufacturing processes, hence it is obviously unrealistic to presume that every unit contains exactly 
the same amount of the active ingredient as indicated on the label. Therefore, pharmacopoeial 
standards and specifications have been established to provide generic limits for allowable variations 
for the active ingredients in single dosage units considering fitness-for-use and production capability 
considerations [46]. It was previously reported that (single dose) ALB is more efficacious against 
hookworm than (triple dose) MEB [47], which may partly be explained by our quality results revealing 
that all ALB and TNZ samples fulfill the acceptance criteria for dosage uniformity while 19.1% (8/42) 
of MEB samples did not meet these pharmacopoeial acceptance criteria.  
Friability test is conducted to check whether the weight loss during handling is within 1.0% loss 
specification limit. As indicated in Table 6, 5 ALB, and 3 MEB and 3 TNZ tablet samples failed the 
pharmacopoeial acceptance criteria of friability. The percent weight loss for all the drug samples 
failing the specification criteria ranges between 2.2 to 6.0%, where the largest weight loss was 
registered from a MEB tablet sample. Taking into consideration the single dose regimen and the 
already substandard drugs with content less than 90 %lc, this maximum weight loss from friability 
study by MEB sample could further pose more risk of drug resistance leading to treatment failure 
than the other two drugs, ALB and TNZ.  
In the present study, since all the drug samples tested for disintegration have met the 
pharmacopoeial acceptance criteria, there is no risk associated with disintegration as a quality 
attribute. However, 42% of the ALB samples and 18% of the TNZ samples which were tested for 
dissolution have been found to be out of the pharmacopoeial specification limit. For low solubility 
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drugs, raw material and process variables could have impact on clinical safety and efficacy through 
their effects on dissolution. Therefore, the risk of clinical failure is higher for ALB than TNZ as more 
delayed dissolution was observed, which could be due to changes in the drug substance particle size, 
failure to control granulation, and increased level of binder in the formulation [48].   
The information available on the effectiveness of various BZs derivatives (e.g. ALB and MEB) is 
somewhat inconsistent [49, 50]. Thus the observations of different therapeutic outcomes have been 
to some extent attributed to the different polymorphs with different dissolution rates and 
anthelmintic activities. Solid-state properties play crucial role in dissolution rate and solubility, 
especially when different polymorphs are involved affecting the in-vivo performance of the drugs 
[51-54]. For example, MEB exists as polymorphs and solvates in the solid state. Of particular 
importance is the difference in the physicochemical properties of the three known polymorphs A, B, 
and C. The polymorphic forms of MEB display significant differences in solubility and therapeutic 
efficacy and form C is preferred clinically due to its optimal bioavailability and reduced toxicity. This is 
important because polymorph A has no anthelmintic activity alone or when present above 30% in 
polymorphic mixtures. Literatures indicate that at temperatures typically found in countries located 
in ICH climatic zones III (hot and dry) and IV (hot and humid) trace amounts of form A in tablets 
significantly accelerate the transformation of the clinically active polymorph C to form A. This 
transformation significantly reduces the shelf lives and the dissolution rates of these tablets [55].  
ALB also exhibits some polymorphic forms by forming solvated crystals. Each of these crystals, 
including the un-solvated form, may exhibit all the aspects of polymorphism. However, solid state 
characterization of ALB indicated that both forms are physically quite stable [51]. A literature report 
indicated that TNZ also exhibits crystal polymorphism [56].   
Regarding the use of ALB or MEB, specific attention should be given to the dose appropriate for 
infants (12 months and less). Apart from the likelihood of both prevalence and intensity being 
relatively low in infants in areas where soil-transmitted helminthiasis is endemic, there are questions 
of efficacy and safety when using an anthelmintic drug in very young children [57]. Some studies 
reveal that the no observed effect level/no observed adverse effect level (NOEL/NOAEL) for ALB is 7 
mg/kg/day and that of MEB was found to be 7.8 and 8.4 mg/kg/day in males and females, 
respectively in experimental animals [58]. Taking the studied ALB tablets, it is possible to assess the 
associated risk due to the overdosed assay values. The standard treatment guideline for Ethiopia 
recommends 400 mg tablet as a single dose for treatment of different helminths infections [58]. 
Assuming an average body weight of 70 kg (body mass index: 23 and height: 175 cm), the 
NOEL/NOAEL value for ALB can be calculated to be 490 mg per day (taking a safety factor of 1), 
equivalent with 122.5 %lc for a 400 mg tablet. All the assay values for ALB drug products were found 
to be less than or equal to 111.0 %lc, indicating absence of clinically significant risk for the ALB 
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overdosed formulation related to adverse effects. For MEB, since the treatment guideline 
recommends 200 mg per day [59] and the NOEL/NOAEL value is much higher, the over-dose in the 
assay values is not a direct clinical concern related to adverse effects.  
The assay distribution of the analyzed TNZ samples was found to be from 86.1 to 120.6 %lc. 
Considering the 2 g single dose regimen of TNZ for treatment of giardiasis and the high level 
NOEL/NOAEL value of 150 mg/kg together with the relative clinical safety of TNZ, the over-dose in 
the assay values is also not a direct clinical concern related to the adverse effects.  
Under-dosing, which could be caused by degradation due to inappropriate storage conditions, might 
pose toxicity risks due to the degradant impurities. It can be one of the risk factors for the 
development of anthelmintic resistance. Sub-optimal regimens are the rule in human treatment: 
anthelmintics are administered in single doses that never achieve 100% efficacy. Taking into account 
the limited efficacy of single dose anthelmintic treatments, the currently recommended regimens 
could constitute a significant contributing factor to the development of anthelmintic resistance in 
STH [60]. In addition to the single dose regimen, the substandard drugs with content less than 90 %lc, 
could further exacerbate the problem of drug resistance leading to treatment failure. Therefore, the 
risk of development of drug resistance to MEB is higher than the other two drugs, ALB and TNZ since 
four of the six under-dosed substandard drug samples were MEB.  
 
Risk-based approach to medicines quality 
FMEA is a well-known assessment tool used to identify the critical components most likely to cause 
failures and to enhance system reliability, through the development of suitable corrective and 
preventive actions (CAPAs) [61]. Typically, the criticality is evaluated either with the criticality 
number (CN), or with the risk priority number (RPN). Although the CN is considered more consistent 
and accurate, the RPN approach is generally preferred, especially for its easiness of use [62], where 
the higher RPN values indicate the criticality of the quality attribute.  
 
The desirability function and its application in evaluation of quality of 
medicines  
Optimizing parameters is a critical issue during the development of any method and/or product. A 
special set of functions called desirability functions have been used in optimizing methods [63, 64] 
and products characteristics [65, 66]; but the application of such desirability functions for the 
assessment of the quality of pharmaceutical products is new.  
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The overall desirability function D is obtained from the individual desirabilities (di) using Equation 2. It 
can provide a way to assess the quality according to one property, the overall D-value. By mapping all 
properties onto a desirability scale between 0 and 1, the individual desirability scores due to multiple 
properties may be easily combined as a geometric mean even if the properties have different scales 
or units of measurement [67]. 
In the calculation of the overall D-value using Equation 2, pi = 3 was used for assay since quality risk 
associated to it was found to be more important (RPN = 512). Similarly, pi = 2 was used for dissolution 
since the risk associated with dissolution was of more concern (RPN = 336) than others. For each of 
identity and dosage uniformity, pi = 1 was assigned. The risk assessment revealed that friability was 
not critically important with calculated RPN value of only 2 and thus was not considered for the 
desirability study.  
The risk analysis conducted indicated that the failure effects due to the failure modes (non-complying 
quality attributes) was found to be almost similar for the three products analyzed. For example, for 
all, the over-dose in the assay values was evaluated to be not a direct clinical concern related to the 
adverse effects. Moreover, since all the three drugs are in BCS class II [26], dissolution is equally a 
concern. Therefore, the same Derringer’s desirability function was applied to all the drug products.    
 In general, comparing the two quality evaluation approaches, it is reported that 29.2% of the 
samples were of poor quality when using the pharmacopoeial method of quality evaluation, while it 
is 28.3% using the new innovative risk-based desirability function approach. Even though it seems 
that there is no discrepancy between the results of the conventional and D-function approach, we 
still want to argue that the D-approach provides more weight to the clinically more critical quality 
attributes and thus fit-for-purpose in resource-limited economies. Resources could thus be 
prioritized and reliable decisions can be made on the available data using only the clinically more 
critical quality attributes (assay and dissolution) than the less critical ones (friability and 
disintegration tests). Moreover, the new QbD and risk-based approach will less heavily penalize 
marginal out-of-specification medicines, and therefore, we believe it is especially important for poor-
resource countries.      
 
 
5.  CONCLUSIONS 
The study indicated that all sampled products (MEB, ALB and TNZ) did contain the stated active 
ingredient, but poor quality products were identified in all three medicines and collection sites in the 
country due to non-compliant assays, inadequate drug release of required dose or toxicity concerns 
due to over-dosage of some of the medicines containing higher level of active ingredient. Over-dose 
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in the assay values of the three studied drugs is not a direct clinical concern related to adverse effects 
where as under-dosing constituted one of the risk factors for the development of resistance.    
The study further identified the most critical quality attributes in product quality assessment using 
FMEA risk-based quality evaluation of the three drugs where assay was found to be the most critical 
quality attribute with highest RPN. Moreover, it was revealed that Derringer’s desirability function 
can be applied to pharmaceutical quality assessment using Psychophysical Harrington’s scale of 
quality where products could be classified into excellent, good, acceptable, low and bad quality.  
Our study suggests policy strategies of containing the problems related to poor quality medicines 
using this proactive risk-based and desirability function approaches in nation-wide surveillance of the 
quality of medicines circulating in their respective markets. Furthermore, other possible strategies for 
containing the problem of these poor quality medicines are e.g.:  
 strengthening the capacity of drug regulatory authorities for quality assurance and quality 
control activities; 
 harmonization and regional sharing of information about manufacturing and distribution 
quality; 
 enforcement of regulations and legal prosecutions; 
 empowerment and capacity building of medicines inspectors; 
 continuous inspection and monitoring of the different levels of medicines supply chain; 
 continuous and sustainable product quality surveillance studies with strong monitoring and 
evaluation activities 
 
 
6. REFERENCES 
[1] Coulibaly JT, Fürst T, Silué KD, Knopp S, Hauri D, Ouattara M, Utzinger J, N’Goran EK. Intestinal 
parasitic infections in schoolchildren in different settings of Côte d’Ivoire: effect of diagnostic 
approach and implications for control. Parasit Vectors 2012; 5: 135. 
[2] Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, Diemert D, Hotez PJ. Soil-transmitted 
helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 2006; 367: 1521–1532. 
[3] Hotez PJ, Molyneux DH, Fenwick A ,Kumaresan J, Sachs SE, Sachs JD, Savioli L. Control of 
neglected tropical diseases. N. Engl. J. Med. 2007; 357: 1018-1027. 
[4] Stephenson LS. Helminth parasites, a major factor in malnutrition. World Health Forum 1994; 
15: 169-172.  
CHAPTER V – QUALITY OF MEDICINES USED FOR THE TREATMENT OF SOIL TRANSMITTED HELMINTHS AND GIARDIA IN ETHIOPIA: A NATIONWIDE SURVEY 
  
 
150 
[5] Vecchiato NL. Digestive worms: ethnomedical approaches to intestinal parasitism in southern 
Ethiopia. In Inhorn MC, Brown PJ, editors. The Anthropology of Infectious Disease: 
international health perspectives. Amsterdam: Gorden and Breach publishers. 1997; pp. 241-
266.  
[6] Wiwanitkit V. Intestinal parasite infestation in HIV infected patients. Curr. HIV Res. 2006; 4: 87-
96. 
[7] Keiser J, Utzinger J.  The drugs we have and the drugs we need against major helminth 
infections. Adv. Parasitol. 2010; 73: 197-230. 
[8] World Health Organization (WHO). Preventive chemotherapy in human helminthiasis: 
coordinated use of anthelminthic drugs in control interventions: a manual for health 
professionals and programme managers. Geneva. Switzerland; 2006.  
[9] Minvielle MC, Basualdo JA, Ciarmela ML, Niedfeld G. Anthelmintic efficacy of tinidazole against 
the progression of Toxocara canis larvae to the brain in mice. Parasitol. Res. 1999; 85: 830-832. 
[10] Keiser J and Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: 
systematic review and meta-analysis. JAMA 2008; 299: 1937-1948. 
[11] Olsen A. Experience with school-based interventions against soil-transmitted helminths and 
extension of coverage to non-enrolled children. Acta Trop. 2003; 86: 255-266. 
[12] Heyman ML, Williams RL. Ensuring global access to quality medicines: Role of the US 
pharmacopeia. J.  Pharm. Sci. 2011; 100: 1280-1287. 
[13] World Health Organization (WHO). Medicines: spurious/falsely-labelled/falsified/counterfeit 
(SFFC) medicines.  Geneva, Switzerland; 2012.  
[14] Caudron JM, Ford N, Henkens M, Mace C, Kiddle‐Monroe R, Pinel J. Substandard medicines in 
resource‐poor settings: a problem that can no longer be ignored. Trop. Med. Int. Health 2008; 
13:1062-72. 
[15] Juillet Y. Update on counterfeit drugs: a growing risk for public health. Bull. Acad. Natl. Med. 
2008; 192: 1423-1434. 
[16] Nsimba SE. Problems associated with substandard and counterfeit drugs in developing 
countries: A review article on global implications of counterfeit drugs in the era of anti-
retroviral (ARVS) drugs in a free market economy. East Afr. J. Public Health 2008; 5: 205-210. 
[17] Ten Ham M. Health risks of counterfeit pharmaceuticals. Drug Safety 2003; 26: 991-997. 
[18] World Health Organization (WHO). Survey of the quality of selected anti-malarial medicines 
circulating in six countries of sub-Saharan Africa. Geneva, Switzerland; 2011.  
[19] World Health Organization (WHO). Specifications for prepackaging anti-malarial medicines. 
Geneva, Switzerland; 1999.  
 CHAPTER V – QUALITY OF MEDICINESUSED FOR THE TREATMENT OF SOIL TRANSMITTED HELMINTHS AND GIARDIA IN ETHIOPIA: A NATIONWIDE SURVEY 
 
  
 
151 
[20] Nasr N. Risk Based CMC Review Paradigm. Presentation at FDA Advisory Committee for 
Pharmaceutical Science Meeting, July 20-21, 2004.  
[21] Chakraborty AK, Borah GK. An application of the concept of desirability functions in evaluating 
erection quality. Qual. Eng. 1989; 1: 443-452. 
[22] Derringer GC. A balancing act: optimizing a product’s properties. Quality Progress, 51-58. 
American Society for Quality; 1994. 
[23] Newton PN, Lee SJ, Goodman C, Fernández FM, Yeung S, Phanouvong S, Kaur H, Amin AA, 
Whity CJM, Kokwaro GO, Lindegardh N, Lukulay P, White LJ, Day NPJ, Green MD, White NJ. 
Guidelines for field surveys of the quality of medicines: A proposal. PLoS Med. 2009; 6: 
e1000052.  
[24] Jung H, Medina L, Garcia L, Fuentes I, Esparza MR. Absorption studies of albendazole and some 
physicochemical properties of the drug and its metabolite albendazole sulphoxide. J. Pharm. 
Pharmacol. 1998; 50: 43-48. 
[25] Subramanian S, Singireddy A, Krishnamoorthy K, Rajappan M. Nanosponges: A novel class of 
drug delivery system – review. J. Pharm. Pharmaceut. Sci. 2012; 15: 103-111. 
[26] Dressman JB, Reppas C. In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs. 
Eur. J. Pharm. Sci. 2000; 11: S73-S80. 
[27] Harry MJ, Mann PS, De Hodgins OC, Hulbert RL, Lacke CJ. Practitioner’s guide to statistics and 
lean six sigma for process improvements. A John Wiley and Sons, Inc, NY; 2010. 
[28] International Conference on Harmonization (ICH) Q9. Quality Risk Management, 2006.  
[29] Braglia M. MAFMA: Multi-attribute failure mode analysis. Int. J. Qual. Reliab Manage. 2000; 17: 
1017-1033. 
[30] Chang KH. Evaluate the orderings of risk for failure problems using a more general RPN 
methodology. Microelectron. Reliab. 2009; 49: 1586-1596. 
[31] Taylor RB, Shakoor O, Behrens RH, Everard M, Low AS, Wangboonskul J, Reid RG, Kolawole JA. 
Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 2001; 357: 1933-
1936. 
[32] Monteiro A, Wanyangu S, Kariuki D, Bain R, Jackson F, McKellar QA. Pharmaceutical quality of 
anthelmintics sold in Kenya. Vet. Rec. 1998; 142: 396-398. 
[33] Kahsay G, G/Egziabher A. Quality Assessment of the Commonly Prescribed Antimicrobial Drug, 
Ciprofloxacin Tablets, Marketed in Tigray, Ethiopia. Memona Ethiop. J. Sci. 2010; 2: 93-107. 
[34] Suleman S, Debella A. Comparative evaluation of invitro characteristics of tablets of the 
commonly prescribed antiepileptic drugs: carbamazepine and phenobarbitone. Ethiop. J. 
Health Sci. 2007; 17: 147-153. 
CHAPTER V – QUALITY OF MEDICINES USED FOR THE TREATMENT OF SOIL TRANSMITTED HELMINTHS AND GIARDIA IN ETHIOPIA: A NATIONWIDE SURVEY 
  
 
152 
[35] Wu FC. Optimization of correlated multiple quality characteristics using desirability function. 
Qual. Engng. 2005; 17:119–126. 
[36] Fogliatto FS. Multiresponse optimization of products with functional quality characteristics. 
Qual. Reliab. Engng. Int. 2008; 24: 927–939. 
[37] Bikbulatov ES, Stepanova IE. Harrington’s Desirability Function for Natural Water Quality 
Assessment. Russ. J. Gen. Chem. 2011; 81: 2694–2704. 
[38] International Conference on Harmonization (ICH) Q8. Pharmaceutical Development, 2006.  
[39] Attaran A, Barry D, Bashir S, Bate R, Benton D, Chauvin J, Garrett L, Kickbusch I, Kohler 
JC, Midha K, Newton PN, Nishtar S, Orhii P, McKee M. How to achieve international action on 
falsified and substandard medicines. BMJ 2012; 345: e7381. 
[40] Baert B, De Spiegeleer B. Quality analytics of internet pharmaceuticals. Anal. Bioanal. Chem. 
2010; 398: 125-136. 
[41] World Health Organization (WHO). Survey of the quality of selected anti-malarial medicines 
circulating in Madagascar, Senegal, and Uganda. Geneva, Switzerland; 2009. 
[42] Onwujekwe O, Kaur H, Dike N, Shu E, Uzochukwu B, Hanson K, Okoye V, Okonkwo P. Quality of 
anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. 
Malar. J. 2009; 8: 22. 
[43] Kelesidis T, Kelesidis I, Rafailidis PI and Falagas ME. Counterfeit or substandard antimicrobial 
drugs: a review of the scientific evidence. J. Antimicrob. Chemother. 2007; 60: 214-236. 
[44] Khan MH, Okumura J, Sovannarith T, Nivanna N, Akazawa M, Kimura K. Prevalence of 
counterfeit anthelminthic medicines: a cross‐sectional survey in Cambodia. Trop. Med. Int. 
Health 2010; 15: 639-644. 
[45] Talisuna AO, Karema C, Ogutu B, Juma E, Logedi J, Nyandigisi A, Mulenga M, Mbacham 
WF, Roper C, Guerin PJ, D'Alessandro U, Snow RW. Mitigating the threat of artemisinin 
resistance in Africa: improvement of drug-resistance surveillance and response systems. Lancet 
Infect. Dis. 2012; 12: 888-896. 
[46] Martins JM, Farinha A. Uniformity of dosage units: comparative study of methods and 
specifications between Eur. Pharm. 3rd and USP 23. J. Pharm. Sci. Biomed. Anal. 1998; 18: 487-
495. 
[47] Steinmann P, Utzinger J, Du ZW, Jiang JY, Chen JX, Hattendorf J, Zhou H, Zhou XN. Efficacy of 
single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths 
and taenia sppecies: a randomized controlled trial. PLoS One 2011; 6: e25003. 
[48] Dickinson PA, Lee WW, Stitt PW, Townsend AI, Smart JP. Clinical relevance of disssolution 
testing in quality by design. AAPS J. 2008; 10: 280-290.   
 CHAPTER V – QUALITY OF MEDICINESUSED FOR THE TREATMENT OF SOIL TRANSMITTED HELMINTHS AND GIARDIA IN ETHIOPIA: A NATIONWIDE SURVEY 
 
  
 
153 
[49] Chung MS, Joo KH, Quan FS, Kwon HS, Cho SW. Efficacy of flubendazole and albendazole 
against Trichinella spiralis in mice. Parasite 2001; 8: S195–S198. 
[50] Siriyasatien P, Yingyourd P, Nuchprayoon S. Efficacy of albendazole against early and late stage 
of Trichinella spiralis infection in mice. J. Med. Assoc. Thai. 2003; 86: S257–S262. 
[51] Pranzo MB, Cruickshank D, Coruzzi M, Caura MR, Bettini R. Enantiotropically related 
albendazole polymorphs. J. Pharm. Sci. 2010; 99: 3731-3742. 
[52] García-Rodrigueza JJ, de la Torre-Iglesias PM, Vegas-Sáncheza MC, Torrado-Duránb S, Bolás-
Fernándeza F. Changed crystallinity of mebendazole solid dispersion: improved anthelmintic 
activity. Int. J. Pharmaceutics 2011; 403: 23-28.  
[53] Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, Ponce-Gordo F, Torrado JJ. The effect of 
solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int. J. 
Pharmaceutics 2004; 272: 29-36. 
[54] Honorato SB, Farfan S, Viana A, Filho JM, Camarão GC. Polymorphism evaluation in generic 
tablets containing mebendazole by dissolution tests. J. Braz. Chem. Sos. 2012; 23: 220-227 
[55] Brits M, Liebenberg W, De Villers MM. Characterization of polymorph transformations that 
decrease the stability of tablets containing the WHO essential drug mebendazole. J. Pharm. Sci. 
2010; 99: 1138-1151.  
[56] Borka L, Haleblian JK. Crystal polymorphism of pharmaceuticals. Acta Pharm. Jugosl. 1990; 40: 
71-94. 
[57] World Health Organization (WHO). Strategy development and monitoring for parasitic diseases 
and vector control (PVC), control, prevention and eradication (CPE) programme on 
communicable diseases (CDS). Geneva, Switzerland; 2002. 
[58] Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and 
pharmacokinetics. Acta Trop. 2003; 86: 141-159. 
[59] Ethiopian Food, Medicine and Health care Adminstration and Control Authority (EFMHACA). 
Standard Treatment Guidelines for General Hospitals. Drug Adminstration and Control 
Authority, Addis Ababa, Ethiopia; 2010.  
[60] Vercruysse J, Albonico M, Behnke JM, Kotze AC, Prichard RK, McCarthy JS, Montresor 
A, Levecke B. Is anthelmintic resistance a concern for the control of human soil-transmitted 
helminths? Int. J. Parasitol.: Drugs and Drug Resistance 2011; 1: 14-27. 
[61] Hung GQ, Nie M, Mark KL. Web-based failure mode and effect analysis. Comput. Ind. Eng. 
1999; 37: 177--180. 
[62] United States MIL-STD 1629-A. Procedure for performing a failure mode, effects and criticality 
analysis. Department of Defense, Washington DC, USA; 1998. 
CHAPTER V – QUALITY OF MEDICINES USED FOR THE TREATMENT OF SOIL TRANSMITTED HELMINTHS AND GIARDIA IN ETHIOPIA: A NATIONWIDE SURVEY 
  
 
154 
[63] Safa F, Hadjmohammadi MR. Simultaneous optimization of the resolution and analysis time in 
micellar liquid chromatography of phenyl thiohydantoin amino acids using Derringer’s 
desirability function. J. Chromatogr. A 2005; 1078: 42–50. 
[64] Sivakumar T, Manavalan R, Valliappan K. Global optimization using Derringer’s desirability 
function: Enantioselective determination of ketoprofen in formulations and in biological 
matrices. Acta Chromatogr. 2007; 19: 29-47.  
[65] Van Dorpe S, Adriaens A, Vermeire S, Polis I, Peremans K, De Spiegeleer B. Desirability function 
combining metabolic stability and functionality of peptides. J. Pept. Sci. 2011; 17: 398–404. 
[66] D’Hondt M, Verbeke F, Stalmans S, Gevaert B, Wynendaele E, De Spiegeleer B. Derringer 
desirability and kinetic plot LC-column comparison approach for MS-compatible lipopeptide 
analysis. J. Pharm. Anal. 2014; 4: 173-183..  
[67] Segall MD. Multi-Parameter Optimization: Identifying high quality compounds with a balance of 
properties. Optibrium Ltd, Cambridge, UK; 2009. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER VI – PHARMACEUTICAL REGULATORY FRAME IN ETHIOPIA 
 
 
155 
 
CHAPTER VI 
 
PHARMACEUTICAL 
REGULATORY FRAMEWORK IN 
ETHIOPIA: CRITICAL 
EVALUATION OF ITS LEGAL 
BASIS AND IMPLEMENTATION 
  
 
 
 
“It is very expensive to give bad medical care to poor people in  
a rich country.”  
 
Paul Farmer 
(American anthropologist and physician) 
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ABSTRACT 
Effective and enforceable national regulations describing the manufacture and (re)packaging, export and 
import, distribution and storage, supply and sale, information and pharmaco-vigilance of medicines are 
required to consistently ensure optimal patient benefit. In Ethiopia, a comprehensive regulation of the 
pharmaceutical market was introduced in 1964, and is currently regulated by the “Food, medicine and 
health care Administration and Control Proclamation No.661/2009”. The mere existence of this legal 
framework does not guarantee complete absence of illegal, substandard and falsified products as well as 
illegal establishments in the pharmaceutical chain. Therefore, the objective of the research is to assess 
the pharmaceutical regulatory system in Ethiopia and to reveal possible reasons for deficiencies in the 
pharmaceutical chain. The study revealed that Ethiopia does have a written national drug policy upon 
which the medicines regulatory proclamation 661/2009 is based. According to this proclamation, the 
Ethiopian Food, Medicines and Healthcare Administration and Control Authority is mandated to execute 
the regulatory activities as per the council of ministers regulation 189/2010. The legal framework for 
pharmaceutical regulation of Ethiopia was found to fulfill all the medicines regulatory functions 
potentially enabling to combat illegal, substandard and falsified medicines and illegal establishments. It 
was revealed that there exist illegal sources for medicine in the pharmaceutical market. The main 
reasons for their existence were regulatory factors including weak regulatory enforcement (64.5%), lack 
of informal market control (60.8%), weak port control (50.0%), and poor cooperation between executive 
bodies (39.6%); and resource constraint (27.8%), which is an institutional factor. 
 
CHAPTER VI – PHARMACEUTICAL REGULATORY FRAME IN ETHIOPIA 
 
 
157 
CHAPTER VI 
PHARMACEUTICAL REGULATORY 
FRAMEWORK IN ETHIOPIA: CRITICAL 
EVALUATION OF ITS LEGAL BASIS AND   
IMPLEMENTATION 
Main focus in this chapter: 
 To critically review the legal basis for pharmaceutical regulation in Ethiopia. 
 To assess the implementation of the pharmaceutical regulatory frame in Ethiopia. 
 
1. INTRODUCTION 
The fundamental purpose of medicine regulation is the protection of public health and to ensure that 
medicines on national markets and in international commerce are safe, effective and of good quality, 
and used in accordance with good practices. Medicines are important aspects of public health and 
must be available and accessible to the public.  To improve access to medicines, good governance is 
crucial and contributes to health systems strengthening. Good governance in the pharmaceutical 
sector refers to the formulation and implementation of appropriate policies and procedures that 
ensure the effective, efficient and ethical management of medicine regulation, in a manner that is 
transparent, accountable and follows the rule of law [1-4].  
Since the mid-1930s, many new pharmaceutical products have flourished and trade in the 
pharmaceutical industry has taken on international dimensions. However, the circulation of toxic, 
substandard and counterfeit drugs on the national and international market has increased. This is 
mainly due to ineffective regulation of production and trade in pharmaceutical products in both 
exporting and importing countries. The use of these poor quality medicines may also threaten the 
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health and lives of patients [5]. WHO estimates that from one million deaths that occur from malaria 
annually, 200,000 would be avoidable if the medicines available were effective, of good quality and 
used correctly. A study conducted in South-East Asia in 2001 revealed that 38% of 104 anti-malarial 
drugs on sale in pharmacies did not contain any active ingredient and resulted in a number of 
preventable deaths [6]. Moreover, in-efficiencies in medicines regulatory system can delay entry of 
needed medicines in a market; hence, a barrier to access for users and to the profits and growth of 
the pharmaceutical business [7].  
According to WHO, about 20% of countries have well-developed and operational medicines 
regulation. Of the rest, approximately half have regulation of varying capacity and level of 
development, and 30% have either no or very limited medicines regulation; revealing that many low-
income countries cannot ensure safety, efficacy and quality of medicines circulating on their markets. 
The problems of ineffective regulation have global implications [8] and minimum requirements for 
effective medicines regulation should exist in any country to counter poor quality medicines [9].  
The situation is severe in sub-Saharan African countries where there is limited resources and 
pharmaceutical manufacturing capacity with a high disease burden. Thus, parallel, unregulated 
medicines markets, are posing serious risks for individual and public health [10]. As far as Ethiopia is 
concerned, there is no comprehensive evaluation of the basic medicines regulatory framework and 
associated unregulated medicines and their sources.  
Ethiopia is one of the sub-Saharan African countries where the pharmaceutical sector is being guided 
by a national medicine policy [11]. “The Pharmacists and Druggists Proclamation No 43/1942” was 
the basis for pharmaceutical regulation where both pharmacists and druggists together with the 
facilities where they practiced were regulated. Comprehensive regulation of the pharmaceutical 
sector was started in the early stages by a regulation called “Pharmacy Regulation No. 288/ 1964”, 
which formed the legal basis for official establishment of drug regulation in the history of the 
Ethiopia. Pharmacy and laboratory department under the then Ministry of Health was responsible for 
medicines regulation until June 1999 when a new regulation called the “Drug Administration and 
Control Proclamation No. 176/1999” was promulgated on 29 June 1999. Following this proclamation, 
the regulatory component of pharmacy department was transformed to an independent Drug 
Administration and Control Authority (DACA) of Ethiopia in September 2001 [12]. DACA was re-
structured as Food, Medicine and Health Care Administration and Control Authority (EFMHACA) of 
Ethiopia by the “Proclamation No. 661/2009” in 2010 bearing additional responsibilities like 
regulation of food, health care personnel and settings [13].  
The rapid growth and development of pharmaceutical sector after the downfall of the Dergue regime 
in Ethiopia has led to majority of pharmaceuticals and medical supplies being provided by both the 
public and private sectors. Currently there are 32 plants (small and large scale) involved in the 
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manufacturing of pharmaceuticals and related products of which only 12 are manufacturers of 
generic finished pharmaceutical dosage forms and the remaining are involved in the small scale 
manufacturing of medical devices, supplies, laboratory reagents, cosmetics, and disinfectants [14]. 
According to EFMHACA website (www.efmhaca.gov.et), there are 133 importers, 272 wholesalers, 
377 pharmacies, 1699 drug shops and 1392 rural drug venders currently existing in Ethiopia.  
Some primary data sources reveal that poor quality pharmaceutical products are in the market, 
because of in-efficiencies in pharmaceutical regulatory functions in Ethiopia [15]. In the past few 
years, more than 60% of foreign manufacturers have failed to comply with GMP and hence marketing 
authorization [16]. In the area of post registration testing, low income countries tended to collect 
fewer samples and report higher rates of products failing testing [17].  For example, the result of 
trend analysis on quality control laboratory tests carried out in Ethiopia for samples submitted from 
the year 2007-2011 shows that most of failures of samples submitted for post-marketing surveillance 
(PMS) was higher (9.5%-15.5%) than samples submitted for the purpose of marketing authorization 
(4.7% - 10.7%) [16]. Such public health problems should be investigated through critical evaluation of 
the legal basis and implementation of the pharmaceutical regulatory framework in Ethiopia. 
Regular regulatory systems assessment is important for the policy makers in designing or updating 
policies and strategies to prevent public health from medicines whose safety, efficacy and quality are 
not ensured and authorized to circulate in the market. The legal basis of the existing pharmaceutical 
regulatory system in Ethiopia was critically reviewed in comparison with relatively good regulatory 
systems of three African countries (South Africa, Tanzania and Uganda) and the current EU regulatory 
system. The comprehensiveness of the legislation to protect the public health was critically evaluated 
and its practical implementation was assessed through institution-based cross-sectional survey.  
 
 
2. METHODS 
The study was conducted to critically assess the legal framework of the pharmaceutical regulatory 
system based on Proclamation No.661/2009 and its implementation status on the institutions 
regulated under the national medicine regulatory authority of Ethiopia.  
An archival review, in-depth interviews (with key informants selected from institutions involved in 
the pharmaceutical sector) and institution-based cross-sectional survey using semi-structured 
questionnaires developed based on WHO guideline were used to gather data [18, 19]. A critical 
review on the drug regulation was undertaken followed by semi-structured interviews with key 
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informants from academia, industry and EFMHACA to supplement information gathered from the 
legal sources.  
 
Record/archival review 
For the review process, archival review guide was used as a data collection tool. The tool was 
developed based on WHO guideline [20] and contained detail description on the general content of 
the medicine legislation and a checklist for the functions of the medicine regulatory authority as 
evaluation points. The basic purpose for record/archival review was to assess comprehensiveness of 
the legal framework to protect public health in comparison to medicine regulatory authorities 
(MRAs) of three selected African countries (South Africa, Tanzania and Uganda) and EU’s European 
Medicines Agency (EMA).  According to a study conducted by WHO in 2006, South Africa had a “fully 
functional” MRA, where as Uganda did have a “functional” MRA. The study further reported that the 
MRA of Tanzania and Ethiopia had “potential” [21]. Therefore, selection of the three African 
countries was based on this literature. EU was selected for its strict medicine regulatory system.  
The review process further assessed the availability of basic resources to implement the medicines 
law in relation to marketing authorization/regulatory approvals and regulatory inspections and 
enforcement in Ethiopia. Overall, records on legal framework; resource for implementation and 
implementation reports in protecting public health were assessed. Financial and human resource 
documents; registry for regulatory approval/marketing authorization of medicines, breaches of the 
law related to unauthorized medicines and their sources, and the associated regulatory measures 
taken on violations in comparison to penalties provided in the legislation and guidelines were the 
other focus areas in the record review. Moreover, references on quality of products from the 
national market were included. 
 
In-depth interview 
The purpose of in-depth interview was to get details and new insights from the horse’s mouth. A 
total of 12 key informants selected from different institutions in Ethiopia (EFMHACA, custom 
authority, Ethiopian pharmaceutical association, Ethiopian druggist association, Ethiopian 
pharmaceuticals manufacturers association and academia) were interviewed. In-depth interviews 
were conducted with individuals selected based on their involvement in the regulatory system, 
and/or role as a representative of an industry or stakeholder group. Interviewees were based within 
different institutions and from various disciplines: pharmacy, law, chemistry, food technology and 
management. Several of the individuals interviewed were expert participants with work experience 
of more than 20 years while the minimum work experience was 10 years. Points of interview 
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included: (1) the problems related to safety, efficacy and quality pharmaceuticals in the market; (2) 
government’s political commitment at different levels; (3) adequacy and comprehensiveness of the 
current legal provision in addressing all the pharmaceutical regulatory activities; (4) the capacity and 
organization of the regulatory system at various levels in terms of resources and regulatory 
infrastructures; (5) cooperation and collaboration between these medicine regulatory bodies at 
different level and their collaboration with other law enforcing agencies such as custom, police and 
judiciary bodies; and (6) the public support for medicine regulation particularly in reporting illegal 
medicines circulation. 
 
Cross-sectional study 
Institutional-based cross-sectional survey was conducted to assess the implementation of those 
regulatory functions described in the legislation. Semi-structured questionnaires developed based on 
WHO guideline containing personal information, details of general information on medicines 
regulation, and unauthorized sources and/or products if any was used to collect data. The 
institutions-based cross-sectional study was conducted during March to April 2013 to assess the 
existing regulatory system and its implementation status in Ethiopia. The source population consisted 
of all pharmacy professionals working in EFMHACA and institutions regulated by EFMHACA. Selected 
pharmacy professionals from EFMHACA with work experience of two years and above as well as 
technical managers and marketing personnel of the regulated institutions were included in the study.  
There were 346 institutions regulated by EFMHACA, from which a sampling frame of 30% (n = 105) 
was randomly selected for the study.  From each of the 105 institutions, two study participants were 
purposively selected. Out of a total of 84 pharmacy professionals in EFMHACA, 52 participants were 
included. One hundred ninety seven technical and marketing managers participated in the study, 
making the total number 249. 
 
Data collection tools 
Archival review guide, self-administered questionnaires and key informant interviews guide were 
used as data collection tools. 
 
Data analysis 
Quantitative data were edited, coded, and analyzed using SPSS Statistics version 16.0 software. 
Descriptive analyses were conducted and outputs were presented using frequency tables and charts. 
The data obtained from key informants’ interview were summarized, analyzed and presented in a 
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descriptive way per thematic area. Similarly, summaries were made from the archival review findings 
on the critical features of medicine regulation. A multivariable logistic regression was used to 
investigate the relationship between the different reported factors for the existence of illegal 
pharmaceutical business.   
 
 
3.  RESULTS 
The legal basis of pharmaceutical regulation in Ethiopia: archival review  
Legal framework 
An overview of medicines regulatory framework in Ethiopia, Tanzania, Uganda, South Africa, and EU 
is presented in Table 1; while the legal framework of the respective medicine regulatory authorities is 
presented in Table 2. For all the countries, there exists a well-defined law for medicine regulation 
with clearly articulated objectives of protecting public health from unsafe, inefficacious and poor 
quality medicines. Medicine legislation of Ethiopia is based on proclamation 661/2009 with the 
objective of safeguarding and protecting the public health through ensuring that all medicines 
(produced locally or imported) that circulate in the market and used in the country are safe, 
effective, and consistently meet the acceptable quality standards. 
In Ethiopia, Parliament approves Proclamations, while regulations are approved by council of 
ministers similar to that of Tanzania, Uganda and South Africa. In EU, legislations and directives are 
all approved jointly by European parliament and the council of EU.  
 
Governing body 
A good medicines law creates administrative governing bodies to put rules in to practice [22]. In all 
the studied countries (Ethiopia, South Africa, Tanzania, Uganda and EU), medicine legislations ensure 
legal provisions for the establishment of a governing body called MRA responsible for enforcing the 
legislation. EFMHACA is empowered by council of ministers legislation 189/2010 as the governing 
body for medicine regulation in Ethiopia with its organizational structure presented in Figure 1. 
Tanzanian Food and Drugs Administration (TFDA), National Drug Authority (NDA), and Medicine 
Control Council (MCC) are the executive organs to enforce medicines law in Tanzania, Uganda and 
South Africa, respectively. European Medicines Agency (EMA) is responsible for enforcing medicines 
law in EU.  
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Table 1. An overview of the medicine regulatory framework in the selected countries. 
Features Ethiopia Tanzania Uganda South Africa EU 
Current medicine law of 
the country 
Food, 
Medicine 
and Health 
care 
Administra
tion and 
control 
proclamati
on 
No.661/20
09 
Tanzanian 
Food, Drugs 
and 
cosmetics 
Act No. I of 
2003 
The national drug 
policy and 
authority act 
establish a 
national drug 
policy and a 
national drug 
authority. 
Chapter 206 of 
the law of Uganda 
Commenced: 3 
December, 1993 
Medicine 
and Related 
substances 
Act 101 of 
1965 as 
amended 
act 59 of 
2002 of 
South Africa 
European 
Medicines 
Agency 
(EMA) 
(Regulation 
(EC) No. 
726/2004) 
Objectives of the current 
law/proclamation/regulati
on 
Protect 
public 
health 
from 
unsafe, 
inefficaciou
s and poor 
quality 
medicine 
To ensure 
that only 
safe, quality 
and 
efficacious 
products are 
approved 
for use in 
the country. 
To ensure the 
availability at all 
times of essential, 
efficacious and 
cost-effective 
drugs to the 
entire population 
of Uganda 
To provide 
for the 
registration 
of medicines 
and related 
substances 
intended for 
human and 
animal use 
Protection of 
public health 
on the basis 
of scientific 
criteria of 
quality, 
safety and 
efficacy of 
medicinal 
products 
concerned. 
Provision/
Approvals 
  
Proclamation
/Act 
Parliament  Parliament  Parliament Parliament European  
parliament/t
he council of 
EU 
Regulations/ 
Directives   
Council of 
Ministers 
Ministry 
upon advise 
of TFDA 
Ministry upon 
advise of NDA 
Department 
of Health 
Guidelines  EFMHACA TFDA NDA MCC EMA 
Official 
 Journal 
Negarit 
Gazette 
Gazette Gazette Gazette Official 
Journal for 
EU  L 136 
Executive organ to enforce 
the law 
EFMHACA 
and RRBs 
TFDA NDA MCC EMA, EDQM, 
national 
competent 
authorities 
EFMHACA: Food, medicine and healthcare administration and control authority of Ethiopia; TFDA: Tanzania food and drug 
administration; NDA: National drug authority of Uganda; MCC: Medicine control council of South Africa. 
 
The overall responsibility and accountability for all aspects of medicine regulation is given to a single 
agency in Tanzania, Uganda, South Africa and EU, while it is distributed horizontally between 
EFMHACA and Ministry of agriculture and rural development, and vertically between EFMHACA and 
regional state regulatory bodies (RRBs) in the case of Ethiopia. Ministry of agriculture and rural 
development is responsible to regulate veterinary medicinal products, where as RRBs are responsible 
to regulate establishments in the distribution chain except importers and wholesalers.  
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Table 2. The legal framework of the medicine regulatory authorities (MRAs). 
 Ethiopia Tanzania Uganda South Africa  EU 
Legal status of the 
regulatory authority 
A A A B  A 
Main regulatory 
authority 
EFMHACA TFDA NDA MCC  EMA 
Supervisory body MOH and RHB MOH MOH MOH  MOH 
Links with other local 
regulatory agency 
MOARD & RRB NA NA NA  Member 
states 
Line of command Multiple agencies Single 
agency 
Single 
agency 
Single agency  Single 
agency 
Power to hire or fire 
personnel 
Yes* Yes Yes Yes  Yes 
Financial independence Yes Yes Yes Yes  Yes 
A = semi-autonomous statutory authority under Ministry of Health (MOH), B = council under MOH, NA = not applicable, 
RHB= Regional states Health Bureau, * available at federal level 
 
 
Figure 1. Organizational structure of Food, Medicine and Health care Administration and Control Authority of 
Ethiopia. 
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Regulatory provisions to MRAs 
The content and domains of regulations of Ethiopia, Tanzania, Uganda, South Africa and EU is 
presented in Table 3. In terms of its content and domain of regulation, proclamation 661/2009 of 
Ethiopia covers most of the critical features for medicine regulation with provisions for the major 
regulatory processes. Pharmaceuticals are subject to numerous controls at all levels, and EFMHACA is 
granted to regulate their manufacture, distribution, marketing, prescribing, labeling and dispensing. 
However, there were some differences between legal provisions in Ethiopia and the other countries 
whose legislations were reviewed for comparison. The variations lie on the domains of regulation like 
scope of regulated products (e.g. veterinary medicines are excluded from EFMHACA), price control 
and overall responsibility distribution for medicines regulation. 
 
Product classification 
Pharmaceutical legislations provide product classifications based on definitions for medicines or 
medicinal products. Product classification is important for executing pharmaceutical laws governing 
medicines production, marketing and utilizations.  
According to Article 1 of Directive 2001/83/EC of EU, a medicinal product is defined as: (a) any 
substance or combination of substances presented as having properties for treating or preventing 
disease in human beings/animals; and/or (b) any substance or combination of substances which may 
be used in, or administered to, human beings, either with a view to restoring, correcting or modifying 
physiological functions by exerting a pharmacological, immunological or metabolic action, or to 
making a medical diagnosis. Moreover, Article 2(2) of the Directive provides classification of a 
product into a medicinal product, where doubt remains as to its classification as a medicine or 
another type of product; but the European Court of Justice judgment is helpful. Product classification 
in EU considers presentation and/or purpose/function aspects of the products.  
Article 2(6) of Proclamation No. 661/2009 of Ethiopia defines medicine as any substance or mixture 
of substances used in the diagnosis, treatment, mitigation or prevention of a disease in human and 
includes narcotic drugs, psychotropic substances and precursor chemicals, traditional medicines, 
complementary or alternative medicine; poisons, blood and blood products, vaccine, radioactive 
pharmaceuticals, cosmetics and sanitary items and medical instruments. 
Product classification in Ethiopia (and the three African countries) addresses only the functional issue 
of products and neglects the presentation aspects, which are well described in EU. It poses greater 
challenges to classify products that are on the borderline between medicinal products and food 
supplements, biocides, cosmetic products and medical devices. Moreover, advanced therapy 
medicinal products (ATMP) like gene therapy, somatic cell therapy and tissue engineering are not 
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classified in Ethiopia and in either of Tanzania, Uganda and South Africa. Therefore, EU’s product 
classification is much broader and provides a wider scope of products to be regulated under the law. 
 
Table 3. Content of medicine laws and some regulatory activities of Ethiopia, the three African countries and 
EU. 
Content of the law Ethiopia Tanzania Uganda South Africa EU 
Product 
classification 
      
 Human medicine ● ● ● ● ● 
Veterinary medicine ○ ● ● ● ● 
Medical devices ● ● ● ● ● 
Blood & blood products ● ● ● ● ● 
Tissue transplant ● ● ● ● ● 
Cosmetics ● ● ● ● ● 
Narcotics & psychotropic ● ● ● ● ● 
Herbal products ● ● ● ● ● 
Functional foods ● ● ● ● ● 
Food and additives ● ● ● ● ● 
ATMP ○ ○ ○ ○ ● 
 Border-line products ○ ○ ○ ○ ● 
Regulatory 
functions 
      
Product 
assessment 
and 
registration 
Human medicine ● ● ● ● ● 
Veterinary medicine □ ● ● ● ● 
Herbal products  ● ● ● ● ● 
Biological products ● ● ● ● ● 
Cosmetics ● ● ● ● ● 
Foods and additives ● ● ● ● ● 
Premise 
licensing  
Manufacture ● ● ● ● ● 
importers /wholesalers ● ● ● ● ● 
retail outlets ○ ● ● ● ● 
Inspection GMP inspection ● ● ● ● ● 
 Supply chain inspection ○
a 
● ● ● ● 
Quality control ● ● ● ● ● 
Pharmacovigilance ● ● ● ● ● 
Control of product promotion ● ● ● ● ● 
Clinical trial control ● ● ● ● ● 
Import/export control ● ● ● ● ● 
Price control ○ ● ● ● ● 
Sources of  
products 
regulated 
Private manufacture ● ● ● ● ● 
Government manufacture ● ● ● ● ● 
Private import ● ● ● ● ● 
 Government import ● ● ● ● ● 
Control of 
raw materials 
Active pharmaceutical 
ingredient (API) 
● ● ● ● ● 
Excipients ● ● ● ● ● 
Registration harmonization ○ EAC and 
SADC 
EAC EAC and SADC ICH 
●
Present; 
○
Absent; EAC: East African community; SADC: South African development communities; ICH: International 
conference on harmonization; 
□
not under FMHACA; 
a
Except importer/wholesalers, lower supply chains are regulated by 
regional state regulatory bodies in Ethiopia; ATMP: Advanced therapy medicinal products; Border-line products: between 
medicinal products and food supplements, biocides, cosmetic products or medical devices. 
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Product assessment and registration 
Medicines registration, also called marketing authorization, is often a major element in national 
pharmaceutical law. It is carried out by MRAs to ensure that a medicinal product has been 
adequately tested and evaluated for safety, efficacy and quality and the product information 
provided by the manufacturer is accurate.  
The comparative presentation of market authorization by EFMHACA, TFDA, NDA, MCC and EMA is 
given in Table 4. All the MRAs have a legal basis for marketing authorization of the pharmaceutical 
products with guidance for applicants and standard operating procedures for assessors. Except 
EFMHACA, all the MRAs make use of external experts in the form of various committees and are 
involved in regional or international harmonization of registration process. EFMHACA has a single 
advisory committee, and is not currently participating in regional harmonization for registration, even 
though Ethiopia is very recently working towards harmonization of quality assurance for 
pharmaceutical and medical products with Intergovernmental Authority on Development (IGAD) 
member countries.  
 
Table 4. Marketing Authorization process in five regulatory authorities. 
Particulars  Countries 
Ethiopia Tanzania Uganda South Africa EU 
Legal basis  for authorization ● ● ● ● ● 
Guidance for applicants  ● ● ● ● ● 
SOP for assessment ● ● ● ● ● 
Advisory committee(s) □ ● ● ● ● 
Assessors      
 External Assessors ○ ● ● ● ● 
 Full time assessors ● ● ● ● ● 
Legal provision to publish list of 
approved products  
● ● ● 
 
● ● 
Recognition of  other MRA decision ●
s
 ● ● ●
s
 ● 
Harmonization of registration ○ EAC, SADC EAC SADC ICH 
Fast track registration ● ● ● ● ● 
Collect fee for application ● ● ● ● ● 
Target time frame to assess (in Months)      
 New medicines  6 12 24 7 
 Generic medicines  6 4.5 12 1 
 Fast track applications  6 1.5 6 ● 
Registration validity period (years) 4 5 1 5 5 
S: Stringent MRA and recognized by WHO prequalification program; ●: Yes, ○: No; □: Yes but not functional during the 
assessment; SADC: Southern African Development Communities; EAC: East African Community: ICH: International 
Conference on Harmonization. 
 
Article 20 of Regulation 299/2013 of Ethiopia grants special permit for importation of unregistered 
medicinal products for clinical trials, scientific investigations, personalized use of a patient, laboratory 
quality testing for the purpose of registration, disaster and emergency aids, diplomatic missions and 
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treatment of diseases with no adequate attention. Even though very limited, EU also provides 
exceptions for medicinal products for clinical trials, emergency situation and compassionate use. 
Similar to other MRAs, the market authorization process in Ethiopia includes manufacturing premise 
inspection for GMP compliance, assessment of product dossiers and laboratory testing, where 
applicable. The requirements for Ethiopian market authorization are: (1) the medicinal product has to 
be included in to national medicine list; (2) the manufacturing site has to be approved and certified 
for compliance with GMP either by EFMHACA or other recognized stringent regulatory authorities 
and (3) such GMP certified or waived manufacturers have to submit application for dossier 
evaluation and product quality assessment accompanied with application fee.  
 
Licensing and inspection  
Law should create mechanisms to ensure that relevant parties are licensed and inspected so that the 
community can have confidence in them [21]. Proclamation 661/2009 states that involvement of any 
person or institution in the pharmaceutical sector without being authorized or licensed is legally 
prohibited. A breach of law to trade medicine without certificate of competence shall be punishable 
with imprisonment of 5-7 years and fine of 2,700-5,400 USD [15].  
Medicines retail outlets and supply chain inspections are mandated to RRBs, while EFMHACA is 
responsible for manufacturers, importers and wholesales inspection and licensing unlike TFDA, NDA, 
MCC and EMA. Moreover, the EFMHACA proclamation does not include requirements for obtaining 
licenses, terms and conditions for suspending or revoking activity and product licenses. It does not 
define the norms, standards and specifications to be applied in assessing the quality, safety and 
efficacy of medicinal products. These points and other similar details were left to be stated in the 
directives and guidelines to be prepared by EFMHACA based on the proclamation. 
A review of 2010-2012 performance and activity reports indicated that EFMHACA is striving to 
exercise the legal mandate through preparations and approvals of different directives, standards, 
guidelines, standard operating procedures and check lists. Accordingly, the authority has prepared 39 
standards, 14 directives and various guidelines in the last three years since proclamation 661/2009 
has been enacted.  
 
Control of raw materials 
Proper quality management of pharmaceutical raw materials and excipients during collection,  
import, export, transport, distribution, storage, processing, and documentation is a base to obtain 
safe, efficacious and good quality pharmaceutical products. Therefore, the source, origin and 
suitability of the starting material should be clearly defined and controlled.  
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In all the assessed MRAs, the finished pharmaceutical product (FPP) manufacturers are responsible 
for the control of raw materials (active pharmaceutical ingredients (APIs) and excipients). For EU, all 
imported active substances must have been manufactured in compliance with standards of good 
manufacturing practices (GMP) at least equivalent to the GMP of the EU [23], where as for Ethiopia, 
compliance with Pharmacopoeia specifications and GMP procedures is adequate. 
 
Implementation of Medicines regulation in Ethiopia 
To address the implementation status of medicines regulatory system in Ethiopia, the results of 
in-depth interview of key informants and institutions-based cross-sectional survey were used.  
 
Key informants perspective 
All the key informants agreed that proclamation 661/2009 is comprehensive in addressing all the 
pharmaceutical regulatory activities to protect public health. However, the key informants stressed 
that the important regulatory tools that enable implementation of the proclamation have to be put 
in action since the sole existence of the law does not ensure its implementation.  
 
Government’s political commitment  
All the key informants believe that there is strong political commitment from the government to 
support the pharmaceutical sector in general and the regulatory system in particular. The 
government has already denoted the regulatory system as one of the pillars in the health sector. It 
produced provisions of proclamation for regulation of the pharmaceutical sector, empowered the 
regulatory authority to hire staff and acquire resources, established procurement system to supply 
government health institutions with pharmaceuticals and planned to enhance local production in its 
growth and transformation plan (GTP). The GTP capacitates local manufacturers and attracts 
investors to the pharmaceutical sector. However, the informants emphasized that more should be 
done to establish a strong medicine regulatory. According to them, the physical existence of the law, 
unless supported with a proper organization, qualified human resource and adequate finances, is not 
a guarantee for effective medicines regulation.  
 
Product smuggling 
According to the key informants, pharmaceutical products smuggling is recently emerging in Ethiopia 
and much worsening in remote areas of the country due to weak custom control. Some even claimed 
that they have had observed similar problems even in the central part of the country including Addis 
Ababa.  
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The key informants mentioned that legally imported products were also diverted to the private 
sector. Some added that the problem was not only smuggling, but also the condition in which such 
products were transported and stored. The smuggled products are usually transported using animals 
through deserts without any care for the storage conditions, which could cause further damage or 
degradation to these products.  
The majority of the key informants believed that both professionals and non-professionals in the 
legal and illegal institutions were stakeholders and responsible for the problems. Although some 
importers and distributors may be involved, the primary destinations of such illegal products were 
retail outlets and unregulated markets from which they were dispensed to the end users. Some of 
the key informants claimed that clinics were providing diagnostic and pharmaceutical services 
together for which they were not licensed.  
As per the key informants, the main factors contributing to the existence of illegal products in the 
market were weak regulatory enforcement (64.5%), poor inter-agency cooperation between law 
enforcing bodies (62.2%), and weak boarder control (50%). Decentralization of the regulatory 
activities to lower-level administrations with weak control capabilities created regulatory gaps and 
contributed for smuggling or diversion of the pharmaceutical products in Ethiopia. 
 
Harmonization with-in law enforcing agencies at various administrative levels 
Efforts of cooperation have been undertaken between medicine regulatory bodies at federal, 
regional states and other law enforcing agencies according to the EFMHACA informants. However, 
there is no established system with clearly defined roles and responsibilities of parties involved 
including inter-agency standard operating procedures. The informants added that in particular there 
is weak cooperation between the authority and the prosecutors at court, and thus most illegal cases 
taken to court were not successful. 
 
Cross-sectional survey  
Data were collected from a total of 249 respondents using self administered questionnaire with the 
response rate of 94.3%. The majority of the institutions, 175 (71.1%) were from the central part of 
the country, i.e. Addis Ababa and its surrounding, since the majority of the institutions were 
concentrated around the capital.  
 
Awareness about medicine regulation in Ethiopia 
Of the total 249 respondents, 197 (79.1%) were not staff of EFMHACA, of which only 83 (42.1%) 
reported awareness about the current medicine legislation of Ethiopia. The majority, 67(80.7%), of 
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those who have had awareness, reported that the medicine legislation is comprehensive enough to 
cover important pharmaceutical regulatory activities to protect public health.  
 
Resources for medicine regulation  
The study participants were EFMHACA staff members. They revealed that there is significant 
shortage of qualified and skilled human resource for medicine regulation in Ethiopia. Low salary, lack 
of attractive carrier structure and incentives were reported to be the leading contributing factors to 
hire and retain qualified and skilled personnel within the regulatory system. Regarding the financial 
resources, the study participants confirmed that there was no adequate financing to perform the 
routine regulatory activities due to insufficient government funding and weak revenue generating 
system from services, even though EFMHACA is mandated to use the revenue it generates from 
service delivery.  
 
Unauthorized medicines sources 
Out of the total respondents, 102 (41.0%) reported that there were institutions and/or individuals 
involved in pharmaceutical business without being authorized or licensed to provide such services. 
According to the study participants, these unauthorized/illegal institutions are involved in 
importation and distribution to the medicine retail outlets (pharmacies, drug shops, rural drug 
venders, clinics), and even dispensing directly to the users. The study revealed that there were 
unauthorized sources for pharmaceutical products in all the major commercial cities of the country; 
with majority in the eastern part (71.4%, 10 of 14) followed by the northern region (53.6%, 15 of 28) 
of the country.  
 
Illegal pharmaceutical products 
Seventy eight (31.3%) respondents reported that illegal pharmaceutical products are circulating in 
the pharmaceutical market of the country in the last 12 months preceding the study. It was reported 
that illegal pharmaceutical products enter into the distribution channel either through legal or illegal 
ports. However, the majority of the respondents believed that these products enter through illegal 
entry routes as presented in Figure 2. 
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Figure 2.  Reported entry route and destination of illegal products (n = 73), Ethiopia, March 2013. 
 
The majority of the study participants (158, 63.5%) reported that the main contributing factor for the 
presence of illegal sources was weak law enforcement. All the reported factors are presented in 
Figure 3. 
It was reported that legally imported pharmaceutical products are diverted from public to private 
sectors. Anti-infective medicines (50%) were the most frequently reported illegal pharmaceutical 
products (from which anti-malarial medicines cover more than a third) followed by hormonal drugs 
(insulin and oral anti diabetics, and sex hormone preparations) and contraceptives (21%).   
In a binary logistic regression analysis, variables such as, inadequate law enforcement/regulatory 
measures on illegal institutions, lack of informal market control, poor control at entry ports, poor 
cooperation between FMHACA and regions, availability of illegal medicines, extra profit from illegal 
products, and reporting illegal product were found to have significantly association (p < 0.05 at 95% 
CI) with the existence of illegal institutions in the pharmaceutical sector of the country (Table 5). 
From the multivariate logistic regression analysis performed on these variables, it was found that 
inadequate regulatory measures (enforcement), lack of informal market control, availability of illegal 
pharmaceutical products and location (site) of the country from the entry ports were remained 
significantly associated with the existence of illegal institutions.  
Inadequate regulatory measures/enforcement on violations was found to be strong contributing 
factor for the existence of unauthorized sources. Illegal institutions or individuals are more than 
three times significantly likely to exist in the pharmaceutical market when regulatory measures/ 
Enforcements are inadequate than when such measures are adequate (AOR = 3.5, 95% CI = (1.84, 
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6.65), at p < 0.001). Similarly, illegal institution are two times more likely to exist in the 
pharmaceutical market when informal market is unregulated than when it is regulated (AOR = 1.97, 
95% CI = (1.08, 3.595 at p < 0.05). The illegal sources are three times significantly more likely to exist 
in the presence illegal pharmaceutical products circulating in the market (AOR = 2.785, 95% CI for OR 
(1.52, 5.11), at p ≤ 0.001). 
 
 
Figure 3. Factors contributing to the availability of illegal pharmaceutical sources (n = 245), Ethiopia, March 
2013. 
 
Table 5. Selected factors on existence of illegal pharmaceutical institutions and products, Ethiopia, March 2013. 
Variables 
Existence of illegal 
institutions 
Crude OR (95%CI) 
p-value 
Adjusted OR (95%CI) 
 p-value 
Yes No 
Inadequate regulatory measures 
Yes 84(53.2%) 74(46.8%) 4.35 (2.38, 7.97) 0.000 3.50 (1.84, 6.65 ) 0.000 
No 18(20.5%) 70(79.5%) 1.00  
Port control     
Yes 42(34.1%) 81(65.9%) 1.00 1.00 
No 60(48.8%) 63(51.2%) 1.84 (1.09, 3.03) 0.023 1.13 (0.63, 2.03) 0.689 
Lack of informal market control 
Yes 74(49.7%) 75(50.3%) 2.40 (1.39, 4.1) 0.002 1.97 (1.08, 3.60) 0.027* 
No 28(28.9%) 69(71.1%) 1.00 1.00 
Lack cooperation b/n FMHACA & regions 
             Yes  50(33.6%) 99(66.4%) 1.00 1.00 
             No 52(53.6%) 45(46.4%) 2.29 (1.35, 3.87) 0.002 1.56 (1.00, 3.40) 0.153 
Illegal product exist 
Yes 46(59%) 32(41%) 2.88 (1.65, 5.00) 0.000 2.79 (1.52, 5.11) 0.001 
              No 56(33.3%) 112(66.7%) 1.00 1.00 
Reporting illegal product 
Yes 20(60.4%) 13(39.4%) 1.00 1.38 (0.53, 3.74) 0.532 
No 82(38.5%) 131(61.5%) 2.46 (1.16, 5.21) 0.019  
Extra profit from illegal product 
Yes 50(49%) 52(51%) 1.68 (1.00, 2.82) 0.048 1.04 (0.57, 1.90) 0.892 
No 52(36.1%) 92(63.9%) 1.00 1.00 
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The majority of the respondents claimed that they did not usually report the presence of illegal 
pharmaceutical institutions (53.9%, 55/102) and products (59.0%, 46/78). Details on awareness and 
reporting practice of the respondents is presented in Table 6. The main reasons for not reporting the 
problems were lack of formal reporting system, fear of security problems from smugglers, absence of 
legal measures for previous reports and lack of awareness to whom to report.  
 
Table 6. Awareness and reporting practice of respondents on problems related to pharmaceutical products in 
the market, Ethiopia, March 2013. 
Problems related to pharmaceutical 
product 
Aware of problem Reported problem 
Frequency              (%)* 
Illegal institutions Yes 102(41.5%) Yes 47(46.1%) 
No 144(58.5%) No 55(53.9%) 
Total 246 Total 102 
Illegal products Yes 78(31.7%) Yes 32(41%) 
No 168(68.3%) No 46(59%) 
Total 246 Total 78 
Safety problems Yes 98(39.8%) Yes 32(32.65%) 
No 148(60.2%) No 66(67.35%) 
Total 246 Total 98 
Drug abusers Yes 38(17%) Yes 13(34.2%) 
No 186(83%) No 25(65.8%) 
Total 224 Total 38 
Misleading/in-accurate 
 medicine promotion materials 
Yes 43(17.5%) Yes 18(41.9%) 
No 203(82.5%) No 25(58.1%) 
Total 246 Total 43 
*Percentage calculated of total aware or ‘yes’ at each point not of total respondents which is 246 
 
 
 
4.  DISCUSSION 
An effective national pharmaceutical law is a primary means of ensuring that pharmaceutical policy 
goals are achieved while the unique character of pharmaceutical products, personnel and facilities is 
preserved. Therefore, when assessing the pharmaceutical regulatory system in Ethiopia from the 
legislation point of view, in terms of its purpose and content, comparative review had shown that the 
medicine legislation in Ethiopia provides basic legal framework and covers all products for which 
medicinal claims are made, as well as related pharmaceutical activities, in both the public and private 
sectors. In line with this, the cross-sectional study revealed that the legislation is comprehensive 
enough to cover all pharmaceutical regulatory activities important to protect public health.  
Considering the significant public health implications of veterinary medicines in human health, the 
legislation in Ethiopia does not have provisions for the control of veterinary medicines in contrast to 
all other countries with which the comparative review was conducted. However, Ethiopia has a 
separate authority called veterinary drugs and animal feed administration and control authority 
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established by Proclamation No. 728/2011 to regulate the proper production, distribution and use of 
veterinary drugs to ensure safety, efficacy and quality of the products and to enhance the 
productivity and health of the livestock population. In fact, there should be at least exchange of 
information between this authority and EFMHACA with regard to full regulation of products, 
premises and practicing personnel. 
The Ethiopian legislation mandated EFMHACA to prepare and approve or submit to appropriate 
organ for approval of regulatory standards and specifications to be applied in assessing the quality, 
safety and efficacy of medicinal products and upon approval to ensure the implementation. 
Accordingly, a number of guidelines including guidelines for human medicine evaluation, registration, 
and premises licensing and inspection have been prepared by EFMHACA got approval. However, the 
problem with such mandate is that, guidelines approved by the regulatory authority are only 
administrative tools rather than statutory instrument in the court unless approved by council of 
ministers; which in turn has an influence on enforcement of the law. Moreover, there were no 
reports found on joint operations between EFMHACA and other law enforcing agencies such as police 
and custom authority and this could be taken as additional evidence for lack of inter-agency 
cooperation in Ethiopia, which are very critical for effective medicine regulation [5, 8]. Such 
operational cooperation was reported in other African countries and the experience in Uganda 
revealed a success story. A number of unregistered drug outlets were uncovered and many 
counterfeit products were identified during joint operations between law enforcing agencies (MRA, 
custom, and police) in the span of 2007-2011 in Uganda [24]. The other major finding was that the 
responsibilities for pharmaceutical regulation in Ethiopia are distributed horizontally between two 
ministries; and vertically between federal and regional state governments. Such fragmented systems 
among agencies could lead to overlap of responsibilities and regulatory ineffectiveness [24, 25] 
resulting in wastage of resources in the already poor-economy [26].  
Literatures recommend harmonized optimal drug registration approach for resource-limited settings, 
which should reliably evaluate safety, efficacy, and quality of drugs for use [27-29]. However, 
Proclamation 661/2009 of Ethiopia does not have any article on regulatory harmonization with 
respect to market authorization unlike that of Tanzania, Uganda, South Africa and EU. 
Even though medicine legislation in Ethiopia prohibits the involvement in medicine trade without 
being licensed and sales by licensed importer and wholesaler to person or institution without 
certificate of competence, there exist institutions and/or individuals involved in pharmaceutical 
business without being certified to provide such services. Illegal transits and distributions are usually 
secret for regulatory inspections by custom or medicine regulatory bodies [30], and their existence 
could not only indicate inefficiencies in regulating the sector but also the presence of either 
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unauthorized sources of medicine to the country or pharmaceuticals diversions. Therefore, it is 
reasonable to assume that these unlicensed institutions were the destinations for smuggled or 
diverted pharmaceutical products. This is in line with the reports of the study participants that such 
illegal institution or individuals are in an informal market for medicines and similar finding reported 
the existence of non-conventional market for pharmaceutical products in Ethiopia [31], which could 
lead to the high prevalence of poor quality medicines.   
The study participants reported that illegal medicines included both registered and unregistered 
products of which anti-infective medicines take the major share. Among those medicines imported 
illegally, it is obvious that some were counterfeits and/or substandard. A national quality survey 
study conducted in Ethiopia reported a significant proportion of poor quality albendazole, 
mebendazole and tinidazole tablets on the Ethiopian market from which 29% was substandard [32].  
This study reported diversion of medicines. Another study conducted on assessment of anti-malarial 
diversion in 11 African cities including Addis Ababa showed that 6.5% (58 of 894) samples of anti-
malarial medicines collected from market were found to be diverted across at least one national 
border as determined by visual inspection [33]. Diversion of medicine primarily affects sustainable 
procurement systems, because it exacerbates stock outs in public health sector exposing patients to 
extra costs and making criminals profitable from diversion.  
Inadequate enforcement of law was found to be the leading contributing factor for the presence of 
illegal institutions and/or products. Similarly, literatures revealed that inadequate legislation and 
weak or insufficient law enforcement along with resource constraints to effectively implement the 
law are among the regulatory factors that have contributed to the illegal circulation of medicines in 
many countries [34]. Experiences in Australia, Canada, and the United States have shown that 
adequate legislation and its enforcement result in fewer poor-quality medicines and greater public 
confidence in the quality of the medicines [30]. Although the evidence for the feasibility of strict 
regulatory enforcements is very limited in low income countries, such interventions to improve 
regulatory compliance was reported to have impact on illegal sources in Vietnam and Lao Peoples 
Democratic Republic [35].  
The strength of the study is that it included the strict EU regulatory framework and that of three 
African MRAs to evaluate the legal basis of Ethiopian pharmaceutical regulation. Moreover, it tried to 
address both the regulator and the regulated firms and professionals in the pharmaceutical sector. 
The other strength was the geographic coverage of the study, which was wider and encompassed the 
major trade cities and parts of the country. 
Most archival data are collected for nonscientific reasons and thus often do not suit the purpose of 
the researcher. Moreover, pharmaceutical sector regulation is so sensitive and obtaining reliable and 
genuine data could be difficult.   
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5.  CONCLUSIONS 
The study revealed that medicines regulation as a system in place in Ethiopia has potential capacity 
to develop in comparison with EU; and the three African countries like South Africa, which was 
reported by WHO in 2006 to have fully functional MRA. But this study revealed that 
unauthorized/illegal medicine sources exist in the sector due to some in-efficiencies in the 
implementation of this regulatory system into the real practice. For instance, resource constraints as 
a basic factor along with other reported factors such as lack of informal market regulation, weak 
enforcement of the law and availability of illegal products are regulatory factors. Less reporting 
practice of illegal activities by professionals in the sector was also another important factor 
associated with the existence of illegal institutions in the pharmaceutical market.  
The majority of reported medicines as illegally imported were anti-infective medicines including anti-
malarial and other antibiotics. These reported products included both registered and unregistered 
products. Unregistered products do not only escape the necessary government tax but they are also 
medicines for which quality, safety and efficacy are not ensured. Hence, they could be counterfeit, 
substandard and/or degraded products because of their transportation and storage conditions to 
hide from customs and regulatory authority. In fact, registration is not a guarantee of quality for 
those medicines which are illegally supplied (may be in bad transportation and/or storage conditions) 
but which have passed the formal registration process.  
Proclamation 661/2009 should be amended to include critical legislative gaps like harmonization. 
Product classification should be revised so that a strong autonomous regulatory system should take 
place. RRBs should have mechanisms of cooperating with EFMHACA. EFMHACA should improve 
awareness about the current legal provision for medicine regulation. Moreover, detail national 
assessment of pharmaceutical malpractices and poor quality medicines should be conducted.  
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“If … the past may be no rule for the future, all experience becomes 
useless and can give rise to no inferences or conclusions.” 
 
David Hume 
(°1711 - †1776, Scotish philosopher and economist) 
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GENERAL CONCLUSIONS 
In Chapter I, we described the general introduction about the thesis with the thesis outline and 
objectives. As described in Chapter I, quality of pharmaceutical drugs is a topic of global concern and 
the most important public health aspect. Quality concepts and definitions were clearly described and 
related to factors that cause poor quality medicines. Quality is built into a medicine during its design, 
development, and manufacture. Therefore, manufacturers are primarily responsible for the quality of 
the pharmaceuticals they produce following good manufacturing practices (GMP). After a 
pharmaceutical product leaves the manufacturer’s premises, distributors, procurement agencies 
(purchasers), dispensers, and users are responsible for maintaining the quality of the product 
through proper storage, transport, distribution, dispensing, and use.  National medicines regulatory 
authorities are responsible for ensuring that manufacturers comply with current GMP requirements 
and execute the key regulatory functions that are required to maintain product safety, efficacy and 
quality through out the supply chain until the end user; which may present a challenge for countries 
with limited resources. Therefore, the overall objective of this thesis was described to be to 
contribute to quality of medicines circulating in resource-limitted settings in general and Ethiopia in 
particular from analytical and regulatory point of view. 
In Chapter II, we applied a risk-based QbD approach to establish a drug quality laboratory by the 
name Jimma University Laboratory of Drug Quality (JuLaDQ) in Jimma, Ethiopia. The establishment of 
the laboratory considered the various categories of quality risks associated with the expected routine 
analytical procedures using failure mode effect analysis (FMEA) and devised control measures using 
quality system model that define the end results, analytical quality with reduced variability. 
Therefore, the analytical results produced by JuLaDQ are accurate, traceable and reliable and the 
established laboratory is fit-for-purpose.  
In Chapter III, a stability-indicating HPLC-UV method for the determination of lumefantrine in FDC 
products was developed and validated. Then, an exhaustive impurity profiling of lumefantrine was 
performed using HPLC-UV/ESI-ion trap MS. From unstressed, stressed and accelerated stability 
samples of lumefantrine API and FPPs, nine compounds were detected and characterized to be 
lumefantrine related impurities. One new lumefantrine related compound, DBK, was identified and 
characterized as a specified degradation impurity of lumefantrine in real market samples (FPPs). The 
in-silico toxicological investigation (Toxtree® and Derek®) indicated overall a lesser toxicity for the 
specified impurity DBK compared to the API lumefantrine itself. Moreover, a GC-FID method for 
GENERAL CONCLUSIONS 
  
 
184 
lumefantrine assay in pharmaceutical preparations was also developed and validated within an 
analytical QbD approach. The method is linear, precise and sensitive. It makes use of simple sample 
preparation procedures and is not solvent consuming. The retention time of lumefantrine was 26.0 
min and there was no interference from its related synthesis and degradation impurities and 
excipients. The developed method was successfully applied to analyze lumefantrine content in 
different marketed anti-malarial FPPs and can thus be applied to routine quality control of 
lumefantrine in pharmaceutical preparations.  
In Chapter IV, a stability-indicating HPLC method for simultaneous assay of β-artemether and 
lumefantrine fixed dose combination anti-malarial products was developed, using a fused-core 
reversed-phase amide stationary phase combined with an isocratic acetonitrile sodium phosphate 
mobile phase [Acetonitrile/1 mM phosphate buffer pH 3.0 (52:48, v/v)]. It is a rapid (four minutes 
total run time), precise and accurate method that can be utilized to quantify these anti-malarials in 
the presence of their related degradation products or impurities produced during inadequate 
transportation and storage. This method can be applied in the routine regulatory quality control of β-
artemether and lumefantrine containing FDC drug products. The in-silico toxicological investigation 
using Derek Nexus® indicated overall a toxicity risk for β-artemether-related impurities comparable 
to that of the API β-artemether itself. Moreover, quality survey of ACT FDC anti-malarial products 
was conducted in Jimma zone (Oromia regional state), southwest Ethiopia. The study revealed that 
there were no falsified packages and labels for the samples obtained from formal outlets. All the 
sampled ACT products did contain the stated active ingredient and all (except one sample with 111% 
lc for lumefantrine) comply with the acceptance criteria set in Ph. Int. for assay (90-110 % lc) and Ph. 
Eur. for mass uniformity. Even though this is good for the malaria control program of the country, it 
does not necessarily imply the efficiency of the overall national regulatory system of Ethiopia, 
including the private sector as well. Therefore, regulatory and policy strategies including nationwide 
surveys of quality of medicines for the containment of poor quality anti-malarials should always be 
active and implemented.  
In Chapter V, nationwide quality survey of MEB, ALB and TNZ was conducted in the legal distribution 
chain of Ethiopia as a reality check. The survey study indicated that all sampled products did contain 
the stated active ingredient, but poor quality products were identified in all three medicines and 
collection sites in the country due to non-compliant assays, inadequate drug release of required dose 
or toxicity concerns due to over-dosage of some of the medicines containing higher level of active 
ingredient. Over-dose in the assay values of the three studied drugs is not a direct clinical concern 
related to adverse effects where as under-dosing constituted one of the risk factors for the 
development of resistance. The study further identified the most critical quality attributes in product 
quality assessment using FMEA risk-based quality evaluation of the three drugs where assay was 
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found to be the most critical quality attribute with highest RPN. Moreover, it was revealed that 
Derringer’s desirability function can be applied to pharmaceutical quality assessment using 
Psychophysical Harrington’s scale of quality where products could be classified into excellent, good, 
acceptable, low and bad quality.  
In Chapter VI, the pharmaceutical regulatory framework of Ethiopia is critically reviewed from legal 
basis and implementation point of view. From legislation point of view, medicines regulation as a 
system in place in Ethiopia has potential capacity to develop in comparison with EU; and the three 
African countries such as South Africa, which was reported by WHO in 2006 to have fully functional 
MRA. But this study revealed that unauthorized/illegal medicine sources exist in the sector due to 
some in-efficiencies in the implementation of this regulatory system into the real practice. For 
instance, resource constraints as a basic factor along with other reported factors such as lack of 
informal market regulation, weak enforcement of the law and availability of illegal products are 
regulatory factors. Less reporting practice of illegal activities by professionals in the sector was also 
another important factor associated with the existence of illegal institutions in the pharmaceutical 
market. The majority of reported medicines as illegally imported were anti-infectives including anti-
malarial and other antibiotics. These reported products included both registered and unregistered 
products. Unregistered products do not only escape the necessary government tax but also they are 
medicines for which quality, safety and efficacy are not ensured. Hence could be counterfeit and 
substandard products or degraded products because of their transportation and storage condition to 
hide from customs and regulatory authority.  
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BROADER INTERNATIONAL CONTEXT, 
RELEVANCE AND FUTURE PERSPECTIVES 
Sir Winston S. Churchill (1874 – 1965: UK prime minster from 1940 to 1945 and 1951 to 1955) quoted 
that “Healthy citizens are the greatest assets any country can have”. For the wellbeing of all citizens, 
access to health services of appropriate quality is critical. According to the world health organization 
(WHO), access to quality medicines was identified as one of the prerequisites in the universal health 
coverage; but is often a neglected issue in developing countries. To improve this situation, the overall 
objective of this PhD dissertation was to contribute to the quality enhancement of medicines in 
Ethiopia and the whole region of the horn of Africa (HOA). 
According to international conference on harmonization (ICH), product quality does not happen by 
accident, nor is it acceptable under the current regulatory guidelines to use end-product testing to 
achieve quality by scrapping product that does not meet specifications. Rather, quality must be 
created into the process and product, and this can be accomplished only when there is extensive 
scientific knowledge of the desired product characteristics and the processes that transform the 
incoming materials into the final product. Such quality-by-design (QbD) principles, already used since 
decades in other industries, have been slowly -but now broadly- applied in the pharmaceutical field 
for process and product development; as well as in analytical method development. However, its 
application in setting-up facilities like pharmaceutical quality control (QC) laboratories is new. This 
new insight of extending the existing product and analytical QbD semantics to laboratory QbD is 
getting formal recognition from WHO prequalification inspectors as it was explicitly described in their 
Jimma University Laboratory of Drug Quality (JuLaDQ) inspection (October 2015) result report of 
November 2015. Utilizing the knowledge, skills and experience obtained from and during this PhD 
activity, we were able to set-up a pharmaceutical QC laboratory in a resource-limited setting by 
applying a scientific risk-based QbD approach. JuLaDQ, the fully functional GMP-compliant QC-lab 
set-up in Jimma/Ethiopia, can contribute to the quality enhancement of medicines both nationally 
and in the whole HOA region. The capacity developed at this particular facility could serve as a hub to 
strengthen both national and HOA-regional pharmaceutical quality systems. It can contribute to the 
supply of quality medicines of direct relevance to priority national and regional health programs by 
providing QC analytical services through collaboration with both national and international 
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stakeholders, contributing in countering the problem of poor quality medicines, the enormous global 
public concern with major prominence in developing countries. 
Since the QC-lab is university-based, it also aims at integrating QC-services, training (short- and long-
term, and on the job training) and research in the area of advanced pharmaceutical quality-related 
sciences. These roles will ensure that the lab provides the technical leadership and global advocacy 
regarding the importance of medicines quality and its required analytics. Through its research and 
development, improved quality tools and methods for medicines can be developed and 
disseminated. Moreover, broader and focused long term and high level knowledge and skill based 
research projects that can accommodate new PhD programs are being developed. 
In this PhD dissertation, we developed improved and advanced analytical methods of separation and 
detection for the selected medicines. The methods were communicated to the international 
community through publications and symposia presentations: these can thus be evaluated by other 
laboratories, eventually adapted, and transferred to interested manufacturing companies, regulatory 
authorities, research organizations and institutions, national and/or international laboratories. The 
developed methods were technically kept as simple as required to solve the quality question, while 
also considering the economics of time, solvents and equipment/columns for the lab-users.  
In this PhD project, we developed also a new risk-based desirability function approach which can be 
used in surveys of medicines quality. This approach combined the existing knowledge about the 
chemical analytics of the medicines of interest with that of the ICH-recommended risk-based quality 
ranking by incorporating the clinical relevance of quality attributes. Moreover, by combining the 
individual quality attributes into one global quality number using the desirability function approach, 
this allows a more quantitative overall quality ranking.  This is a new approach in medicines quality 
assessment, which can be applied in for example the comparative and time-based quality evaluations 
by national and international authorities. 
This PhD project also critically evaluated the Ethiopian pharmaceutical regulatory framework from a 
broader international perspective, leading to some recommendations for policy strategies in order to 
restrict the problems related to poor quality medicines: strengthening the capacity of drug regulatory 
authorities for inspection activities; harmonization and regional sharing of information about 
manufacturing and distribution quality; enforcement of regulations and legal prosecutions; 
empowerment and capacity building of medicines inspectors; continuous monitoring of the different 
levels of medicines supply chain; continuous and sustainable product quality surveillance studies with 
strong corrective measures where required. 
Experience gained from this PhD work made the Jimma University realize that capacity building for 
research is a prerequisite for developing a lasting research tradition and for ensuring that the 
research outcomes are translated into practical recommendations for decision makers to ultimately 
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improve the health of the citizens. Moreover, by establishing this medicine GMP QC-laboratory, the 
importance of quality systems has been generally recognized, and will thus not be limited to this 
medicine laboratory but will also overflow to other R&D university laboratories. 
To summarize, this PhD thesis contributes to a better understanding of quality of medicines both 
from analytical and regulatory perspectives for possible evidence-based interventions in the process 
of medicines quality systems in Ethiopia and in the whole HOA region.  
The outlook for the future resulting from this PhD work can be exemplified by following prospects: 
(1) Routine analytical QC services under GMP can be delivered to different stakeholders. 
Appropriate, rapid, stability-indicating and economical chromatographic analytical 
techniques were developed so that resource-limited economies in general and Ethiopia in 
particular could use them in the routine regulatory QC of medicines which are circulating in 
the markets. In addition, we are working with EFMHACA and other related national and 
international stakeholders to make JuLaDQ a center of excellence for drug quality both at 
national and regional level in the horn of Africa. Moreover, we are working recklessly with 
WHO for JuLaDQ WHO-prequalification as well as with the Ethiopian Ministry of Science and 
Technology for ISO-accreditation based on ISO/IEC 17025 quality management requirements. 
The first inspection results of both were encouraging. Finally, this GMP-aspect will also 
continuously be monitored and will be included in future research projects. 
(2) Further research and development activities on advanced medicines analytics. 
The advanced knowledge obtained from this PhD work and the establishment of JuLaDQ 
laboratory created a good opportunity for further R&D activities. Our research group would 
like to continue working in the following areas already started up: 
Quality evaluation of different essential medicines in Ethiopia and the HOA region: This study 
is a continuation of this PhD thesis and thus quality surveys of different medicines from 
essential drug list in Ethiopia will be conducted. Currently, quality survey of essential 
medicines including the anti-malarial drugs (quinine and chloroquine), antimicrobials 
(amoxicillin, norfloxacin, ciprofloxacin, and co-trimoxazole) and anthelminthic medicines is 
being conducted. 
The development of dissolution systems, including in-vitro/in-vivo correlation studies, on anti-
malarial and anthelmintic medicines, seen their health importance and bioavailability issues. 
This study is a PhD project that has recently been started up, in a joint collaboration effort 
between Ghent and Jimma University. 
Analytical and bio-functional evaluation of different endemic plants of Ethiopia. Firstly, 
ethnobotanical studies will be conducted, endemic plants of Ethiopia with traditional claims 
of anti-infective property will be phytochemically screened and the molecular 
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characterization the different secondary metabolites responsible for the bio-functionality will 
be conducted. One PhD project on anti-malarial bio-functionality evaluation of the endemic 
plants of Ethiopia is already launched and preliminary results are being generated. We will 
extend this project to lead compound investigation and characterization towards optimized 
anti-infective agent discovery. 
(3) Human resource capacity building. 
We need to further develop human capacity with regard to quality analytics of medicines. 
The strategies are: (a) short-term training: continuous professional development in various 
areas of quality analytics of medicines, GMP/GLP and regulatory aspects; (b) long-term 
training: strengthening existing Master of Science (MSc) programs and launching new MSc 
and PhD programs in pharmaceutical quality sciences including student exchange programs. 
(4) Scientific communications. 
We will be involved in participating and organizing both national and international 
workshops and symposia on a wide range of drug quality and related fields of Pharmaceutical 
Sciences. Policy briefs will be communicated to the responsible regulatory authorities to 
improve the system and decisions. Research outputs will be communicated in reputable 
national and international journals. 
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“In all human affairs there are efforts, and there are results, and the 
strength of the effort is the measure of the result.” 
 
 
James Allen 
(°1864 - †1912, English author and poet) 
 
 
 
CURRICULUM VITAE 
  
 
194  
    CURRICULUM VITAE 
  
 
195 
 
CURRICULUM VITAE 
SULTAN SULEMAN 
PERSONAL INFORMATION 
Surname: Suleman 
First name: Sultan 
Nationality: Ethiopian 
Place & date of birth: Thursday, 28 May 1977 
 
Private address: PO. Box: 1925 
  Jimma, Ethiopia 
 
Professional address: Jimma University Laboratory of Drug Quality 
  School of Pharmacy 
  Jimma University 
  PO. Box: 378 
  Jimma, Ethiopia 
Phone:  (+251) 911 74 23 54 
E-mail:  sultan.suleman@ju.edu.et 
URL:  http://www.ju.edu.et 
 
EDUCATION 
1996 – 2001:  Bachelor of Pharmacy (B.Pharm), School of Pharmacy, Addis Ababa 
University, Addis Ababa, Ethiopia 
2003 – 2005:  Master of Science (M.Sc) in Pharmaceutical Analysis and Quality Assurance, 
School of Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia 
2006:  ‘Developing Vaccinology expertise for sub-saharan Africa’ of Ethioian 
Paediatric Society, Addis Ababa, Ethiopia 
2010:  ‘Scientific Paper Writing’ at Jimma University, Jimma, Ethiopia 
CURRICULUM VITAE 
  
 
196  
2010:  ‘Transcriptomics’ of VIB Research and Training course at Ghent University, 
B-9000 Ghent, Belgium 
2014: ‘Investigators Safety’ of Johnson-Johnson Pharma at Jimma University, 
Jimma, Ethiopia  
2014: ‘Good Clinical Practice (GCP) and best Practices when Managing Clinical 
Trials’ of Johnson-Johnson Pharma at Jimma University, Jimma, Ethiopia 
2014: ‘Interregional Seminar for Quality Control Laboratories involved in WHO 
Prequalification’, Potchefstroom, South Africa 
2014: ‘Industrial Pharmacy Training’ of Gulf Pharmaceutical Industries, Ras Al 
Khaimah, United Arab Emirates 
2015: ‘Good Manufacturing Practices (GMP)’, Julphar Pharmaceuticals, Addis 
Ababa, Ethiopia 
 
PROFESSIONAL EXPERIENCE 
September 2001 – August 2002: Graduate Assistant II, School of Pharmacy, Jimma University, 
Jimma, Ethiopia 
September 2002 – August 2003: Assistant Lecturer, School of Pharmacy, Jimma University, 
Jimma, Ethiopia 
September 2005 – January 2009: Lecturer, School of Pharmacy, Jimma University, Jimma, 
Ethiopia 
February 2009 – May 2014: Assistant Professor, School of Pharmacy, Jimma University, 
Jimma, Ethiopia 
June 2014 – Present: Associate Professor, School of Pharmacy, Jimma University, 
Jimma, Ethiopia 
 
POSITIONS 
October 2005 – January 2008: Head, School of Pharmacy, Jimma University, Jimma, Ethiopia 
April 2008 – March 2009: Deputy Leader (south), Infectious Disease and Modeling 
Project, VLIR IUC-JU Program, Jimma University, Jimma, 
Ethiopia 
January 2008– December 2010: Country Case study leader-Ethiopia: International 
Pharmaceutical Federation (FIP)-World Health Organization 
(WHO)-World Bank Tripartate Pharmacy Education Taskforce  
    CURRICULUM VITAE 
  
 
197 
April 2010 – Present: Leader (south), Drug Quality and Therapeutics sub-project of 
Infectious Disease Epiedmiology Project, VLIR IUC-JU Program, 
Jimma University, Jimma, Ethiopia 
August 2015 – Present: Director, Jimma University Laboratory of Drug Quality 
(JuLaDQ), Jimma University, Jimma, Ethiopia 
 
 
PUBLICATIONS IN JOURNALS WITH PEER REVIEW 
PUBLISHED AND/OR ACCEPTED 
Suleman S, Debella A. Comparative Evaluation of in vitro Characteristics of tablets of the commonly 
prescribed antiepileptic drugs, Carbamazepine and Phenobarbitone. Ethiopian Journal of Health 
Sciences 2007; 17: 147-154.  
 
Suleman S, Mekonnen Z, Tilahun G, Chatterjee S. Utilization of Traditional Antimalarial 
Ethnophytotherapeutic Remedies among Assendabo Inhabitants in (South-West) Ethiopia. Current 
Drug Therapy 2009; 4: 78-91. 
 
Suleman S, Ketsela A, Mekonnen Z. Assessment of self-medication practices in Assendabo town, 
Jimma zone, south-western Ethiopia. Research in Social and Administrative Pharmacy 2009; 5: 76-81. 
 
Mekonnen Z, Ali S, Belay G, Suleman S, Chatterjee S. Evaluation of the performance of CareStartTM 
Malaria Pf/Pv Combo rapid diagnostic test for the diagnosis of malaria in Jimma, southwestern 
Ethiopia. Acta Tropica 2010; 113: 285–288. 
 
Bekele A, Baay M, Mekonnen Z, Suelman S, Chatterjee S. Human Papilomavirus type distribution 
among women with cervical pathology- a study over 4 years at Jimma Hospital, southwest Ethiopia. 
Tropical Medicine and International Health 2010; 15: 890-893. 
 
Suleman S, Verbeken M, Baert B, Vangheluwe E, Van Dorpe S, Burvenich C, Duchateau L, Jansen FH, 
De Spiegeleer B. Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug 
lumefantrine. Malaria Journal 2011; 10: 51.  
 
CURRICULUM VITAE 
  
 
198  
Morankar S, Tegene A, Kassahun W, Suleman S, Negatu YA, Yazachew M, Pagnoni F. Validity and 
reliability of RDT for diagnosis of malaria among febrile children in Jimma Town: southwest Ethiopia.  
Ethiopian Medical Journal 2011; 49: 131-8. 
 
Peggy SO, Tadeg H, Don D, Suleman S, Bedada W, Pawulos G, Mekonnen H, Mekonnen N, Rebecca B, 
Andy S. Instructional Design and Assessment. Strengthening Pharmaceutical Care Education in 
Ethiopia Through Instructional Collaboration. American Journal of Pharmaceutical Education 2011; 
75: Article 34. 
 
Fayera G, Tajure N, Tarekegn M, Suleman S, Hussien N, Hussien S, Adem M, Hassen A. Attitude of 
modern medical practitioners towards the integration of modern and traditional medical practices in 
Ethiopia. Spatula DD 2011; 1: 199-205. 
 
Tajure N, Hussein J, Suleman S, Abdella K. In vitro antifungal susceptibility of Candida albicans isolates 
from oral cavities of patients infected with human immunodeficiency virus in Ethiopia. 
Retrovirology 2012; 9: P44. 
 
Suleman S, Alemu T. A survey on utilization of Ethnomedicinal Plants in Nekemte town, East Wellega 
(Oromia), Ethiopia. Journal of Herbs, Spices and medicinal plants 2012; 18: 34-57. 
 
Mulualem Y, Kassa T, Mekonnen Z, Suleman S. Occurrence of extended spectrum beta (β)-lactamases 
in multi-drug resistant Escherichia coli isolated from a clinical setting in Jimma University Specialized 
Hospital, Jimma, south-west Ethiopia. East African Journal of Public health 2012; 9: 58-61. 
 
Hawaze S, Deti H, Suleman S. In-vitro anti-microbial activity and Phytochemical screening of Clematis 
Species indigenous to Ethiopia. Indian Journal of Pharmaceutical Sciences 2012; 74: 29-35. 
 
Hussien N, Musa S, Stergachis A, Tajure N, Suleman S. Drug information: Prescriber’s need for and 
access to drug information resources in Ethiopia. Therapeutic Innovation and Regulatory Science 
2013; 47: 219-225. 
 
Woldu M, Suleman S, Workneh N, Berhane H. Retrospective Study of the Pattern of Antibiotic Use in 
Hawassa University Referral Hospital Pediatric Ward, Southern Ethiopia. Journal of Applied 
Pharmaceutical Sciences 2013; 3: 093-098.  
 
    CURRICULUM VITAE 
  
 
199 
Berhane A, Ali E, Peggy SO, Suleman S. Implementing ward based clinical pharmacy services in an 
Ethiopian University Hospital. Pharmacy Practice 2013; 11: 51-57. 
 
Suleman S, Vandercruyssen K, Wynendaele E, D’Hondt M, Duchateau L, De Spiegeleer B. A rapid 
stability-indicating fused core HPLC method for simultaneous determination of β-artemether and 
lumefantrine in anti-malarial fixed dose combination products. Malaria Journal 2013; 12: 145. 
 
Berhane A, Elias Ali, Peggy SO, Suleman S. Physicians’ expectations of clinical pharmacists’ roles in 
Jimma University Specialized Hospital, South west Ethiopia. International Journal of Pharmacy 
Teaching and Practices 2013; 4: 571-574. 
 
Hawaze S, Deti H, Suleman S. Wound healing activity of the methanol extracts of Clematis species 
indigenous to Ethiopia. International Journal of Green Pharmacy 2013; 7: 304-8. 
 
Suleman S, Zeleke G, Deti H, Mekonnen Z, Duchateau L, Levecke B, Vercruysse J, De Spiegeleer B. 
Quality of medicines used in the treatment of soil transmitted helminthes (STH) and giardia in 
Ethiopia: a nationwide survey. Plos Neglected Tropical Diseases 2014; 8: e3345.  
 
Mekonnen Z, Meka S, Zeynudin A, Suleman S. Schistosoma mansoni infection and undernutrition 
among school age children in Fincha'a sugar estate, rural part of West Ethiopia. BMC Research Notes 
2014; 7: 763.  
 
Likisa J, Suleman S, Belachew T, Abebe G. Mortality of Adults on Antiretroviral Therapy with and 
without TB co-infection in Jimma University Hospital, Ethiopia: Retrospective Cohort Study.  Journal 
of AIDS and Clinical Research 2014; 5: 350.  
 
Sano M, Hiko D, Suleman S. Treatment Outcomes of Nevirapine- Versus Efavirenz-Based Highly Active 
Antiretroviral Therapy Regimens Among Antiretroviral-Naive Adult Patients in Ethiopia: A Cohort 
Study. Therapeutic  Innovation and Regulatory Sciences 2015; 49: 443-449.  
 
Suleman S, Yannick V, Dumoulin A, Wynendaele E, D’Hondt M, Vandercruyssen K, Veryser L, 
Duchateau L, De Spiegeleer B. Gas chromatographic method for the determination of lumefantrine in 
anti-malarial finished pharmaceutical products (FPPs). Journal of Food and Drug Analysis 2015; 23: 
552-559.  
 
CURRICULUM VITAE 
  
 
200  
Alemu Y, Zeynudin A, Belachew T, Desalegn Z, Suleman S. Assessment of therapeutic efficacy and 
safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium 
falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study. 
Malaria Journal 2015; 14: 236. 
 
Dana D, Debalke S, Mekonnen Z, Kassahun W, Suleman S, Getahun K, Yewhalaw D. A community-
based cross-sectional study of the epidemiology of onchocerciasis in unmapped villages for 
community directedtreatment with ivermectin in Jimma Zone, southwestern Ethiopia. BMC Public 
Health 2015; 15: 595. 
 
Likisa J, Suleman S, Belachew T, Abebe G. Outcomes of highly active antiretroviral therapy and its 
predictors: a cohort study focusing on tuberculosis co‑infection in South West Ethiopia. BMC 
Research Notes 2015; 8: 446. 
 
Belew S, Getachew M, Suleman S, Mohammed T, Deti H, D'Hondt M, Wynendaele E, Mekonnen Z, 
Vercruysse J, Duchateau L, De Spiegeleer B, Levecke B. Assessment of Efficacy and Quality of Two 
Albendazole Brands Commonly Used against Soil-Transmitted Helminth Infections in School Children 
in Jimma Town, Ethiopia. Plos Neglected Tropical Diseases 2015; 9: e0004057.  
 
Suleman S, Woliyi A, Woldemichael K, Tushune K, Duchateau L, Degroote A, Vancauwenberghe R, 
Bracke N, De Spiegeleer B. Pharmaceutical regulatory framework in Ethiopia: critical evaluation of its 
legal basis and implementation. Ethiopian Journal of Health Sciences 2015 (Accepted for publication). 
 
SUBMITTED 
Suleman S, Mohammed T, Belew S, Wynendaele E, D’Hondt M, Duchateau L, De Spiegeleer B. Quality 
of anti-malarial drugs in Ethiopia: survey on artemisinin-based fixed dose combination products in 
Jimma zone, southwest Ethiopia (PLOS One 2015). 
 
IN PREPARATION 
Suleman S, Belew S, Wynendaele E, Duchateau L, De Spiegeleer B. Quality-by-Design principles 
applied to the establishment of a pharmaceutical quality control laboratory in a resource-limited 
setting: lab-water system. 
 
Kebebe D, Suleman S, Belew S, Duchateau L, De Spiegeleer B. Traditional medicinal knowledge fights 
back against malaria: the case of Ethiopia. 
    CURRICULUM VITAE 
  
 
201 
 
PRESENTATIONS AT (INTER)NATIONAL CONFERENCES 
Suleman S. Pharmaceutical Education and the pharmacy workforces in Ethiopia as a case study of 
Global Pharmacy Education Taskforce, International Pharmaceutical Federation (FIP) Congress 2008, 
Basel; Switzerland. 
Oral presentation 
 
Suleman S, Tajure N, Hussien J. In-vitro susceptibility of candida isolates from oral cavities of 
HIV/AIDS patients to the commonly used antifungal agents in Jimma University specialized hospital, 
southwest Ethiopia.  International Pharmaceutical Federation (FIP) Congress 2009, Istanbul, Turkey. 
Poster presentation 
 
Suleman S, Baert B, Vangheluwe E, Duchateau L, De Spiegeleer B. Related Impurities profiling of anti-
malarial drug lumefantrine. Scientific Afternoon in the Faculty of Pharmaceutical Sciences (FFW), May 
2010, Faculty of Pharmacutical Sciences, University of Ghent, 9000 Ghent, Belgium. 
Poster presentation 
 
Suleman S, Baert B, De Spiegeleer B. Lumefantrine related impurities evaluation. 30th Ethiopian 
Pharmaceutical Association Annual Conference, UN Convention Center, August 28, 2010, Addis 
Ababa, Ethiopia. 
Oral presentation 
 
Suleman S, Baert B, Vangheluwe E, Duchateau L, Van Dorpe S, De Spiegeleer B. Analysis of 
Lumefantrine for related impurities. Drug Analysis symposium, September 21-24, 2010, Antwerp, 
Belgium. 
Poster presentation 
 
Suleman S, Verbeken M, Baert B, Vangheluwe E, Van Dorpe S, Burvenich C, Duchateau L, Jansen FH, 
De Spiegeleer B.  Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug 
lumefantrine.  Malaria Research Network of Ethiopia, August 25, 2011, Jimma University, Jimma, 
Ethiopia. 
Oral presentation 
CURRICULUM VITAE 
  
 
202  
Suleman S, Baert B, Vangheluwe E, Duchateau L, De Spiegeleer B. Related impurities profile and in 
silico toxicity potential of the anti-malarial drug lumefantrine,  IUC Research Conference. 17th 
September 2011, Jimma University, Jimma, Ethiopia. 
Poster presentation 
 
Suleman S, Vandercruyssen K, D’hondt M,  De Spiegeleer B. A rapid stability-indicating fused core 
HPLC method for simultaneous determination of β-artemether and lumefantrine in anti-malarial 
fixed dose combination products. Scientific Afternoon in the Faculty of Pharmaceutical Sciences 
(FFW), May 2012, Faculty of Pharmacutical Sciences, University of Ghent, 9000 Ghent, Belgium. 
Poster presentation 
 
Suleman S. Selected functional quality challenges: from specification settings to traceability, March 
2013, Jimma, Ethiopia. 
Oral presentation 
 
Suleman S, Vandercruyssen K, D’hondt M,  De Spiegeleer B. A rapid stability-indicating fused core 
HPLC method for simultaneous determination of β-artemether and lumefantrine in anti-malarial 
fixed dose combination products. 32nd Ethiopian Pharmaceutical Association Annual Conference, 
African Union (AU) Convention Center, September 2013, Addis Ababa, Ethiopia. 
Oral presentation 
 
Belew S, Suleman S, Kebebe D, Duchateau L, De Spiegeleer B. Anthelminthic medicines: does the 
early bird always catch the worm? 9th symposium of the Ghent Africa Platform – GAPSYM9, 17 
December 2015, Gent, Belgium. 
Poster presentation 
 
Kebebe D, Suleman S, Belew S, Duchateau L, De Spiegeleer B. Traditional medicinal knowledge fights 
back against malaria. 9th symposium of the Ghent Africa Platform – GAPSYM9, 17 December 2015, 
Gent, Belgium. 
Poster presentation 
 
Kosgei A, Suleman S, Duchateau L, De Spiegeleer B. The role of medicines in trade, civil and interstate 
conflicts. and  9th symposium of the Ghent Africa Platform – GAPSYM9, 17 December 2015, Gent, 
Belgium. 
Poster presentation 
    CURRICULUM VITAE 
  
 
203 
Suleman S, Belew S, Kebebe D, Wynendaele E, Duchateau L, De Spiegeleer B. Quality-by-Design 
principles applied to the establishment of an African Medicines Quality Control laboratory: the lab 
water system. 9th symposium of the Ghent Africa Platform – GAPSYM9, 17 December 2015, Gent, 
Belgium. 
Poster presentation 
 
PROFESSIONAL AND TRAVEL AWARDS 
7 – 9 September 2013:  Gold Medal and Certificate of Merit of the year 2012 for the 
contribution to Pharmaceutical Research and Development in 
Ethiopia from Ethiopian Pharmaceutical Association (EPA), Addis 
Ababa, Ethiopia.  
 
 
31 August – 04 September 2008:  International Pharmaceutical Federation (FIP) full financial support 
to attend the FIP World Congress of Pharmacy and Pharmaceutical 
Sciences in Basel, Switzerland. 
 
3 – 8 September 2009:  International Pharmaceutical Federation (FIP) Congress Travel Grant 
award: The travel grant was awarded to attend the international 
pharmaceutical federation (FIP) congress in Istanbul, Turkey.  
 
  
 
 
 
 
 
 
 
 
  
 
 
  
 
 
